Human papillomavirus vaccines and uses thereof
Non-naturally occurring HPV polypeptides encoded by engineered polynucleotides in adenovirus vectors address the limitations of current vaccines, providing broad-spectrum immunity against HPV-related diseases and cancers.
Patent Information
- Application Number
- JP2020547085
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-03-06
- Filing Date
- 2019-03-06
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2039-03-06
AI Technical Summary
Current HPV vaccines provide limited protection against multiple HPV strains and do not effectively target HPV-related cancers, necessitating a broad-spectrum vaccine that induces immune responses against HPV-related diseases.
Development of non-naturally occurring polynucleotides encoding HPV polypeptides, such as E5, E6, and E7, combined with adenovirus vectors for therapeutic vaccines, utilizing bioinformatics and protein engineering to enhance immune response induction.
The engineered HPV vaccines elicit robust immune responses against multiple HPV strains, potentially reducing the incidence of HPV-related cancers by inducing broad-spectrum immunity.
Smart Images

Figure 0007581048000008 
Figure 0007581048000009 
Figure 0007581048000010
Abstract
Description
[Technical field]
[0001] Reference to sequence listing The contents of the Sequence Listing (Name: 2584_156PC01_SeqListing_ST25; Size: 444,182 bytes; Creation Date: March 5, 2019) submitted electronically and filed with this application are hereby incorporated by reference in their entirety.
[0002] Field of the Disclosure The present disclosure relates to improved broad-spectrum HPV molecular vaccines designed through the use of evolutionary principles in bioinformatics and protein engineering. [Background technology]
[0003] Tens of millions of people worldwide are currently infected with human papillomavirus (HPV), and millions more become newly infected each year. HPV has been determined to be a precursor to cervical cancer and other cancers, such as head and neck cancer. Tens of thousands of women suffer from cervical cancer each year. Currently, vaccination protects against HPV-caused disease when administered to recommended age groups, but there is a strong need for an HPV vaccine with broad coverage (against multiple HPV strains) and functionality against HPV-associated cancers.
[0004] The present disclosure relates to improved broad-spectrum HPV molecular vaccines designed through the use of evolutionary principles in bioinformatics and protein engineering. These novel HPV vaccines can be used as therapeutic vaccines against HPV-associated diseases.
[0005] Incorporation by Reference All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. Summary of the Invention
[0006] Provided herein are non-naturally occurring polynucleotides that encode a polypeptide comprising at least one of one or more immune response-inducing Human Papillomavirus (HPV) polypeptides.
[0007] In some embodiments, the non-naturally occurring polynucleotide encodes a polypeptide comprising two or more HPV polypeptides. In some embodiments, the two or more HPV polypeptides comprise one or more immune response-inducing HPV-16 polypeptide sequences. In some embodiments, the HPV-16 peptide comprises at least one of an E5 peptide, an E6 peptide, or an E7 peptide. In some embodiments, the HPV-16 peptide comprises an E5 peptide, the E5 peptide having a sequence set forth in SEQ ID NO: 47. In some embodiments, the HPV-16 peptide comprises an E6 peptide, the E6 peptide having a sequence set forth in SEQ ID NO: 45. In some embodiments, the HPV-16 peptide comprises an E7 peptide, the E7 peptide having a sequence set forth in SEQ ID NO: 46. In some embodiments, the one or more HPV peptides comprise an HPV-18 peptide. In some embodiments, the HPV-18 peptide comprises at least one of an E5 peptide, an E6 peptide, or an E7 peptide. In some embodiments, the HPV-18 peptide comprises an E5 peptide, the E5 peptide having a sequence set forth in SEQ ID NO:50. In some embodiments, the HPV-18 peptide comprises an E6 peptide, the E6 peptide having a sequence set forth in SEQ ID NO:48. In some embodiments, the HPV-18 peptide comprises an E7 peptide, the E7 peptide having a sequence set forth in SEQ ID NO:49. In some embodiments, the polypeptide has a sequence set forth in SEQ ID NO:51. In some embodiments, at least one of the one or more HPV peptides is linked to an agonist peptide. In some embodiments, the agonist peptide has a sequence comprising an agonist peptide sequence set forth in Table 2. In some embodiments, the polypeptide has a sequence set forth in SEQ ID NO:53.
[0008] Provided herein is a polynucleotide comprising any of the polynucleotides provided herein, further comprising one or more polynucleotides encoding a gene switch system for inducible control of heterologous gene expression, wherein the heterologous gene expression is regulated by the gene switch system; the heterologous gene comprises any of the polynucleotides described herein. In some embodiments, the gene switch system is an ecdysone receptor-based (EcR-based) gene switch system. In some embodiments, the one or more HPV polypeptides are HBV polypeptides for use in vaccines.
[0009] Provided herein is a vector comprising any of the polynucleotides provided herein. In some embodiments, the vector is an adenovirus vector. In some embodiments, the adenovirus vector is a gorilla adenovirus vector.
[0010] Provided herein is a method of regulating expression of a heterologous gene in a cell, the method comprising: introducing into the cell one or more polynucleotides comprising (i) an inhibitory gene switch or an inducible gene switch, and (ii) a heterologous immune response-inducible gene whose expression is regulated by the gene switch, the heterologous immune response-inducible gene encoding at least one of one or more HPV polypeptides; and exposing the cell to a compound in an amount sufficient to inhibit or induce expression of the heterologous immune response-inducible gene.
[0011] In some embodiments, the target cell is a mammalian cell in the method of regulating expression of a heterologous gene in a cell described herein. In some embodiments, the gene switch comprises a ligand-binding domain derived from at least one of ecdysone receptor (EcR), ubiquitous receptor, orphan receptor 1, NER-1, steroid hormone nuclear receptor 1, retinoid X receptor interacting protein 15, liver X receptor beta, steroid hormone receptor-like protein, liver X receptor, liver X receptor alpha, farnesoid X receptor, receptor interacting protein 14, and farnesol receptor.
[0012] Provided herein is an E6 peptide comprising an E18A amino acid substitution and at least one of the following amino acid substitutions: L50G, E148A, T149A, Q150A, and L151A, compared to wild-type E6 peptide. In some embodiments, the E6 peptide comprises the E18A amino acid substitution and at least one of the following amino acid substitutions: L50G, E148A, T149A, Q150A, and L151A. In some embodiments, the E6 peptide has a sequence as shown in SEQ ID NO: 45. In some embodiments, the E6 peptide is fused to an agonist peptide. In some embodiments, the agonist peptide is fused to at least one of the C-terminus and N-terminus of the E6 peptide. In some embodiments, the wild-type E6 peptide is derived from HPV-16.
[0013] Provided herein is an E6 peptide comprising a deletion compared to wild-type E6 peptide, said deletion comprising the C-terminus of said wild-type E6 peptide. In some embodiments, said deletion comprises amino acids 121 to the C-terminus of said wild-type E6 peptide. In some embodiments, said E6 peptide comprises at least one of E18A and L50G substitutions compared to said wild-type E6 peptide. In some embodiments, said wild-type E6 peptide is derived from HPV-18. In some embodiments, said E6 peptide has the sequence shown in SEQ ID NO:48.
[0014] Provided herein is an E7 peptide comprising a deletion compared to a wild-type E7 peptide, the deletion comprising the N-terminus of the wild-type E7 peptide. In some embodiments, the deletion comprises amino acids 1-39 of the wild-type E7 peptide. In some embodiments, the E7 peptide comprises at least one of the following substitutions compared to the wild-type E7 peptide: E55A and L74R. In some embodiments, the wild-type E7 peptide is derived from HPV-18. In some embodiments, the E7 peptide has the sequence set forth in SEQ ID NO:49.
[0015] Provided herein are E5 peptides that include a deletion compared to a wild-type E5 peptide, the deletion including amino acids 41-57 of the wild-type E5 peptide. In some embodiments, the E5 peptide has the sequence set forth in SEQ ID NO: 47. In some embodiments, the wild-type E5 peptide is derived from HPV-16.
[0016] Provided herein are E5 peptides that include a deletion compared to a wild-type E5 peptide, the deletion including at least one of amino acids 27-40 or amino acids 54-57 of the wild-type E5 peptide. In some embodiments, the E5 peptide has a sequence set forth in SEQ ID NO: 50. In some embodiments, the wild-type E5 peptide is derived from HPV-18.
[0017] Provided herein are polypeptide constructs comprising any one of E5, E6, and E7 as described herein.
[0018] Provided herein is a polypeptide construct comprising an HPV-16 E6 peptide, said HPV-16 E6 peptide comprising an E18A amino acid substitution and at least one of the following amino acid substitutions: L50G, E148A, T149A, Q150A, and L151A, compared to wild-type HPV-16 E6 peptide. In some embodiments, said HPV-16 E6 peptide comprises the E18A amino acid substitution and at least one of the following amino acid substitutions: L50G, E148A, T149A, Q150A, and L151A. In some embodiments, said HPV-16 E6 peptide has a sequence as shown in SEQ ID NO: 45. In some embodiments, said polypeptide construct further comprises an HPV-16 E7 peptide, said HPV-16 E7 peptide comprising at least one of the following amino acid substitutions: H2P, C24G, E46A, and L67R, compared to wild-type HPV-16 E7 peptide. In some embodiments, the HPV-16 E7 peptide comprises the H2P, C24G, E46A, and L67R amino acid substitutions. In some embodiments, the HPV-16 E7 peptide has a sequence set forth in SEQ ID NO: 46. In some embodiments, the polypeptide construct further comprises an HPV-16 E5 peptide. In some embodiments, the HPV-16 E5 peptide comprises a deletion of one or more amino acids compared to a wild-type HPV-16 E5 peptide. In some embodiments, the deletion comprises amino acids 41-57 of the wild-type HPV-16 E5 peptide. In some embodiments, the HPV-16 E5 peptide has a sequence set forth in SEQ ID NO: 47.
[0019] In some embodiments, the polypeptide construct comprises an HPV-16 E6 peptide comprising an E18A amino acid substitution and at least one of the following amino acid substitutions compared to the wild-type HPV-16 E6 peptide: L50G, E148A, T149A, Q150A, and L151A, and further comprises an HPV-18 E6 peptide. In some embodiments, the HPV-18 E6 peptide comprises an E18A and L50G substitution compared to the wild-type HPV-18 E6 peptide. In some embodiments, the HPV-18 E6 peptide comprises a deletion of at least one C-terminal amino acid compared to the wild-type HPV-18 E6 peptide. In some embodiments, the deletion comprises amino acid 121 to the C-terminus of the wild-type HPV-18 E6 peptide. In some embodiments, the HPV-18 E6 peptide has the sequence set forth in SEQ ID NO: 48. In some embodiments, the polypeptide construct further comprises an HPV-18 E7 peptide. In some embodiments, the HPV-18 E7 peptide comprises the substitutions E55A and L74R compared to a wild-type HPV-18 E7 peptide. In some embodiments, the HPV-18 E7 peptide comprises a deletion of at least one amino acid from the N-terminus of the HPV-18 E7 peptide. In some embodiments, the deletion comprises amino acids 1-40 of the wild-type HPV-18 E7 peptide. In some embodiments, the HPV-18 E7 peptide has a sequence set forth in SEQ ID NO:49. In some embodiments, the polypeptide construct further comprises an HPV-18 E5 peptide. In some embodiments, the HPV-18 E5 peptide comprises a deletion of at least one amino acid compared to a wild-type HPV-18 E5 peptide. In some embodiments, the deletion comprises amino acids 27-40 or amino acids 54-57 of the wild-type HPV-18 E5 peptide. In some embodiments, the HPV-18 E5 peptide has a sequence set forth in SEQ ID NO:50. In some embodiments, the polypeptide construct has the sequence set forth in SEQ ID NO: 51. In some embodiments, the polypeptide construct further comprises at least one agonist peptide.In some embodiments, the at least one agonist peptide has a sequence comprising an agonist peptide sequence set forth in Table 2. In some embodiments, the polypeptide construct has a sequence set forth in SEQ ID NO:53.
[0020] Provided herein is a polypeptide construct comprising an ankyrin-like repeat domain and an HPV peptide. In some embodiments, the ankyrin-like repeat protein is a human ankyrin-like repeat protein. In some embodiments, the HPV peptide is linked to the ankyrin-like repeat protein by a linker. In some embodiments, the HPV peptide comprises at least one of an HPV-16 peptide or an HPV-18 peptide. In some embodiments, the HPV peptide comprises an HPV-16 peptide, the HPV-16 peptide comprises at least one of an E5 peptide, an E6 peptide, or an E7 peptide. In some embodiments, the HPV peptide comprises an HPV-18 peptide, the HPV-18 peptide comprises at least one of an E6 peptide or an E7 peptide. In some embodiments, the HPV peptide comprises an HPV-16 E5 sequence, an HPV-16 E6 sequence, an HPV-16 E7 sequence, an HPV-18 E6 sequence, or an HPV-18 E7 sequence as set forth in Table 2. In some embodiments, the polypeptide construct has a sequence as set forth in SEQ ID NO: 52. In some embodiments, the polypeptide construct further comprises at least one agonist peptide. In some embodiments, the polypeptide construct comprises three agonist peptides. In some embodiments, the polypeptide construct has a sequence as set forth in SEQ ID NO: 54.
[0021] Provided herein is a polypeptide construct comprising at least two HPV amino acid sequences as shown in Table 2, said at least two HPV amino acid sequences being connected by a peptide linker, said peptide linker being a KK linker. In some embodiments, said at least two HPV amino acid sequences comprise at least one of the HPV-16 peptides or HPV-18 peptides as shown in Table 2. In some embodiments, said at least two HPV amino acid sequences comprise an HPV-16 peptide, said HPV-16 peptide comprising at least one of the HPV-16 E5 peptide, HPV-16 E6 peptide, or HPV-16 E7 peptide as shown in Table 2. In some embodiments, said at least two HPV amino acid sequences comprise an HPV-18 peptide, said HPV-18 peptide comprising at least one of the HPV-18 E6 peptide or HPV-18 E7 peptide as shown in Table 2. In some embodiments, said at least two HPV amino acid sequences comprise each of the amino acid sequences as shown in Table 2. In some embodiments, each of the amino acid sequences is connected to another of the amino acid sequences by a KK linker. In some embodiments, the polypeptide construct has a sequence as set forth in SEQ ID NO: 55. In some embodiments, any of the polypeptide constructs described herein is a polypeptide construct for use in a vaccine.
[0022] Provided herein is a polynucleotide encoding any of the polypeptide constructs described herein.Also provided herein is a vector comprising said polynucleotide.In some embodiments, said vector is an adenovirus vector.In some embodiments, said adenovirus vector is a gorilla adenovirus vector.
[0023] Provided herein is a vector that includes a polynucleotide encoding at least one HPV peptide, and is an adenoviral vector.
[0024] Provided herein is a vector comprising a polynucleotide encoding at least one HPV peptide, the vector being an adenoviral vector, the adenoviral vector being a gorilla adenoviral vector.
[0025] In some embodiments, any of the polypeptide constructs described herein is a polypeptide construct for use in a vaccine. Also provided herein is a polynucleotide encoding any of the polypeptide constructs described herein. Also provided herein is a vector comprising said polynucleotide. In some embodiments, said vector is an adenovirus vector. In some embodiments, said adenovirus vector is a gorilla adenovirus vector.
[0026] BRIEF DESCRIPTION OF THE DRAWINGS The features of the present disclosure are pointed out with particularity in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the disclosure are utilized, and the accompanying drawings. [Brief description of the drawings]
[0027] [Figure 1] Schematic diagram of the HPV genome. The HPV genome contains seven early genes (E1 to E7) and two late genes (L1 and L2), each with a specific function. The E5, E6, and E7 genes are associated with the development of cancer. [Diagram 2] FIG. 1 shows the overall schematic workflow carried out to design HPV vaccine antigens. [Diagram 3]Schematic diagram of antigen design with HPV16 and HPV18 for HPV design 1 and HPV design 3. Using consensus sequence information, HPV16 / HPV18 reference sequences were selected for design including all major variants. Vaccine composition including different protein components of E6, E7, and E5 with domain boundary and mutation information. These different domains contain the most common peptides predicted from IEDB predictions for binding to MHC-I. HPV design 3 is similar to HPV design 1 but with the addition of enhancer agonist peptides. [Figure 4] 4A and 4B show the homology models for HPV design 2 and HPV design 4, respectively. The homology models were used to evaluate the overall structural features and compare the HPV designs against natural ankyrin repeats. The HPV designs are shown in the same orientation and maintain the same overall fold, but suggest different structural conformations due to peptide shuffling. [Figure 5A] Figure 5A shows HPV design 5 (subject) mapped to HPV design 4 (query) using protein BLAST. Strong and weak binders were identified using netMHC. Figure 5B shows density plots for HPV designs 4 and 5 extracted based on the mapping positions. Similar patterns were observed for predicted strong / weak binding peptides. Predictions of binding affinity were similar in the matched regions of HPV designs 4 and 5. [Figure 5B] Same as above. [Figure 6] FIG. 1 is an exemplary schematic diagram showing sets of short and long primers and probes created for RNA qPCR relative expression assays. Specific primers were designed for each HPV antigen design. [Figure 7A]Figure 7A shows antigenicity prediction by NetMHC 4.0. The binding index of predicted strong and weak binding peptides is plotted against peptide position. Figure 7B shows density plot of antigenicity prediction by NetMHC 4.0. First and second derivatives are used to identify peaks. Figure 7C shows amino acid sequences aligned against consensus sequences to determine coverage across HPV subtypes. [Figure 7B] Same as above. [Figure 7C] Same as above. [Figure 8] FIG. 1 shows a comparison between HPV design 1 (MOD-1755822) and HPV design 3 (MOD-1755825). [Figure 9A] Figure 9A shows a sequence alignment of HPV16 E6 with wild type HPV16 E6 according to UP P03126. Figure 9B shows a sequence alignment of HPV16 E7 with wild type HPV16 E7 according to UP P03129. Figure 9C shows a sequence alignment of HPV16 E5 with wild type HPV16 E5 according to UP P06927. [Figure 9B] Same as above. [Figure 9C] Same as above. [Figure 10A] Figure 10A shows a sequence alignment of HPV18 E6 with wild type HPV18 E6 according to UP P06463. Figure 10B shows a sequence alignment of HPV18 E7 with wild type HPV18 E7 according to UP P06788. Figure 10C shows a sequence alignment of HPV18 E5 with wild type HPV18 E5 according to UP P06792. [Figure 10B] Same as above. [Figure 10C] Same as above. [Figure 11] FIG. 1 shows an overview of IL-12, which promotes immune responses by activating NK and T cells. [Figure 12]FIG. 1 shows various structural components of various IL-12 ligand-inducible gene switch vector systems. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0028] Detailed Description of the Invention The following description and examples further illustrate embodiments of the present disclosure.
[0029] It should be understood that the present disclosure is not limited to the particular embodiments described herein, and as such may vary. Those skilled in the art will recognize that the present disclosure is susceptible to variations and modifications which are encompassed within its scope.
[0030] All terms are intended to be understood as they would be understood by one of ordinary skill in the art. Unless otherwise specified, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains.
[0031] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
[0032] Although various features of the disclosure may be described in the context of a single embodiment, the features may also be presented separately or in any suitable combination. Conversely, although the disclosure may, for clarity, be described herein in the context of separate embodiments, the disclosure can also be practiced in a single embodiment.
[0033] The following definitions complement the definitions in the art, and are directed to this application, and are not attributable to any related or unrelated matter, such as any co-owned patent or application. Any method and material similar or equivalent to the methods and materials described herein can be used in carrying out the testing of this disclosure, but preferred materials and methods are described herein.Therefore, the terminology used herein is intended only to describe specific embodiments, and is not intended to be limiting.
[0034] definition In this application, the use of the singular includes the plural unless specifically stated otherwise. It should be noted that as used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
[0035] In this application, the use of "or" means "and / or" unless stated otherwise. As used herein, the terms "and / or" and "any combination thereof" and their grammatical equivalents can be used interchangeably. These terms may convey that any combination is specifically envisioned. For illustrative purposes only, the following phrases "A, B, and / or C" or "A, B, C, or any combination thereof" may mean "A individually; B individually; C individually; A and B; B and C; A and C; and A, B, and C." The term "or" can be used conjunctively or disjunctively, unless the context dictates otherwise.
[0036] Furthermore, use of the term "including" as well as other forms such as "includes," "including," and "included" are non-limiting.
[0037] References herein to "some embodiments," "an embodiment," "one embodiment," or "other embodiments" mean that a particular feature, structure, or characteristic described in connection with an embodiment is included in at least some embodiments of the present disclosure, but not necessarily in all embodiments.
[0038] As used in the specification and claims, the words "comprising" (any form of "comprising", such as "comprise" and "comprises"), "having" (any form of "having", such as "have" and "has"), "including" (any form of "including", such as "include" and "includes"), or "containing" (any form of "containing", such as "contain" and "contains") are inclusive or open-ended and do not exclude additional, unrecited elements or method steps. It is contemplated that any embodiment discussed herein can be implemented with respect to any method or composition of the disclosure, and vice versa. Additionally, the compositions of the disclosure can be used to achieve the methods of the disclosure.
[0039] As used herein in reference to a numerical value, the term "about" and its grammatical equivalents can include the numerical value itself, as well as values in a range of ±10% from that numerical value.
[0040] The term "about" or "approximately" means within an acceptable error range for a particular value as determined by one of ordinary skill in the art, which error range depends in part on how the value is measured or determined, i.e., on the limitations of the measurement system. For example, "about" can mean within one standard deviation or more than one standard deviation, as is customary in the art. Alternatively, "about" can mean a range of up to 20%, e.g., up to 10%, up to 5%, or up to 1% of a given value. In another example, the amount "about 10" includes any amount between 10 and 9-11. In yet another example, the term "about" in relation to a reference numerical value also includes a value ± 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% of the value. Alternatively, particularly with respect to biological systems or processes, the term "about" can mean within an order of magnitude of a value, preferably within 5-fold, more preferably within 2-fold. When a particular value is described in this application and in the claims, unless otherwise stated, the term "about" should be assumed to mean within an acceptable range of error for the particular value.
[0041] The term "isolated" and its grammatical equivalents as used herein means the removal of a nucleic acid from its natural environment. The term "purified" and its grammatical equivalents as used herein means that a molecule or composition, whether removed from nature (including genomic DNA and mRNA), synthesized (including cDNA), and / or amplified under laboratory conditions, has increased purity, where "purity" is a relative term and not "absolute purity". On the other hand, it should be understood that nucleic acids and proteins may be formulated with a diluent or adjuvant, but for practical purposes may be isolated. For example, nucleic acids are typically mixed with an acceptable carrier or diluent when used for introduction into a cell. The term "substantially purified" as used herein and its grammatical equivalents refers to a nucleic acid sequence, polypeptide, protein, or other compound that is essentially free, i.e., more than about 50% free, more than about 70% free, more than about 90% free, of polynucleotides, proteins, polypeptides, and other molecules with which it is naturally associated.
[0042] As used herein, "polynucleotide," "oligonucleotide," "polynucleotide construct," "gene," "gene construct," "heterologous gene," and grammatical equivalents thereof, refer to a polymeric form of nucleotides or nucleic acids of any length, either ribonucleotides or deoxyribonucleotides. The term refers only to the primary structure of the molecule. Thus, the term includes double-stranded and single-stranded DNA, triplex DNA, as well as double-stranded and single-stranded RNA. The term can also include modified forms of polynucleotides, for example, by methylation and / or capping, as well as unmodified forms of polynucleotides. The term is also intended to include molecules containing non-naturally occurring or synthetic nucleotides, as well as nucleotide analogs. The nucleic acid sequences and vectors disclosed or contemplated herein can be introduced into cells by transfection, transformation, or transduction.
[0043] As used herein, "transfection", "transformation" or "transduction" refers to the introduction of one or more exogenous polynucleotides into host cells by using physical or chemical methods.Many transfection methods are known in the art, including, for example, calcium phosphate DNA co-precipitation (see, for example, Murray EJ (ed.), Methods in Molecular Biology, Vol. 7, Gene Transfer and Expression Protocols, Humana Press (1991)); DEAE-dextran method; electroporation; cationic liposome-mediated transfection; tungsten particle-promoted gene gun method (Johnston, Nature, 346: 776-777 (1990)); and strontium phosphate DNA co-precipitation (Brash et al., Mol. Cell Biol., 7: 2031-2034 (1987)). Phage or viral vectors can be introduced into host cells after propagation of the infectious particles in suitable packaging cells, many of which are commercially available.
[0044] As used herein, "polypeptide", "peptide", "polypeptide construct", "peptide construct", and grammatical equivalents thereof refer to a polymer of amino acid residues. A "mature protein" is a full-length protein, optionally including glycosylation or other modifications typical of proteins in a given intracellular environment. The polypeptides and proteins disclosed herein, including functional portions and functional variants thereof, may contain synthetic amino acids in place of one or more naturally occurring amino acids. Such synthetic amino acids are known in the art and include, for example, aminocyclohexanecarboxylic acid, norleucine, α-amino-n-decanoic acid, homoserine, S-acetylaminomethylcysteine, trans-3-hydroxyproline and trans-4-hydroxyproline, 4-aminophenylalanine, 4-nitrophenylalanine, 4-chlorophenylalanine, 4-carboxyphenylalanine, β-phenylserine, β-hydroxyphenylalanine, phenylglycine, α-naphthylalanine, cyclohexylalanine, cyclohexylglyc ... Lysine, indoline-2-carboxylic acid, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, aminomalonic acid, aminomalonic acid monoamide, N'-benzyl-N'-methyllysine, N',N'-dibenzyllysine, 6-hydroxylysine, ornithine, α-aminocyclopentane carboxylic acid, α-aminocyclohexane carboxylic acid, α-aminocycloheptane carboxylic acid, α-(2-amino-2-norbornane) carboxylic acid, α,γ-diaminobutyric acid, α,β-diaminopropionic acid, homophenylalanine, and α-tert-butylglycine. The present disclosure further contemplates that expression of the polypeptides described herein in engineered cells may be associated with post-translational modification of one or more amino acids of the polypeptide construct.Non-limiting examples of post-translational modifications include phosphorylation, acylation, including acetylation and formylation, glycosylation (including N-linked and O-linked), amidation, hydroxylation, alkylation, including methylation and ethylation, ubiquitination, addition of pyrrolidone carboxylic acid, formation of disulfide bridges, sulfation, myristoylation, palmitoylation, isoprenylation, farnesylation, geranylation, glypionylation, lipoylation, and iodination.
[0045] Nucleic acids and / or nucleic acid sequences are "homologous" if they are derived from a common ancestral nucleic acid or ancestral nucleic acid sequence, natural or artificial. Proteins and / or protein sequences are "homologous" if their coding DNA is derived from a common ancestral nucleic acid or ancestral nucleic acid sequence, natural or artificial. Homologous molecules may be referred to as homologs. For example, any natural protein described herein can be modified by any available mutagenesis method. When expressed, this mutant nucleic acid encodes a polypeptide that is homologous to the protein encoded by the original nucleic acid. Homology is generally inferred from the sequence identity between two or more nucleic acids or proteins (or sequences thereof). The exact percentage of identity between sequences useful for establishing homology varies with the nucleic acid and protein in question, but a sequence identity of at least 25% is used to establish homology. Higher levels of sequence identity, such as 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 99% or more, can also be used to establish homology. Methods for determining percentage sequence identity (e.g., BLASTP and BLASTN, using default parameters) are described herein and are publicly available.
[0046] As used herein, in the context of two nucleic acid or amino acid sequences of a polypeptide, the terms "identical" or "sequence identity" and grammatical equivalents refer to residues in two sequences that are the same when aligned for maximum correspondence over a designated comparison window. As used herein, a "comparison window" refers to a segment of at least about 20, usually about 50 to about 200, more usually about 100 to about 150 contiguous positions within which a sequence may be compared to a reference sequence over the same number of contiguous positions after the two sequences are optimally aligned. Methods of sequence alignment for comparison are well known in the art.Optimal sequence alignment for comparison can be achieved by the local homology algorithm of Smith and Waterman, Adv. Appl. Math., 2:482 (1981); the alignment algorithm of Needleman and Wunsch, J. Mol. Biol., 48:443 (1970); the search for similarity method of Pearson and Lipman, Proc. Nat. Acad. Sci USA, 85:2444 (1988); computerized implementations of these algorithms (including, but not limited to, GAP, BESTFIT, BLAST, FASTA, and TFASTA in the PC / Gene program by Intelligentics, Mountain View Calif., Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, Wis., USA), and the CLUSTAL program can be found in Higgins and Sharp, Gene, 73:237-244. (1988) and Higgins and Sharp, CABIOS, 5:151-153 (1989); Corpet et al., Nucleic Acids Res., 16:10881-10890 (1988); Huang et al., Computer Applications in the Biosciences, 8:155-165 (1992); and Pearson et al., Methods in Molecular Biology, 24:307-331 (1994). Alignment is also often performed by visual and manual alignment. In one class of embodiments, the polypeptides herein are at least 80%, 85%, 90%, 98% 99%, or 100% identical to a reference polypeptide or a fragment thereof, as determined, for example, by BLASTP (or CLUSTAL, or any other available alignment software) using default parameters.Similarly, nucleic acids can also be described in terms of a starting nucleic acid, e.g., they can be 50%, 60%, 70%, 75%, 80%, 85%, 90%, 98%, 99%, or 100% identical to a reference nucleic acid or a fragment thereof, e.g., as measured by BLASTN (or CLUSTAL, or any other available alignment software) using default parameters. When one molecule is said to have a certain percentage of sequence identity to a larger molecule, this means that when the two molecules are optimally aligned, that percentage of residues in the smaller molecule will find matching residues in the larger molecule according to the order in which the two molecules are optimally aligned.
[0047] The term "substantially identical" and its grammatical equivalents as applied to a nucleic acid sequence or an amino acid sequence means that the nucleic acid sequence or amino acid sequence includes a sequence having at least 90% sequence identity or more, at least 95%, at least 98%, and at least 99% sequence identity, as compared to a reference sequence using the programs described above, e.g., BLAST using standard parameters. For example, the BLASTN program (for nucleotide sequences) uses as default a word length (W) of 11, an expectation (E) of 10, M=5, N=-4, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as default a word length (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1992)). Percentage sequence identity is determined by comparing two optimally aligned sequences over a comparison window, where portions of the polynucleotide sequence within the comparison window may contain additions or deletions (i.e., gaps) compared to the reference sequence (which does not contain additions or deletions) due to optimal alignment of the two sequences. The percentage is calculated by determining the number of positions where identical nucleic acid bases or amino acid residues occur in both sequences to determine the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window, and multiplying the result by 100 to determine the percentage sequence identity. In some embodiments, substantial identity exists over a region of the sequences at least about 50 residues long, over a region of at least about 100 residues, and in some embodiments, the sequences are substantially identical over at least about 150 residues. In some embodiments, the sequences are substantially identical over the entire length of the coding regions.
[0048] An "expression vector" or "vector" is any genetic element, e.g., a plasmid, chromosome, virus, transposon, to which another polynucleotide segment has been attached so as to cause the replication and / or expression of the attached segment, that behaves as an autonomous unit of polynucleotide replication in a cell (i.e., capable of replication under its own control) or is capable of replication by insertion into a host cell chromosome. Suitable vectors include, but are not limited to, plasmids, transposons, bacteriophages, and cosmids. A vector may contain polynucleotide sequences necessary to effect ligation or insertion of the vector into a desired host cell and to effect expression of the attached segment. Such sequences vary depending on the host organism and include promoter sequences to effect transcription, enhancer sequences to increase transcription, sequences of ribosome binding sites, and transcription-translation termination sequences. Alternatively, an expression vector may be capable of directly expressing the product of a nucleic acid sequence encoded therein, without ligation or integration of the vector into a DNA sequence of the host cell. In some embodiments, the vector is an "episomal expression vector" or "episome" that is capable of replicating in a host cell and persists as an extrachromosomal segment of DNA in the host cell under appropriate selective pressure (see, e.g., Conese et al., Gene Therapy, 11:1735-1742 (2004)). Representative, commercially available episomal expression vectors include, but are not limited to, episomal plasmids that use the Epstein-Barr nuclear antigen 1 (EBNA1) and Epstein-Barr virus (EBV) origin of replication (oriP). The vectors pREP4, pCEP4, pREP7, and pcDNA3.1 from Invitrogen (Carlsbad, Calif.) and pBK-CMV from Stratagene (LaJolla, Calif.) represent non-limiting examples of episomal vectors that use T antigen and the SV40 origin of replication instead of EBNA1 and oriP. The vector may also contain a selectable marker gene.
[0049] As used herein, the term "adenovirus" refers to an adenovirus that retains the ability to participate in the adenovirus life cycle and has not been physically inactivated, for example, by disruption (e.g., sonication), denaturation (e.g., using heat or solvents), or crosslinking (e.g., via formalin crosslinking). The "adenovirus life cycle" includes (1) virus binding and entry into a cell, (2) transcription into the adenovirus genome and translation into adenovirus proteins, (3) replication of the adenovirus genome, and (4) assembly of viral particles (see, for example, Fields Virology, 5th ed., Knipe et al. (eds.), Lippincott Williams & Wilkins, Philadelphia, PA (2006)). As used herein, the term "adenovirus vector" refers to an adenovirus that has been engineered so that the adenovirus genome is matched with a nucleic acid sequence that is non-native in the context of the adenovirus genome. Typically, adenoviral vectors are generated by introducing one or more mutations (e.g., deletions, insertions, or substitutions) into the adenoviral genome of an adenovirus to accommodate the insertion of a non-native nucleic acid sequence, e.g., for gene transfer into the adenovirus.
[0050] As used herein, the term "selectable marker gene" refers to a nucleic acid sequence that allows cells expressing that nucleic acid sequence to be specifically selected in the presence of a corresponding selection agent, either forward or reverse. Suitable selectable marker genes are known in the art and are described, for example, in International Patent Applications WO 1992 / 08796 and WO 1994 / 28143, Wigler et al., Proc. Natl. Acad. Sci. USA, 77: 3567 (1980), O'Hare et al., Proc. Natl. Acad. Sci. USA, 78: 1527 (1981), Mulligan & Berg, Proc. Natl. Acad. Sci. USA, 78: 2072 (1981), Colberre-Garapin et al., J. Mol. Biol., 150:1 (1981), Santerre et al., Gene, 30: 147 (1984), Kent et al., Science, 237: 901-903 (1984), and the like. (1987), Wigler et al., Cell, 11: 223 (1977), Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA, 48: 2026 (1962), Lowy et al., Cell, 22: 817 (1980), and U.S. Pat. Nos. 5,122,464 and 5,770,359.
[0051] As used herein, a "coding sequence" refers to a segment of a polynucleotide that codes for a protein. A region or sequence is bounded near the 5' end by an initiation codon and near the 3' end by a termination codon. A coding sequence can also be referred to as an open reading frame.
[0052] As used herein, "operably linked" refers to the physical and / or functional linkage of a DNA segment to another DNA segment, such that the segments can function in their intended manner. A DNA sequence encoding a gene product is operably linked to a regulatory sequence, for example, a promoter, an enhancer, and / or a silencer, when it is linked to the regulatory sequence in a manner that allows the transcription of the DNA sequence to be modulated, directly or indirectly. For example, a DNA sequence is operably linked to a promoter when it is ligated to the promoter downstream of the transcription start site of the promoter, in the correct reading frame with respect to the transcription start site, and allows the elongation of transcription to proceed through the DNA sequence. An enhancer or silencer is operably linked to a DNA sequence encoding a gene product when it is ligated to the DNA sequence so that it increases or decreases the transcription of the DNA sequence, respectively. Enhancers and silencers can be located upstream, downstream, or embedded in the coding region of a DNA sequence. A signal sequence DNA is operably linked to a DNA encoding a polypeptide if the signal sequence is expressed as a preprotein that participates in the secretion of the polypeptide. Linkage of a DNA sequence to a regulatory sequence is typically accomplished via adapters or linkers inserted within the sequence by ligation at appropriate restriction sites or using restriction endonucleases known to those skilled in the art.
[0053] As used herein, the terms "induce", "induction", and grammatical equivalents thereof refer to an increase in transcription of a nucleic acid sequence, promoter activity, and / or promoter expression brought about by a transcriptional regulator, relative to some basal transcription level.
[0054] The term "transcriptional regulator" refers to a biochemical element that acts to prevent or inhibit transcription of a promoter-driven DNA sequence under certain environmental conditions (e.g., a repressor protein or nuclear inhibitory protein) or a biochemical element that acts to enable or stimulate transcription of a promoter-driven DNA sequence under certain environmental conditions (e.g., an inducer or enhancer).
[0055] The term "enhancer" as used herein refers to a DNA sequence that, for example, increases the transcription of a nucleic acid sequence to which it is operably linked. Enhancers can be located many kilobases away from the coding region of a nucleic acid sequence and can mediate the binding of regulatory factors, DNA methylation patterns, or changes in DNA structure. Numerous enhancers are known in the art from a variety of different sources and are available as or within cloned polynucleotides (e.g., from depositories such as ATCC, as well as other commercial or personal sources). Many polynucleotides that contain a promoter (such as the commonly used CMV promoter) also contain enhancer sequences. Enhancers can be located upstream, within, or downstream of a coding sequence. The term "Ig enhancer" refers to an enhancer element derived from an enhancer region mapped within the immunoglobulin (Ig) locus, including, for example, the heavy chain (mu) 5' enhancer, the light chain (kappa) 5' enhancer, the kappa intronic enhancer and the mu intronic enhancer, and the 3' enhancer (see generally, Paul WE (ed), Fundamental Immunology, 3rd Edition, Raven Press, New York (1993), pages 353-363, and U.S. Pat. No. 5,885,827).
[0056] "Promoter" refers to a region of a polynucleotide that induces transcription of a coding sequence. A promoter is located near and upstream (towards the 5' region of the sense strand) of the transcription start site of a gene on the same strand of DNA. Some promoters are constitutive, since they are active in all circumstances within a cell, whereas other promoters, e.g., inducible promoters, are regulated and active in response to specific stimuli. As used herein, the term "promoter activity" and its grammatical equivalents refer to the degree of expression of a nucleotide sequence operably linked to a promoter whose activity is measured. Promoter activity can be measured directly, for example, by determining the amount of RNA transcript produced by Northern blot analysis, or indirectly, by determining the amount of a product encoded by a linked nucleic acid sequence, such as a reporter nucleic acid sequence linked to the promoter.
[0057] As used herein, "inducible promoter" refers to a promoter that is induced to be active by the presence or absence of a transcriptional regulator, such as a biotic or abiotic factor. Inducible promoters are useful because the expression of genes operably linked to them can be turned on or off at certain stages of the development of an organism or, in particular, a tissue. Non-limiting examples of inducible promoters include alcohol-regulated promoters, tetracycline-regulated promoters, steroid-regulated promoters, metal-regulated promoters, pathogenesis-regulated promoters, temperature-regulated promoters, and light-regulated promoters. An inducible promoter can be part of a gene switch or a gene switch. An inducible promoter can be a ligand-inducible promoter of a gene switch. In some cases, an inducible promoter can be a small molecule ligand-inducible, two-polypeptide, ecdysone receptor-based gene switch.In some cases, the gene switch may be any of the embodiments described in International Patent Applications Nos. 2001 / 070816; 2002 / 029075; 2002 / 066613; 2002 / 066614; 2002 / 066612; 2002 / 066615; 2003 / 027266; 2003 / 027267; 2003 / 027269; 2003 / 027271; 2003 / 027272; 2003 / 027273; 2003 / 027274; 2003 / 027275 ... Nos. 2005 / 108617; 2009 / 045370; 2009 / 048560; 2010 / 042189; 2010 / 042189; 2011 / 119773; and 2012 / 122025; as well as U.S. Pat. Nos. 7,091,038; 7,776,5 Specification No. 87; Specification No. 7,807,417; Specification No. 8,202,718; Specification No. 8,105,825; Specification No. 8,168,426; Specification No. 7,531,326; Specification No. 8,236,556 Specification No. 8,598,409; Specification No. 8,715,959; Specification No. 7,601,508; Specification No. 7,829,676; Specification No. 7,919,269; Specification No. 8,030,067; Specification No. 7, The polypeptide may be selected from, but is not limited to, the ecdysone-based receptor components of any of the systems described in US Pat. Nos. 5,935,510; 8,076,454; 9,402,919; 9,493,540; 9,249,207; and 9,492,482.
[0058] The term "gene switch" or "genetic switch" refers to a combination of a promoter and associated response element, for example, an EcR-based system that modulates the expression of a gene incorporating the response element and promoter in the presence of one or more ligands. Tightly regulated inducible gene expression systems or gene switches are useful for a variety of applications, including gene therapy, intracellular, large-scale protein production, cell-based high-throughput screening assays, functional genomics, and regulating traits in transgenic plants and animals. Such inducible gene expression systems can include ligand-inducible heterologous gene expression systems.
[0059] "Sleeping Beauty (SB) transposon system" refers to a synthetic DNA transposon system for introducing DNA sequences into vertebrate chromosomes. Some exemplary embodiments of the system are described, for example, in U.S. Pat. Nos. 6,489,458, 8,227,432, 9,228,180, and WO 2016 / 145146. The Sleeping Beauty transposon system is composed of Sleeping Beauty (SB) transposase and SB transposon. In some embodiments, the Sleeping Beauty transposon system can include SB11 transposon system, SB100X transposon system, or SB110 transposon system.
[0060] A "transposon" or "transposable element" (TE) is a vector DNA sequence that changes its location in the genome, possibly creating or reverting mutations and altering the genome size of a cell. Transposition often results in duplication of the TE. Class I TEs are copied in two steps: first, the class I TE is transcribed from DNA to RNA, and then the RNA produced is reverse transcribed into DNA. This copied DNA is then inserted into the new location in the genome. The reverse transcription step is catalyzed by a reverse transcriptase enzyme that may be encoded by the TE itself. The characteristics of retrotransposons are similar to retroviruses such as HIV. The cut-and-paste transposition mechanism by class II TEs does not involve an RNA intermediate. Transposition is catalyzed by several transposase enzymes. Some transposases bind nonspecifically to any target site in DNA, whereas others bind to specific DNA sequence targets. Transposases make staggered cuts at the target site resulting in single-stranded DNA overhangs (sticky ends) at the 5' or 3' ends. This step excises the DNA transposon, which is then ligated to a new target site, a process that involves the activity of DNA polymerase to fill in the gaps and DNA ligase to join the sugar-phosphate backbone. This results in duplication of the target site. The insertion site of a DNA transposon can be identified by a short direct repeat that can be created by staggered cuts in the target DNA and filled in by DNA polymerase, followed by a series of inverted repeats that are important for excision of the TE by the transposase. Cut-and-paste TEs can overlap when transposition occurs during the S phase of the cell cycle, when the donor site has already been replicated but the target site has not yet been replicated. Metastases, both class I and class II TEs, can be classified as autonomous or non-autonomous. Autonomous TEs can migrate on their own, whereas non-autonomous TEs require the presence of another TE to migrate.This is because non-autonomous TEs often lack transposase (in the case of class II) or reverse transcriptase (in the case of class I).
[0061] "Transposase" refers to an enzyme that binds to the ends of a transposon and catalyzes the movement of the transposon to another part of the genome by either a cut-and-paste mechanism or a replicative transposition mechanism.
[0062] As used herein, a "T cell" or "T lymphocyte" is a type of lymphocyte that plays a central role in cell-mediated immunity. A "T cell" or "T lymphocyte" can be distinguished from other lymphocytes, such as B cells and natural killer cells (NK cells), by the presence of a T cell receptor (TCR) on the cell surface.
[0063] "Helper T cells" (T H Helper T cells (helper T cells) assist other white blood cells in immune processes including the maturation of B cells into plasma cells and memory B cells, and the activation of cytotoxic T cells and macrophages. These cells are also known as CD4+ T cells because they express the CD4 glycoprotein on their cell surface. Helper T cells become activated when presented with peptide antigens by MHC class II molecules expressed on the surface of antigen-presenting cells (APCs). Upon activation, helper T cells divide rapidly and secrete small proteins called cytokines that regulate or assist in active immune responses. These cells are known as T H 1. T H 2. T H 3. T H 9. T H 17, T H 22, or T FH T cells can differentiate into one of several subtypes, including follicular helper T cells (FTCs), which secrete different cytokines to facilitate different kinds of immune responses. Signaling from APCs directs T cells toward a particular subtype.
[0064] "Cytotoxic T cells" (TC cells or CTLs) or "cytotoxic T lymphocytes" destroy virus-infected and tumor cells and are also involved in transplant rejection. These cells are also known as CD8+ T cells because they express the CD8 glycoprotein on their surface. These cells recognize their targets by binding to antigens associated with MHC class I molecules, which are present on the surface of all nucleated cells. Through IL-10, adenosine, and other molecules secreted by regulatory T cells, CD8+ cells can be inactivated into an anergic state, thereby preventing autoimmune diseases.
[0065] "Memory T cells" are a subset of antigen-specific T cells that persist for a long time after an infection has cleared. Upon re-exposure to their cognate antigen, memory T cells rapidly expand into large numbers of effector T cells, thereby providing the immune system with a "memory" for past infections. Memory T cells include three subtypes: central memory T cells (TCM cells) and two types of effector memory T cells (TEM cells and TEMRA cells). Memory cells can be CD4+ or CD8+ cells. Memory T cells typically express the cell surface proteins CD45RO, CD45RA, and / or CCR7.
[0066] "Regulatory T cells" (Treg cells), formerly known as suppressor T cells, play a role in maintaining immune tolerance. The primary role of regulatory T cells is to block T cell-mediated immunity, terminating immune responses and suppressing autoreactive T cells that have escaped the negative selection process in the thymus.
[0067] "Natural killer T cells" (NKT cells, not to be confused with natural killer cells of the innate immune system) act as a bridge between the adaptive and innate immune systems. Unlike conventional T cells, which recognize peptide antigens presented by major histocompatibility complex (MHC) molecules, NKT cells recognize glycolipid antigens presented by a molecule called CD1d. Upon activation, these cells act as T helper (T H NKT cells can perform functions ascribed to both NKT (NKT) cells and cytotoxic T (TC) cells (i.e., production of cytokines and release of cytolytic / cell killing molecules). NKT cells can also recognize and eliminate some tumor cells and cells infected with herpes viruses.
[0068] "Adoptive T cell transfer" refers to the isolation and ex vivo expansion of tumor-specific T cells, achieving a greater number of T cells than can be obtained by vaccination alone or the patient's natural tumor response.Tumor-specific T cells are then infused into patients with cancer in an attempt to give their immune system the ability to overwhelm the remaining tumor through T cells that can attack and kill the cancer.Many forms of adoptive T cell therapy for cancer treatment are used, including culturing tumor-infiltrating lymphocytes or TILs, isolating and expanding one specific T cell or clone, and also using T cells engineered to strongly recognize and attack tumors.
[0069] As used herein, "antibody" refers to a monoclonal or polyclonal antibody. As used herein, the term "monoclonal antibody" refers to an antibody produced by a single clone of B cells and binding to the same epitope. In contrast, a "polyclonal antibody" refers to a population of antibodies produced by different B cells and binding to different epitopes of the same antigen. A whole antibody typically consists of four polypeptides: two identical copies of a heavy (H) chain polypeptide and two identical copies of a light (L) chain polypeptide. Each of the heavy chains contains an N-terminal variable (VH) region and three C-terminal constant (CH1, CH2, and CH3) regions, and each light chain contains an N-terminal variable (VL) region and a C-terminal constant (CL) region. The variable regions of each pair of light and heavy chains form the antigen-binding site of the antibody. The VH and VL regions share a common general structure, each region containing four framework regions whose sequences are relatively conserved. The framework regions are connected by three complementarity determining regions (CDRs). The three CDRs, known as CDR1, CDR2, and CDR3, form the "hypervariable region" of the antibody that is responsible for binding to the antigen.
[0070] An "antibody-like molecule" can be, for example, a protein that is a member of the Ig superfamily, capable of selectively binding to a partner. MHC molecules and T cell receptors are such molecules. In one embodiment, the antibody-like molecule is a TCR. In one embodiment, the TCR is modified to increase its binding affinity to the MHC.
[0071] The terms "fragment of an antibody," "antibody fragment," "functional fragment of an antibody," "antigen-binding portion," or grammatical equivalents thereof, are used interchangeably herein to mean one or more fragments or portions of an antibody that retain the ability to specifically bind to an antigen (see generally Holliger et al., Nat. Biotech., 23(9):1126-1129 (2005)). Antibody fragments desirably include, for example, one or more CDRs, a variable region (or portion thereof), a constant region (or portion thereof), or a combination thereof. Non-limiting examples of antibody fragments include (i) a Fab fragment, which is a monovalent fragment consisting of the VL, VH, CL, and CH1 domains; (ii) a F(ab')2 fragment, which is a bivalent fragment comprising two Fab fragments linked by a disulfide bridge in the stalk region; (iii) an Fv fragment, which consists of the VL and VH domains of a single arm of an antibody; and (iv) a single-chain Fv (scFv), which is a monovalent molecule consisting of the two domains (i.e., VL and VH) of an Fv fragment joined by a synthetic linker that allows the two domains to be synthesized as a single polypeptide chain (see, e.g., Bird et al., Science, 242: 423-426 (1988); Huston et al., Proc. Natl. Acad. Sci. USA, 85: 5879-5883 (1988); and Osbourn et al., Nat. Biotechnol., 16: 778-789 (1989)). (1998); and (v) diabodies, which are dimers of polypeptide chains in which each polypeptide chain comprises a VH connected to a VL by a peptide linker that is too short to allow pairing between the VH and VL on the same polypeptide chain, thereby driving pairing between complementary domains on different VH-VL polypeptide chains to create a dimeric molecule having two functional antigen-binding sites. Antibody fragments are known in the art and are described in more detail, for example, in U.S. Patent No. 8,603,950.
[0072] "Antigen recognition moiety" or "antigen recognition domain" refers to a molecule or a portion of a molecule that specifically binds to an antigen. In one embodiment, the antigen recognition moiety is an antibody, an antibody-like molecule, or a fragment thereof, and the antigen is a tumor antigen.
[0073] The term "conservative amino acid substitution" or "conservative mutation" refers to the replacement of one amino acid with another amino acid with common properties. A functional method of defining common properties between individual amino acids is to analyze the normalized frequency of amino acid changes between corresponding proteins of homologous organisms (Schulz, GE and Schirmer, RH, Principles of Protein Structure, Springer-Verlag, New York (1979)). According to such an analysis, it is possible to define groups of amino acids in which amino acids within a group are preferentially exchanged with each other and thus are most similar to each other in their effect on the overall protein structure (Schulz, GE and Schirmer, RH, supra). Examples of conservative mutations include amino acid substitutions of amino acids within the above subgroups, such as substitution of arginine with lysine, and vice versa, which can maintain a positive charge; substitution of aspartic acid with glutamic acid, and vice versa, which can maintain a negative charge; substitution of threonine with serine, which can maintain a free -OH; and substitution of asparagine with glutamine, which can maintain a free -NH2. Alternatively, or in addition, a functional variant may include the amino acid sequence of a reference protein with at least one non-conservative amino acid substitution.
[0074] The term "non-conservative mutation" involves amino acid substitutions between different groups, such as the substitution of tryptophan with lysine or serine with phenylalanine. In this case, the non-conservative amino acid substitution preferably does not interfere with or inhibit the biological activity of the functional variant. The non-conservative amino acid substitution may enhance the biological activity of the functional variant, such that the biological activity of the functional variant is increased compared to the parent protein.
[0075] The term "ankyrin" refers to a family of adaptor proteins that mediate the attachment of integral membrane proteins to the spectrin-actin based membrane cytoskeleton. Ankyrin has binding sites for the beta subunit of spectrin and at least 12 families of integral membrane proteins. This attachment is required to maintain the integrity of the cell membrane and anchor specific ion channels, ion exchangers and ion transporters in the cell membrane. Ankyrin contains four functional domains: an N-terminal domain containing 24 tandem ankyrin repeats, a central domain that binds spectrin, a death domain that binds proteins involved in apoptosis, and a C-terminal regulatory domain that is highly variable among different ankyrin proteins. The 24 tandem ankyrin repeats contribute to the recognition of a wide range of membrane proteins. These 24 repeats contain three structurally significantly different binding sites ranging from 1 to 14 repeats. These binding sites are semi-independent with respect to each other and can be used in combination. The interactions that the site uses to bind to membrane proteins are non-specific and consist of hydrogen bonds, hydrophobic interactions, and electrostatic interactions. These non-specific interactions give ankyrin the property of recognizing a wide range of proteins, since the sequence does not have to conserve the amino acid properties. Semi-independent means that if a binding site is not used, it does not have a large effect on the overall binding. The combination of these two properties results in a large repertoire of proteins that ankyrin can recognize. In mammals, ankyrin is encoded by three genes (ANK1, ANK2, and ANK3). Each gene gives rise to multiple proteins through alternative splicing.
[0076] "Proliferative disease" as referred to herein refers to the unifying concept that excessive cell proliferation and / or excessive cell-matrix turnover contribute significantly to the pathogenesis of disease, including cancer.
[0077] As used herein, a "patient" or "subject" refers to a mammalian subject diagnosed with or suspected of having or developing a proliferative disorder, such as cancer. In some embodiments, the term "patient" refers to a mammalian subject with a higher than average likelihood of developing a proliferative disorder, such as cancer. Exemplary patients can be humans, apes, dogs, pigs, cows, cats, horses, goats, sheep, rodents, and other mammals that may benefit from the therapies disclosed herein. Exemplary human patients can be male and / or female. As used herein, a "patient in need thereof" or a "subject in need thereof" is considered to be a patient diagnosed with or suspected of having a disease or disorder, such as, but not limited to, human papillomavirus (HPV) infection.
[0078] As used herein, "administering" refers to administering one or more compositions described herein to a patient or subject. By way of example and not limitation, administration, e.g., injection, of a composition can be performed by intravenous (iv), subcutaneous (sc), intradermal (id), intraperitoneal (ip), or intramuscular (im) injection. One or more such routes can be utilized. Parenteral administration can be, for example, by bolus injection or by gradual perfusion over time. Alternatively, or contemporaneously, administration can be by oral route. In addition, administration can also be by bolus or cell pellet depot surgery or by placement of a medical device. In certain embodiments, the compositions of the present disclosure can include engineered or host cells expressing a nucleic acid sequence described herein, or a vector comprising at least one nucleic acid sequence described herein, in an amount effective to treat or prevent a proliferative disorder. Pharmaceutical compositions may comprise the target cell populations described herein in combination with one or more pharma- ceutical or physiologically acceptable carriers, diluents, or excipients.Such compositions may comprise buffers such as neutral buffered saline, phosphate buffered saline, carbohydrates such as glucose, mannose, sucrose, or dextran, mannitol, proteins, amino acids such as polypeptides or glycine, antioxidants, chelating agents such as EDTA or glutathione, adjuvants (e.g., aluminum hydroxide), and preservatives.
[0079] As used herein, the terms "treatment", "treating" or their grammatical equivalents refer to obtaining a desired pharmacological and / or physiological effect. In embodiments, the effect is therapeutic, i.e., the effect partially or completely cures the disease and / or adverse symptoms attributable to the disease. To this end, the method of the invention comprises administering a therapeutically effective amount of a composition comprising a host cell expressing a nucleic acid sequence of the invention or a vector comprising a nucleic acid sequence of the invention.
[0080] The terms "therapeutically effective amount", "therapeutic amount", "immunologically effective amount", "antitumor effective amount", "tumor inhibiting effective amount", or their grammatical equivalents refer to an amount effective at the dosage required for the period of time required to achieve the desired therapeutic result. The therapeutically effective amount may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the compositions described herein to induce a desired response in one or more subjects. The exact amount of the composition of the present disclosure to be administered may be determined by a physician, taking into account the individual differences in the patient's (subject's) age, weight, tumor size, degree of infection or metastasis, and condition.
[0081] Alternatively, the pharmacological and / or physiological effect of administration of one or more compositions described herein to a patient or subject may be "prophylactic", i.e., the effect may prevent, completely or partially, a disease or its symptoms. A "prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result (e.g., prevention of the onset of a disease).
[0082] HPV molecular vaccine Human papillomaviruses (HPV) are a group of over 200 related viruses. Within this large group, each HPV virus is given a number, which is called its HPV type (or serotype). HPVs are small, non-enveloped, deoxyribonucleic acid (DNA) viruses that infect skin or mucosal cells. The circular, double-stranded viral genome is approximately 8 kb in length. The genome encodes seven early proteins (E1-E7) that contribute to viral replication, and two late proteins (L1 and L2), which are viral structural proteins. As depicted in FIG. 1, each gene has a specific function. At least 13 of the over 200 known HPV types cause cervical cancer and are also associated with other anogenital and head and neck cancers. The two most common "high-risk" serotypes (HPV-16 and HPV-18) cause approximately 70% of all cervical cancers. In HPV-16 and HPV-18, two major oncoproteins, E6 and E7, are constitutively expressed by HPV-associated tumors and are crucial for the induction and maintenance of cellular transformation in HPV-infected cells. Recent evidence also suggests that the E5 protein also influences viral transformation. HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82 are considered to be oncogenic. Two "low-risk" HPVs, HPV6 and HPV11, are known to cause genital warts, a common benign condition of the external genitalia that causes significant morbidity. HPV is highly contagious, with the incidence of transmission peaking soon after the onset of sexual activity, and most people will acquire an infection at some point in their lives.
[0083] Prophylactic vaccines consisting of virus-like particles only induce immunity against the capsid structure, but not against the nonstructural proteins that contribute to cellular transformation. Early HPV studies in animal models showed that inoculation with species-specific papillomaviruses induces immune responses that confer protection against homologous viral challenge. However, native papillomaviruses are not good substrates for vaccine development, as they cannot be easily grown in tissue culture. Subsequent studies were initiated on the production of virus particles from the expression of structural proteins in heterologous expression systems, such as yeast or baculovirus better. Results showed that expression of L1 alone results in the production of virus-like particles (VLPs) that resemble authentic HPV virions but do not contain viral DNA. These VLPs are produced by self-assembly of the L1 protein when expressed in a heterologous cell substrate. In animal studies, VLPs were shown to protect against high-dose experimental infection with the homologous virus. HPV VLPs are highly immunogenic in mice or rabbits, and the resulting antibodies have been shown to be neutralizing and HPV type restricted when tested in pseudovirion neutralization assays. Immunization with denatured particles does not result in the production of neutralizing antibodies or protect against experimental viral challenge, indicating that the neutralizing epitopes are conformation dependent.
[0084] Provided herein are compositions, kits, and systems that include HPV recombinant vaccines, as well as methods for making the same. The HPV recombinant vaccines (e.g., HPV designs 1-5) in this disclosure are engineered through protein engineering on E5, E6, and E7. These vaccines contain large, protein-level, sequence consensus among different HPV-16 / HPV-18 isolates. In addition, these vaccines contain genetically engineered mutations to circumvent oncogenic activity, improve their expression, and induce a broad immune response. Also provided herein are multi-epitope recombinant antigens that contain immunogenic epitopes of E5, E6, and E7 proteins. Included with the HPV vaccine designs are certain enhancer agonist peptides that have been shown to activate HPV-specific T cells. In some embodiments, the agonist peptides include one or more peptide sequences shown in Table 2.
[0085] The antigen design of each HPV vaccine was inspired through the combinatorial use of bioinformatics analysis and computational protein engineering methods selected by the inventors, such as antigen sequence selection based on consensus sequence, antigenicity prediction, and T cell epitope mapping targeted to bind to MHC-I and induce cytokine production after T cell activation. The overall workflow for HPV vaccine design disclosed herein is shown in Figure 2 and further detailed in Example 2.
[0086] Naturally occurring sequence variation in many HPV strains presents a major obstacle to the development of an effective, broad-spectrum HPV vaccine. As a solution to this problem, the present vaccine design method uses advanced bioinformatics and protein engineering methods to select and design antigen sequences with broad coverage for T cell epitopes, novel mutations, and enhancer agonist peptides. Taking advantage of available information on antigenic regions with extended coverage for CTL-specific epitopes and computational prediction results, the designed HPV vaccine antigens can induce robust HPV-16 / HPV-18 specific responses, potentially benefiting patients at high risk for HPV-driven cancers.
[0087] This disclosure presents five HPV antigen designs (HPV Designs 1-5) constructed in a multiply deleted gorilla adenovector (GC46). Detailed methods for each of the HPV antigen designs are detailed in Examples 1-3. For RNA qPCR relative expression assays, 5'-TGCCAAGAGTGACGTGTCCA-3' (SEQ ID NO: 110) was used as the splice primer and 5'-CCCAGGTCCAACTGCAGCCGG-3' (SEQ ID NO: 111) was used as the splice probe. Specific primers designed for each antigen were used as reverse primers (Figure 6).
[0088] delivery system Gorilla adenovirus shuttle vector Certain aspects of the present disclosure are directed to vectors comprising a polynucleotide encoding a polypeptide comprising one or more immune response-inducing HPV polypeptides described herein. In certain embodiments, the vector is a viral vector. In certain embodiments, the vector is an adenoviral vector. Adenoviruses are generally associated with benign pathologies in humans, and the genome of adenoviruses, which have been isolated from various species, including humans, has been extensively studied. Adenoviruses are medium-sized (90-100 nm), non-enveloped, icosahedral viruses containing approximately 36 kb of double-stranded DNA. The adenoviral capsid mediates key interactions during the early stages of viral infection of cells and is required for packaging the adenoviral genome at the end of the adenoviral life cycle. The capsid contains 252 capsomers, including 240 hexons, 12 penton base proteins, and 12 fibers (Ginsberg et al., Virology, 28: 782-83 (1966)). The hexons contain three identical proteins, namely, polypeptide II (Roberts et al., Science, 232: 1148-51 (1986)). The penton base contains five identical proteins, and the fiber contains three identical proteins. Proteins IIIa, VI, and IX are present in the adenovirus coat and are thought to stabilize the viral capsid (Stewart et al., Cell, 67: 145-54 (1991); and Stewart et al., EMBO J., 12(7): 2589-99 (1993)). Expression of the capsid proteins, with the exception of pIX, is dependent on the adenovirus polymerase protein, and thus the major components of the adenovirus particle are expressed from the genome only if the polymerase protein gene is present and expressed.
[0089] Several characteristics of adenoviruses make them ideal vehicles for introducing genetic material into cells for therapeutic applications (i.e., "gene therapy") or for use as antigen delivery systems for vaccine applications. For example, adenoviruses can be expressed in high titers (e.g., about 10 13 Adenoviruses can be produced in large particle sizes (pu) and can deliver genetic material to non-replicating and replicating cells. The adenovirus genome can be engineered to carry large amounts of exogenous DNA (up to about 8 kb), and the adenovirus capsid can enhance delivery of even longer sequences (Curiel et al., Hum. Gene Ther., 3: 147-154 (1992)). In addition, adenoviruses generally do not integrate into host cell chromosomes but are maintained as linear episomes, thereby minimizing the potential for recombinant adenoviruses to interfere with normal cellular functions.
[0090] In some embodiments, the adenovirus described herein is isolated from a gorilla. Within two species, Gorilla beringei and Gorilla gorilla, there are four widely recognized subspecies of gorillas. The Western gorilla species includes the subspecies Gorilla gorilla gorilla and Gorilla gorilla diehli. The Eastern gorilla species includes the subspecies Gorilla beringei beringei and Gorilla beringei graueri (see, for example, Wilson and Reeder, eds., Mammalian Species of the World, 3rd ed., Johns Hopkins University Press, Baltimore, Maryland (2005)). In some embodiments, the adenovirus of the present disclosure is isolated from Gorilla beringei beringei.
[0091] Various gorilla adenoviruses or gorilla adenovirus vectors are described in International Patent Applications WO 2013 / 052832; WO 2013 / 052811; and WO 2013 / 052799, each of which is incorporated by reference in its entirety.
[0092] The genomes of several such adenoviruses have been analyzed, and it has been determined that adenoviruses may have a number of partial sequences, each of which is used to uniquely define the adenovirus, i.e., nucleic acid sequences SEQ ID NOs: 1-10, and amino acid sequences SEQ ID NOs: 11-20, e.g., nucleic acid sequences SEQ ID NOs: 21, 22, 23, 24, or 25. SEQ ID NOs: 6-10 encode the amino acid sequences SEQ ID NOs: 16-20, respectively. SEQ ID NOs: 1-5 are subsets of the nucleic acid sequences SEQ ID NOs: 6-10, respectively. SEQ ID NOs: 11-15 are subsets of the amino acid sequences SEQ ID NOs: 16-20, respectively.
[0093] Adenoviruses can be modified in the same manner as previously known adenoviruses, for example to be used as adenovirus vectors, e.g., gene delivery vehicles. Adenoviruses and adenovirus vectors can be replication-competent, conditionally replication-competent, or replication-deficient.
[0094] Replication-competent adenovirus or adenovirus vector can replicate in typical host cell, i.e., in cells that adenovirus can typically infect.Replication-competent adenovirus or adenovirus vector can have one or more mutations (e.g., one or more deletions, insertions, and / or substitutions) in the adenovirus genome that do not inhibit viral replication in host cell, compared with wild-type adenovirus.For example, adenovirus or adenovirus vector can have partial or complete deletion of the adenovirus early region, known as E3 region, which is not essential for the propagation of adenovirus or adenovirus genome.
[0095] Conditionally replicative adenovirus or adenovirus vector is an adenovirus or adenovirus vector that is engineered to replicate under certain conditions.For example, the gene function essential for replication, for example the gene function encoded by adenovirus early region, can be operably linked to an inducible transcription control sequence, a repressible transcription control sequence, or a tissue-specific transcription control sequence, for example, a promoter.In such an embodiment, replication requires the presence or absence of a specificity factor that interacts with the transcription control sequence.Conditionally replicative adenovirus vector is further described in US Patent No. 5,998,205.
[0096] A replication-deficient adenovirus or adenoviral vector is an adenovirus or adenoviral vector that requires complementation of one or more gene functions or gene regions of the adenoviral genome that are required for replication, e.g., as a result of a deficiency in one or more replication-essential gene functions or gene regions, such that the adenovirus or adenoviral vector will not replicate in a typical host cell, particularly a human host cell, that is infected with the adenovirus or adenoviral vector.
[0097] As used herein, a deletion of a gene function or genomic region is defined as a disruption (e.g., deletion) of the genetic material of the adenoviral genome sufficient to eliminate or impair the function of the gene (e.g., such that the function of the gene product is reduced at least about 2-fold, 5-fold, 10-fold, 20-fold, 30-fold, or 50-fold) of which part or all of the nucleic acid sequence has been disrupted (e.g., deleted). Deletion of a complete gene region is not required to disrupt a gene function essential for replication. However, removal of a large portion of one or more gene regions may be desired to provide sufficient space within the adenoviral genome for one or more transgenes. Although deletion of the genetic material is preferred, mutation of the genetic material by addition or substitution is also suitable for disrupting gene function. Gene functions essential for replication are those gene functions required for adenovirus replication (e.g., reproduction) and are encoded, for example, by adenovirus early regions (e.g., E1, E2, and E4 regions), late regions (e.g., L1, L2, L3, L4, and L5 regions), genes involved in viral packaging (e.g., the IVa2 gene), and virus-associated RNAs (e.g., VA-RNA-1 and / or VA-RNA-2).
[0098] Whether the adenovirus or adenovirus vector is replication-competent or replication-defective, the adenovirus or adenovirus vector retains at least a part of the adenovirus genome. The adenovirus or adenovirus vector can contain any part of the adenovirus genome, including protein-coding and non-protein-coding regions. It is desirable that the adenovirus or adenovirus vector contains at least one nucleic acid sequence that codes for an adenovirus protein. The adenovirus or adenovirus vector can contain any suitable nucleic acid sequence that codes for an adenovirus protein, such as the protein that is encoded by any one of the early region genes (i.e., E1A, E1B, E2A, E2B, E3, and / or E4 regions) or the protein that is encoded by any one of the late region genes (i.e., L1, L2, L3, L4, and L5 regions), which codes for viral structural proteins.
[0099] It is desirable that the adenovirus or adenovirus vector comprises one or more nucleic acid sequences that code for pIX protein, DNA polymerase protein, penton protein, hexon protein, and / or fiber protein.The adenovirus or adenovirus vector may comprise a full-length nucleic acid sequence that codes for the full-length amino acid sequence of an adenovirus protein.Alternatively, the adenovirus or adenovirus vector may comprise a portion of a full-length nucleic acid sequence that codes for a portion of the full-length amino acid sequence of an adenovirus protein.
[0100] A "portion" of a nucleic acid sequence comprises at least 10 nucleotides (e.g., about 10 to about 5000 nucleotides). Preferably, a "portion" of a nucleic acid sequence comprises 10 or more (e.g., 15 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, 50 or more, or 100 or more) nucleotides, but less than 5,000 (e.g., 4900 or less, 4000 or less, 3000 or less, 2000 or less, 1000 or less, 800 or less, 500 or less, 300 or less, or 100 or less) nucleotides. Preferably, the portion of the nucleic acid sequence is about 10 to about 3500 nucleotides (e.g., about 10, 20, 30, 50, 100, 300, 500, 700, 1000, 1500, 2000, 2500, or 3000 nucleotides), about 10 to about 1000 nucleotides (e.g., about 25, 55, 125, 325, 525, 725, or 925 nucleotides), or about 10 to about 500 nucleotides (e.g., about 15, 30, 40, 50, 60, 70, 80, 90, 150, 175, 250, 275, 350, 375, 450, 475, 480, 490, 495, or 499 nucleotides), or a range defined by any two of the foregoing values. More preferably, a "portion" of a nucleic acid sequence comprises about 3200 nucleotides or less (e.g., about 10 to about 3200 nucleotides, about 10 to about 3000 nucleotides, or about 30 to about 500 nucleotides, or a range defined by any two of the foregoing values).
[0101] A "portion" of an amino acid sequence includes at least 3 amino acids (e.g., about 3 to about 1,200 amino acids). Preferably, a "portion" of an amino acid sequence includes 3 or more amino acids (e.g., 5 or more, 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 40 or more, or 50 or more) but fewer than 1,200 amino acids (e.g., 1,000 or less, 800 or less, 700 or less, 600 or less, 500 or less, 400 or less, 300 or less, 200 or less, or 100 or less). Preferably, the portion of the amino acid sequence is about 3 to about 500 amino acids (e.g., about 10, 100, 200, 300, 400, or 500 amino acids), about 3 to about 300 amino acids (e.g., about 20, 50, 75, 95, 150, 175, or 200 amino acids), or about 3 to about 100 amino acids (e.g., about 15, 25, 35, 40, 45, 60, 65, 70, 80, 85, 90, 95, or 99 amino acids), or a range defined by any two of the preceding values. More preferably, the "portion" of the amino acid sequence contains about 500 amino acids or less (e.g., about 3 to about 400 amino acids, about 10 to about 250 amino acids, or about 50 to about 100 amino acids, or a range defined by any two of the preceding values).
[0102] The adenovirus pIX protein is present within the adenovirus capsid and has been shown to enhance the hexon-nonamer interaction and is essential for packaging the full-length genome (see, e.g., Boulanger et al., J. Gen. Virol., 44: 783-800 (1979); Horwitz MS, “Adenoviridae and their replication” in Virology, 2 nded., BN Fields et al. (eds.), Raven Press, Ltd., New York, pp. 1679-1721 (1990), Ghosh-Choudhury et al., EMBO J., 6: 1733-1739 (1987) and van Oostrum et al, J. Virol., 56: 439-448 (1985). In addition to its contribution to adenovirus structure, pIX has also been shown to exhibit transcriptional properties, such as stimulating the activity of the adenovirus major late promoter (MLP) (see, e.g., Lutz et al., J. Virol., 71(7): 5102-5109 (1997)). Nucleic acid sequences encoding all or part of the adenovirus pIX protein include, for example, SEQ ID NO:6 and SEQ ID NO:1. Amino acid sequences including the full-length pIX protein or portions thereof include, for example, SEQ ID NO:16 and SEQ ID NO:11.
[0103] Adenovirus DNA polymerase protein is essential for viral DNA replication both in vitro and in vivo. The polymerase is co-purified as a complex with the precursor of the terminal protein (TP) (pTP) covalently attached to the 5' end of adenovirus DNA (Field et al., J. Biol. Chem., 259: 9487-9495 (1984)). Both adenovirus DNA polymerase and pTP are encoded by the E2 region. The polymerase protein is required for the expression of all structural proteins except pIX. Without the gene sequence of the polymerase protein, the polymerase protein is not produced. As a result, the viral genome is not replicated, the major late promoter is not activated, and the capsid protein is not expressed. Nucleic acid sequences encoding all or part of the adenovirus DNA polymerase protein include, for example, SEQ ID NO:7 and SEQ ID NO:2. Amino acid sequences containing full length adenoviral DNA polymerase or portions thereof include, for example, SEQ ID NO:17 and SEQ ID NO:12.
[0104] Adenovirus hexon protein is the largest and most abundant protein in adenovirus capsid.Hexon protein is essential for viral capsid assembly, determining the icosahedral symmetry of capsid (which defines capsid capacity and DNA packaging size), and capsid integrity.In addition, hexon is the first target for modification to reduce the neutralization of adenovirus vectors (see, for example, Gall et al., J. Virol., 72: 10260-264 (1998) and Rux et al., J. Virol., 77(17): 9553-9566 (2003)). The major structural features of the hexon protein are shared by adenoviruses across serotypes, although the hexon proteins differ in size and immunological properties between serotypes (Jornvall et al., J. Biol. Chem., 256(12): 6181-6186 (1981)). Comparison of 15 adenovirus hexon proteins revealed that the major antigenic and serotype-specific regions of the hexon are loops 1 and 2 (i.e., LI or l1, and LII or l2, respectively), within which there are seven distinct hypervariable regions (HVR1-HVR7) that vary in length and sequence between adenovirus serotypes (Crawford-Miksza et al., J. Virol., 70(3): 1836-1844 (1996)). Nucleic acid sequences encoding all or part of the adenovirus hexon protein include, for example, SEQ ID NO:9 and SEQ ID NO:4. Amino acid sequences containing the full-length adenoviral hexon protein, or portions thereof, include, for example, SEQ ID NO:19 and SEQ ID NO:14.
[0105] Adenovirus fiber proteins are homotrimers of adenovirus type IV polypeptides with three domains: tail, shaft, and knob (Devaux et al., J. Molec. Biol., 215: 567-88 (1990), Yeh et al., Virus Res., 33: 179-98 (1991)). The fiber protein mediates primary virus binding to receptors on the cell surface via the knob and shaft domains (Henry et al., J. Virol., 68(8): 5239-46 (1994)). The amino acid sequence for trimerization is located within the knob, which is thought to be necessary for proper association of the amino terminus (tail) of the fiber with the penton base (Novelli et al., Virology, 185: 365-76 (1991)). In addition to recognizing cellular receptors and binding to the penton base, the fiber also contributes to serotype discrimination. Fiber proteins from different adenovirus serotypes vary considerably (see, e.g., Green et al., EMBO J., 2: 1357-65 (1983), Chroboczek et al., Virology, 186: 280-85 (1992); and Signas et al., J. Virol., 53: 672-78 (1985)). Thus, fiber proteins have multiple functions that are important in the adenovirus life cycle. Nucleic acid sequences encoding all or portions of adenovirus fiber proteins include, for example, SEQ ID NO:10 and SEQ ID NO:5. Amino acid sequences comprising full-length adenovirus fiber proteins, or portions thereof, include, for example, SEQ ID NO:20 and SEQ ID NO:15.
[0106] The adenovirus penton base protein is located at the vertices of the icosahedral capsid and contains five identical monomers. The penton base protein provides a structure that bridges the hexon proteins on multiple facets of the icosahedral capsid, providing an essential interface for fiber proteins to be incorporated into the capsid. Each penton base monomer contains an RGD tripeptide motif (Neumann et al., Gene, 69: 153-157 (1988)). The RGD tripeptide mediates binding to αv integrins, and adenoviruses with point mutations in the RGD sequence of the penton base are restricted in their ability to infect cells (Bai et al., J. Virol., 67: 5198-5205 (1993)). Thus, the penton base protein is essential for the architecture of the capsid and for maximum efficiency of virus-cell interactions. Nucleic acid sequences encoding all or a portion of an adenoviral penton base protein include, for example, SEQ ID NO: 8 and SEQ ID NO: 3. Amino acid sequences including a full-length adenoviral penton base protein, or a portion thereof, include, for example, SEQ ID NO: 18 and SEQ ID NO: 13.
[0107] The "identity" of a nucleic acid or amino acid sequence as described herein may be determined by comparing a nucleic acid or amino acid sequence of interest with a reference nucleic acid or amino acid sequence. The number of nucleotides or amino acid residues that are changed and / or modified (e.g., by point mutation, insertion, or deletion, etc.) in the reference sequence to result in the sequence of interest is counted. The total number of such changes is subtracted from the total length of the sequence of interest, and the difference is divided by the length of the sequence of interest and expressed as a percentage. Numerous mathematical algorithms are known and incorporated into many available software programs for obtaining optimal alignment and calculating the identity between two or more sequences. Examples of such programs include CLUSTAL-W, T-Coffee, and ALIGN (for aligning nucleic acid and amino acid sequences), BLAST programs (e.g., BLAST 2.1, BL2SEQ, and their latest versions), and FASTA programs (e.g., FASTA3x, FASTM, and SSEARCH) (for sequence alignment and searching for sequence similarity).Sequence alignment algorithms are also disclosed, for example, in Altschul et al., J. Molecular Biol., 215(3): 403-410 (1990), Beigert et al., Proc. Natl. Acad. Sci. USA, 106(10): 3770-3775 (2009), Durbin et al., eds., Biological Sequence Analysis: Probabilistic Models of Proteins and Nucleic Acids, Cambridge University Press, Cambridge, UK (2009), Soding, Bioinformatics, 21(7): 951-960 (2005), Altschul et al., Nucleic Acids Res., 25(17): 3389-3402 (1997) and Gusfield, Algorithms on Strings, Trees and Sequences, Cambridge University Press, Cambridge UK (1997).
[0108] The adenovirus or adenoviral vector may comprise one, two, three, four, or all five of the above sequences, either alone or in any combination. In this regard, the adenovirus or adenoviral vector may comprise any two, any combination of the above sequences, any three, any combination of the above sequences, any four, any combination of the above sequences, or all five of the above sequences.
[0109] As discussed herein, adenovirus or adenovirus vector can be replication-competent, conditionally replicating, or replication-defective.Preferably, adenovirus or adenovirus vector is replication-defective, so that replication-defective adenovirus or adenovirus vector requires the complementation of at least one replication-essential gene function of one or more regions of adenovirus genome for reproduction (e.g., for forming adenovirus vector particle).
[0110] Replication-defective adenovirus or adenovirus vector can be modified in any suitable manner to cause the deficiency of one or more replication-essential gene functions in one or more regions of the adenovirus genome for reproduction. Complementation of the deficiency of one or more replication-essential gene functions in one or more regions of the adenovirus genome refers to the use of exogenous means to bring about the deletion of the replication-essential gene functions. Such complementation can be made in any suitable manner, for example, by using the complementation of cells and / or exogenous DNA (e.g., helper adenovirus) that codes for the disrupted replication-essential gene functions.
[0111] Adenoviruses or adenoviral vectors can be deleted for one or more replication-essential gene functions in only the early region of the adenoviral genome (i.e., E1-E4 region), only the late region of the adenoviral genome (i.e., L1-L5 region), both the early and late regions of the adenoviral genome, or all adenoviral genes (i.e., high-capacity adeno vectors (HC-Ad)). See Morsy et al., Proc. Natl. Acad. Sci. USA, 95: 965-976 (1998); Chen et al., Proc. Natl. Acad. Sci. USA, 94: 1645-1650 (1997); and Kochanek et al., Hum. Gene Ther., 10: 2451-2459 (1999). Examples of replication-defective adenoviral vectors are disclosed in U.S. Pat. Nos. 5,837,511; 5,851,806; 5,994,106; 6,127,175; 6,482,616; and 7,195,896, as well as International Patent Application Publication Nos. WO 1994 / 028152, WO 1995 / 002697, WO 1995 / 016772, WO 1995 / 034671, WO 1996 / 022378, WO 1997 / 012986, WO 1997 / 021826, and WO 2003 / 022311.
[0112] The early regions of the adenoviral genome include the E1, E2, E3, and E4 regions. The E1 region includes the E1A and E1B subregions, and one or more deletions in the E1 region of the gene functions essential for replication are deletions in one or both of the E1A and E1B subregions of the gene functions essential for replication, thereby requiring complementation of the E1A and / or E1B subregions of the adenoviral genome for the adenovirus or adenoviral vector to propagate (e.g., to form adenoviral vector particles). The E2 region comprises the E2A and E2B subregions, and one or more deletions in gene functions essential for replication within the E2 region can include deletions in one or both of the E2A and E2B subregions in gene functions essential for replication, such that an adenovirus or adenoviral vector requires complementation of the E2A and / or E2B subregions of the adenoviral genome in order to propagate (e.g., to form adenoviral vector particles).
[0113] The E3 region does not contain gene functions essential for replication, so that a partial or complete deletion of the E3 region does not require the complementation of any gene functions in the E3 region for the adenovirus or adenovirus vector to propagate (e.g., form adenovirus vector particles). In the context of the present disclosure, the E3 region is defined as the region beginning with an open reading frame encoding a protein with high homology to the 12.5K protein (NCBI reference sequence: AP_000218) from the E3 region of human adenovirus 5, and ending with an open reading frame encoding a protein with high homology to the 14.7K protein (NCBI reference sequence: AP_000224.1) from the E3 region of human adenovirus 5. The E3 region can be partially or completely deleted, or partially or completely retained. The size of the deletion can be fine-tuned to retain the adenovirus or adenovirus vector whose genome closely matches the optimal genome packaging size. Large deletions may accommodate the insertion of large heterologous nucleic acid sequences within the adenovirus or adenovirus genome. In one embodiment of the present disclosure, the L4 polyadenylation signal sequence present in the E3 region is retained.
[0114] The E4 region contains multiple open reading frames (ORFs). An adenovirus or adenoviral vector in which all open reading frames in the E4 region, except ORF6, and optionally, except ORF3, have been deleted, does not require complementation of any gene functions within the E4 region for the adenovirus or adenoviral vector to propagate (e.g., form adenoviral vector particles). Conversely, adenoviruses or adenovirus vectors with disruption or deletion of ORF6 of the E4 region, optionally with disruption or deletion of ORF3 (e.g., deleting replication-essential gene functions based on ORF6 and / or ORF3 of the E4 region), with or without disruption or deletion of any of the other open reading frames of the E4 region or the native E4 promoter, polyadenylation sequence, and / or right ITR (inverted terminal repeat), require complementation of the E4 region (specifically, complementation of ORF6 and / or ORF3 of the E4 region) for the adenovirus or adenovirus vector to propagate (e.g., to form adenovirus vector particles). The late regions of the adenovirus genome include the L1, L2, L3, L4, and L5 regions. The adenovirus or adenoviral vector can also have a mutation in the major late promoter (MLP) that can render the adenovirus or adenoviral vector replication-deficient, if desired, as discussed in International Patent Application Publication No. WO 2000 / 000628.
[0115] It is desirable that the one or more regions of the adenoviral genome containing one or more deletions in gene functions essential for replication be one or more early regions of the adenoviral genome, i.e., the E1, E2, and / or E4 regions, optionally with a deletion in part or all of the E3 region.
[0116] Replication-defective adenovirus or adenovirus vector can also have one or more mutations (e.g., one or more deletions, insertions, and / or substitutions) in the adenovirus genome that do not inhibit viral replication in host cells, compared to wild-type adenovirus.Thus, in addition to one or more deletions of the gene functions essential for replication, adenovirus or adenovirus vector can also be defective in other respects that are not essential for replication.For example, adenovirus or adenovirus vector can have partial or complete deletion of the adenovirus early region known as E3 region, which is not essential for the propagation of adenovirus or adenovirus genome.
[0117] In one embodiment, the adenovirus or adenovirus vector is replication-defective and requires at most the complementation of the E1 region or E4 region of the adenovirus genome for reproduction (e.g., for forming adenovirus vector particles).Therefore, the replication-defective adenovirus or adenovirus vector requires the complementation of at least one replication-essential gene function of the E1A subregion and / or E1B region of the adenovirus genome (represented as E1-defective adenovirus vector) or the E4 region of the adenovirus genome (represented as E4-defective adenovirus vector) for reproduction (e.g., for forming adenovirus vector particles).The adenovirus or adenovirus vector can be deficient in at least one replication-essential gene function (desirably all replication-essential gene functions) of the E1 region of the adenovirus genome and at least one gene function of the non-essential E3 region of the adenovirus genome (represented as E1 / E3-defective adenovirus vector). The adenovirus or adenoviral vector can be deleted for at least one replication-essential gene function in the E4 region of the adenoviral genome (desirably, all replication-essential gene functions), and for at least one non-essential gene function in the E3 region of the adenoviral genome (denoted an E3 / E4-defective adenoviral vector).
[0118] In one embodiment, adenovirus or adenovirus vector is replication-defective and requires at most the complementation of the E2 region of the adenovirus genome, preferably the E2A subregion, for reproduction (e.g., for forming adenovirus vector particles).Therefore, replication-defective adenovirus or adenovirus vector requires the complementation of at least one replication-essential gene function of the E2A subregion of the adenovirus genome (represented as E2A-defective adenovirus vector) for reproduction (e.g., for forming adenovirus vector particles).Adenovirus or adenovirus vector can be deficient in at least one replication-essential gene function (preferably all replication-essential gene functions) of the E2A region of the adenovirus genome and at least one gene function of the non-essential E3 region of the adenovirus genome (represented as E2A / E3-defective adenovirus vector).
[0119] In one embodiment, the adenovirus or adenovirus vector is replication-deficient and requires the complementation of the E1 and E4 regions of the adenovirus genome for reproduction (e.g., for forming adenovirus vector particles). Thus, the replication-deficient adenovirus or adenovirus vector requires the complementation of at least one replication-essential gene function of both the E1 and E4 regions of the adenovirus genome (denoted as E1 / E4-deficient adenovirus vector) for reproduction (e.g., for forming adenovirus vector particles). The adenovirus or adenovirus vector can be deficient in at least one replication-essential gene function (desirably all replication-essential gene functions) of the E1 region of the adenovirus genome, at least one replication-essential gene function of the E4 region of the adenovirus genome, and at least one gene function of the non-essential E3 region of the adenovirus genome (denoted as E1 / E3 / E4-deficient adenovirus vector). The adenovirus or adenovirus vector preferably requires, at most, a complementation of the E1 region of the adenovirus genome for reproduction, but does not require a complementation of any other defects of the adenovirus genome for reproduction. More preferably, the adenovirus or adenovirus vector requires, at most, a complementation of the E1 and E4 regions of the adenovirus genome for reproduction, but does not require a complementation of any other defects of the adenovirus genome for reproduction.
[0120] Adenoviruses or adenoviral vectors, when multiple replication-essential gene functions of the adenoviral genome are deleted (e.g., E1 / E4-deleted adenoviral vectors), may contain a spacer sequence that results in viral growth in a complementing cell line similar to that achieved by an adenovirus or adenoviral vector (e.g., E1-deleted adenoviral vector) that is deleted for a single replication-essential gene function. The spacer sequence may contain any one or more nucleotide sequences of any desired length, such as at least about 15 base pairs (e.g., between about 15 nucleotides and about 12,000 nucleotides), preferably about 100 nucleotides to about 10,000 nucleotides, more preferably about 500 nucleotides to about 8,000 nucleotides, even more preferably about 1,500 nucleotides to about 6,000 nucleotides, and most preferably about 2,000 to about 3,000 nucleotides in length, or a range defined by any two of the preceding values. The spacer sequence may be a coding or non-coding sequence, a natural or non-natural sequence in the context of the adenovirus genome, but does not restore essential functions for replication to the deleted region. The spacer may also contain an expression cassette. More preferably, the spacer comprises a polyadenylation sequence and / or a polyadenylation gene that is non-native in the context of the adenovirus or adenovirus vector. The use of spacers in adenovirus vectors is further described, for example, in U.S. Pat. No. 5,851,806 and WO 1997 / 021826.
[0121] By removing all or part of the adenovirus genome, for example, the E1, E3 and E4 regions of the adenovirus genome, the resulting adenovirus or adenovirus vector can accept the insertion of an exogenous nucleic acid sequence while retaining the ability to be packaged into adenovirus capsid.The exogenous nucleic acid sequence can be inserted into any position in the adenovirus genome, as long as the insertion into the position allows the formation of an adenovirus particle or an adenovirus vector particle.The exogenous nucleic acid sequence is preferably located in the E1, E3 or E4 region of the adenovirus genome.
[0122] The replication-defective adenovirus or adenovirus vector of the present disclosure can be produced in a complementing cell line that provides gene functions that are not present in the replication-defective adenovirus or adenovirus vector, but are required for the virus to propagate at an appropriate level to generate high-titer virus vector stocks.Such complementing cell lines are known and include, but are not limited to, 293 cells (e.g., as described in Graham et al., J. Gen. Virol., 36: 59-72 (1977)), PER.C6 cells (e.g., as described in International Patent Application Publication No. 1997 / 000326, and U.S. Patent Nos. 5,994,128 and 6,033,908), and 293-ORF6 cells (e.g., as described in International Patent Application Publication No. 95 / 34671 and Brough et al., J. Virol., 71: 9206-9213 (1997)). Other complementing cell lines suitable for producing the replication-defective adenovirus or adenovirus vector of the present disclosure include complementing cells (see, for example, US Patent Application Publication No. 2008 / 0233650) that are made to propagate adenovirus vectors, whose expression encodes a transgene that inhibits viral growth in host cells.Additional suitable complementing cells are described, for example, in US Patent Nos. 6,677,156 and 6,682,929 and International Patent Application Publication No. 2003 / 020879.In some cases, the intracellular genome does not need to contain the nucleic acid sequence whose gene product complements all of the defects of the replication-defective adenovirus vector. One or more replication-essential gene functions that are lacking in a replication-deficient adenoviral vector can be provided by a helper virus, e.g., an adenoviral vector, which provides in trans one or more essential gene functions required for replication of the replication-deficient adenovirus or adenoviral vector.Alternatively, the adenovirus or adenoviral vector of the present invention may contain a non-native replication-essential gene that complements one or more replication-essential gene functions that are lacking in the replication-deficient adenovirus or adenoviral vector of the present invention. For example, an E1 / E4-deficient adenovirus vector can be engineered to contain a nucleic acid sequence encoding E4 ORF 6 obtained or derived from a different adenovirus (e.g., an adenovirus of a different serotype than the adenovirus or adenoviral vector of the present invention, or an adenovirus of a different species than the adenovirus or adenovirus vector of the present invention).
[0123] The adenovirus or adenoviral vector may further comprise a transgene. As used herein, the term "transgene" is defined as a non-natural nucleic acid sequence that is operably linked to a suitable regulatory element (e.g., promoter) to express the non-natural nucleic acid sequence to produce a protein (e.g., peptide or polypeptide). The regulatory element (e.g., promoter) may be native or non-native to the adenovirus or adenoviral vector.
[0124] A "non-native" nucleic acid sequence is any nucleic acid sequence (e.g., a DNA sequence, an RNA sequence, or a cDNA sequence) that is not a naturally occurring nucleic acid sequence of an adenovirus in its naturally occurring location. Thus, a non-native nucleic acid sequence may be naturally found in an adenovirus, but may be located in a non-native location in the adenovirus genome and / or may be operably linked to a non-native promoter. In the context of the present disclosure, the terms "non-native nucleic acid sequence", "heterologous nucleic acid sequence", and "exogenous nucleic acid sequence" are synonymous and may be used interchangeably. A non-native nucleic acid sequence is preferably DNA and is preferably protein-coding (i.e., one or more nucleic acid sequences that code for one or more proteins).
[0125] The non-naturally occurring nucleic acid sequence may code for a therapeutic protein that can be used to prophylactically or therapeutically treat a mammal for a disease. Examples of suitable therapeutic proteins include cytokines, toxins, tumor suppressor proteins, growth factors, hormones, receptors, mitogens, immunoglobulins, neuropeptides, neurotransmitters, and enzymes. Alternatively, the non-naturally occurring nucleic acid sequence can code for an antigen of a pathogen (e.g., a bacterium or virus), and the adenovirus or adenoviral vector can be used as a vaccine.
[0126] Viral-Based Delivery Systems The present disclosure also provides delivery systems, such as the nucleic acid-inserted virus-based systems described herein. Representative viral expression vectors include, but are not limited to, adeno-associated virus vectors, adenovirus-based vectors, lentivirus-based vectors, retrovirus vectors, and herpes virus-based vectors. In an embodiment, the viral vector is a lentivirus vector. Vectors derived from retroviruses, such as lentiviruses, are suitable tools for achieving long-term gene transfer, since they allow long-term, stable integration and propagation of transgenes in daughter cells. Lentivirus vectors have the added advantage over vectors derived from oncoretroviruses, such as murine leukemia viruses, in that they can transduce non-proliferating cells, such as hepatocytes. Lentivirus vectors also have the added advantage of low immunogenicity. In a further embodiment, the viral vector is an adeno-associated virus vector. In a further embodiment, the viral vector is a retrovirus vector. Generally, and in embodiments, a suitable vector contains an origin of replication functional in at least one organism, a promoter sequence, convenient restriction endonuclease sites, and one or more selectable markers.
[0127] Further suitable vectors include integrating expression vectors, which may be randomly integrated into the DNA of a host cell or may contain recombination sites that allow specific recombination of the expression vector with the host cell chromosome. Such integrating expression vectors can use the endogenous expression control sequences of the host cell chromosome to provide the expression of the desired protein. Examples of site-specific integrating vectors include, for example, the flp-in system from Invitrogen (Carlsbad, Calif.) (e.g., pcDNA™5 / FRT) or components of the cre-lox system, such as the cre-lox system found in the pExchange-6 Core Vectors from Stratagene (LaJolla, Calif.). Examples of vectors that randomly integrate into a host cell chromosome include, for example, pcDNA3.1 (when introduced in the absence of T antigen) from Invitrogen (Carlsbad, Calif.), and pCI or pFN10A(ACT)FLEXI™ from Promega (Madison, Wis.). Additional promoter elements, such as enhancers, regulate the frequency of transcription initiation. Typically, promoter elements are located within the region 30-110 bp upstream of the start site, although many promoters have recently been shown to contain functional elements downstream of the start site as well. The spacing between promoter elements is often flexible so that promoter function is preserved even when elements are inverted or moved relative to each other. In the thymidine kinase (tk) promoter, the spacing between promoter elements can increase to a distance of 50 bp before activity begins to decay. It is believed that individual elements may function synergistically or independently to activate transcription, depending on the promoter.
[0128] One example of a suitable promoter is the cytomegalovirus (CMV) immediate early promoter sequence, which is a strong constitutive promoter sequence capable of driving high levels of expression of any polynucleotide sequence operably linked to it.
[0129] However, other constitutive promoter sequences can also be used, including, but not limited to, simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV), human immunodeficiency virus (HIV) LTR (long terminal repeat) promoter, MoMuLV promoter, avian leukosis virus promoter, Epstein-Barr virus immediate early promoter, Rous sarcoma virus promoter, as well as human gene promoters, such as, but not limited to, actin promoter, myosin promoter, hemoglobin promoter, and creatine kinase promoter. Furthermore, the present disclosure is not intended to be limited to the use of constitutive promoters. Inducible promoters are also contemplated as part of the present disclosure. The use of an inducible promoter provides a molecular switch that can turn on expression of a polynucleotide sequence to which it is operably linked when such expression is desired, or turn off expression when expression is not desired. Examples of inducible promoters include, but are not limited to, metallothionein promoter, glucocorticoid promoter, progesterone promoter, and tetracycline promoter.
[0130] Reporter genes can be used to identify potentially transfected cells and assess the functionality of regulatory sequences. In general, reporter genes are genes that are not present in or expressed by recipient organisms or tissues and code for a polypeptide whose expression is manifested by some easily detectable property, such as enzymatic activity. At a suitable time after the DNA is introduced into the recipient cells, the reporter gene expression is assayed. Suitable reporter genes may include luciferase, beta-galactosidase, chloramphenicol acetyltransferase, genes encoding secreted alkaline phosphatase, or green fluorescent protein genes (e.g., Ui-Tei et al., FEBS Letters 479: 79-82 (2000)). Suitable expression systems are well known and can be prepared using known techniques or purchased commercially. In general, the construct with the minimal 5' flanking region that shows the highest level of reporter gene expression is identified as the promoter. Such promoter regions can be linked to a reporter gene and used to assess agents for their ability to modulate promoter-driven transcription.
[0131] The method of introducing and expressing genes into cells is known in the art.In the context of expression vectors, the vector can be easily introduced into host cells, such as mammalian cells, bacterial cells, yeast cells, or insect cells, by any method in the art.For example, the expression vector can be introduced into host cells by physical means, chemical means, or biological means.
[0132] The physical method for introducing polynucleotide into host cell includes calcium phosphate precipitation, lipofection, gene gun, microinjection, electroporation, etc. The method for making cells containing vector and / or exogenous nucleic acid is well known in the art. For example, see Sambrook et al. (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York (2001)). In some embodiments, the method for introducing polynucleotide into host cell is calcium phosphate transfection or polyethyleneimine (PEI) transfection.
[0133] Biological methods for introducing a polynucleotide of interest into a host cell include the use of DNA vectors and RNA vectors.Viral vectors, and especially retroviral vectors, have become the most widely used method for inserting genes into mammalian cells, such as human cells.Other viral vectors can be derived from lentiviruses, poxviruses, herpes simplex virus I, adenoviruses, and adeno-associated viruses, etc.See, for example, U.S. Patent Nos. 5,350,674 and 5,585,362.
[0134] Non-viral-based delivery systems Chemical means for introducing polynucleotides into host cells include macromolecular complexes, nanocapsules, microspheres, beads, and colloidal dispersion systems such as lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. An exemplary colloidal system for use as a delivery vehicle in vitro and in vivo is a liposome (e.g., an artificial membrane vesicle).
[0135] The use of lipid formulations is envisioned for the introduction of nucleic acids into host cells (in vitro, ex vivo, or in vivo). In another embodiment, the nucleic acid can be associated with lipids. The lipid-associated nucleic acid can be encapsulated in the aqueous liposome interior, interspersed within the lipid bilayer of the liposome, can be attached to the liposome via a linking molecule that is associated with both the liposome and the oligonucleotide, can be incorporated within the liposome, can be complexed with the liposome, can be dispersed in a solution containing lipids, can be mixed with lipids, can be combined with lipids, can be contained as a suspension in lipids, can be contained or complexed with micelles, or can be otherwise associated with lipids. The lipid, lipid / DNA, or lipid / expression vector-related compositions are not limited to any particular structure in solution. For example, the composition can be present in a bilayer structure as a micelle, or can be present in a bilayer structure with a "collapsing" structure. The composition can also simply be interspersed in the solution, forming aggregates that are perhaps not homogeneous in size or shape. Lipids are fatty substances that may be natural or synthetic. For example, lipids include the fatty droplets that occur naturally in the cytoplasm, as well as a class of compounds that contain long-chain aliphatic hydrocarbons and their derivatives, such as fatty acids, alcohols, amines, aminoalcohols, and aldehydes.
[0136] Lipids suitable for use can be purchased from commercial sources. For example, dimyristyl phosphatidylcholine ("DMPC") can be purchased from Sigma, St. Louis, Mo., dicetyl phosphate ("DCP") can be purchased from K & K Laboratories (Plainview, NY), cholesterol ("Choi") can be purchased from Calbiochem-Behring, and dimyristyl phosphatidylglycerol ("DMPG") and other lipids can be purchased from Avanti Polar Lipids, Inc. (Birmingham, Ala.). Lipid stock solutions in chloroform or chloroform / methanol can be stored at about -20°C. Chloroform is used as the only solvent because it evaporates more readily than methanol. "Liposome" is a general term that encompasses a variety of single and multi-layered lipid vehicles formed by the creation of bilayers or lipid aggregates of encapsulated lipids. Liposomes can be characterized as having a vesicular structure with a phospholipid bilayer membrane and an internal aqueous medium. Multilamellar liposomes have multiple lipid layers separated by aqueous medium. Multilamellar liposomes form spontaneously when phospholipids are suspended in an excess of aqueous solution. The lipid components undergo autotransition before forming a closed structure, incorporating water and dissolved solutes between the lipid bilayers (Ghosh et al., Glycobiology 5: 505-10 (1991)). However, compositions with structures in solution that differ from the normal vesicular structure are also encompassed. For example, lipids may adopt micellar structures or exist as heterogeneous aggregates of lipid molecules. Lipofectamine-nucleic acid complexes are also contemplated.
[0137] In some cases, the polynucleotide encoding the polypeptide can also be introduced into cells using a non-viral-based delivery system, such as the "Sleeping Beauty (SB) transposon system", which refers to a synthetic DNA transposon system for introducing DNA sequences into vertebrate chromosomes. Some exemplary embodiments of the system are described, for example, in U.S. Patent Nos. 6,489,458 and 8,227,432. The Sleeping Beauty transposon system is composed of Sleeping Beauty (SB) transposase and SB transposon. In some embodiments, the Sleeping Beauty transposon system can include SB11 transposon system, SB100R transposon system, or SB110 transposon system.
[0138] DNA transposons translocate from one DNA site to another in a simple cut-and-paste manner. Transposition is a precise process in which a defined DNA segment is excised from one DNA molecule and moved to another site within the same DNA molecule or genome, or within a different DNA molecule or genome. Like other Tc1 / mariner-type transposases, SB transposase inserts the transposon into a TA dinucleotide base pair in the recipient DNA sequence. The insertion site can be another site within the same DNA molecule or another DNA molecule (or chromosome). There are approximately 200 million TA sites in mammalian genomes, including the human genome. The TA insertion sites are duplicated during the process of transposon integration. This duplication of the TA sequence is a hallmark of transposition and is used in some experiments to validate the mechanism. Transposase may be encoded in transposon, or transposase may be provided by another source, for example, DNA source or mRNA source, in which case transposon becomes a non-autonomous element.Non-autonomous transposons are most useful as genetic tools because they cannot be excised and reinserted independently after insertion.SB transposon is intended to be used as a non-viral vector for gene introduction into vertebrate genome and gene therapy.
[0139] Regardless of the method used to introduce exogenous nucleic acid into a host cell or otherwise expose the cell to the inhibitor of the present disclosure, various assays can be performed to confirm the presence of recombinant DNA sequences in the host cell. Such assays include molecular assays well known to those skilled in the art, such as Southern and Northern blots, RT-PCR and PCR; "biochemical" assays, such as assays that detect the presence or absence of specific peptides, for example, by immunological means (ELISA and Western blots), or assays described herein for identifying drugs, which are within the scope of the present disclosure.
[0140] In embodiments, the modified effector cells and other genetic elements described herein are delivered to cells using the SB11 transposon system, the SB100X transposon system, the SB110 transposon system, the piggyBac transposon system (see, e.g., Wilson et al, "PiggyBac Transposon-mediated Gene Transfer in Human Cells," Molecular Therapy 15:139-145 (2007) which is incorporated by reference in its entirety), and / or the piggyBat transposon system (see, e.g., Mitra et al., "Functional characterization of piggyBat from the bat Myotis lucifugus unveils an active mammalian DNA transposon," Proc. Natl. Acad. Sci USA 110:234-239 (2013)). For additional transposase and transposon systems, see U.S. Pat. Nos. 6,489,458, 6,613,752, 7,148,203, 7,985,739, 8,227,432, 9,228,180, U.S. Patent Publication No. 2011 / 0117072, Mates et al., Nat Genet, 41(6):753-61 (2009). doi: 10.1038 / ng.343. Epub 2009 May 3, Gene Ther., 18(9):849-56 (2011). doi: 10.1038 / gt.2011.40. Epub 2011 Mar 31, each of which is incorporated herein by reference in its entirety. and Ivics et al., Cell, 91(4):501-10, (1997).
[0141] Further suitable non-viral systems may include an expression vector for integration, which may be randomly integrated into the DNA of a host cell, or may contain a recombination site that allows specific recombination between the expression vector and the host cell chromosome. Targeting the integration of a transgene into a predetermined locus is a desired goal for many applications. First, a first recombination site of a site-specific recombinase is inserted into a genomic site, either randomly or at a predetermined location. Then, the cell is transfected with a plasmid carrying a gene or DNA of interest, as well as a second recombination site and a source of recombinase (expression plasmid, RNA, protein, or virus that expresses the recombinase). Recombination between the first recombination site and the second recombination site results in the integration of the plasmid DNA.
[0142] Such expression vectors for integration can use endogenous expression control sequences of the host cell chromosome to provide expression of the desired protein. In some embodiments, integration targeting is promoted by the presence of sequences on the donor polynucleotide that are homologous to sequences flanking the integration site. For example, integration targeting using the donor polynucleotides described herein can be achieved by conventional transfection methods, such as techniques used to create gene knockouts or knockins by homologous recombination. In other embodiments, integration targeting is promoted by both the presence of sequences on the donor polynucleotide that are homologous to sequences flanking the integration site and contacting the cell with the donor polynucleotide in the presence of a site-specific recombinase. Site-specific recombinase, or simply recombinase, refers to a polypeptide that catalyzes conservative site-specific recombination between its compatible recombination sites. As used herein, site-specific recombinase includes naturally occurring polypeptides, as well as derivatives, mutants, and / or fragments that retain activity, as well as naturally occurring polynucleotides, derivatives, mutants, and / or fragments that encode a recombinase that retains activity.
[0143] Also provided herein is a system for integrating a heterologous gene in a host cell, the system comprising one or more gene expression cassettes. In some cases, the system comprises a first gene expression cassette comprising a first polynucleotide encoding a first polypeptide construct. In other cases, the system may comprise a second gene expression cassette comprising a second polynucleotide encoding a second polypeptide construct. In still other cases, the system may comprise a third gene expression cassette. In one embodiment, one of the gene expression cassettes may comprise a gene switch polynucleotide encoding one or more of: (i) a transactivation domain; (ii) a nuclear receptor ligand binding domain; (iii) a DNA binding domain; and (iv) an ecdysone receptor binding domain. In another embodiment, the system further comprises a recombination junction site and a serine recombinase, such that when the host cell is contacted with at least the first gene expression cassette in the presence of the serine recombinase, the heterologous gene is integrated into the host cell.
[0144] Optionally, the system further comprises a ligand, such that when the host cell is contacted in the presence of the ligand, the heterologous gene is expressed in the host cell. In one case, the system also comprises a recombination junction site. Optionally, one recombination junction site is a phage genomic recombination junction site (attP) or a bacterial genomic recombination junction site (attB). In one case, the host cell is a eukaryotic cell. In another case, the host cell is a human cell. In a further case, the host cell is a T cell or a NK cell.
[0145] promoter "Promoter" refers to a region of a polynucleotide that induces transcription of a coding sequence. A promoter is located near and upstream (towards the 5' region of the sense strand) of a gene's transcription start site on the same strand of DNA. Some promoters are constitutive, since they are active in all contexts within a cell, whereas other promoters, e.g., inducible promoters, are regulated and active in response to specific stimuli. Still other promoters are tissue-specific or activated promoters, including but not limited to T cell specific promoters.
[0146] The term "promoter activity" and its grammatical equivalents as used herein refer to the degree of expression of the nucleotide sequence operably linked to the promoter whose activity is measured.Promoter activity can be measured directly by determining the amount of RNA transcript produced, for example, by Northern blot analysis, or indirectly by determining the amount of product encoded by the linked nucleic acid sequence, such as a reporter nucleic acid sequence linked to the promoter.
[0147] As used herein, "inducible promoter" refers to a promoter that is induced to activity by the presence or absence of a transcriptional regulator, such as a biotic or abiotic factor. Inducible promoters are useful because the expression of a gene operably linked to them can be turned on or off at certain stages of the development of an organism, or in particular, a tissue. Examples of inducible promoters are alcohol-regulated promoters, tetracycline-regulated promoters, steroid-regulated promoters, metal-regulated promoters, pathogenesis-regulated promoters, temperature-regulated promoters, and light-regulated promoters. In one embodiment, the inducible promoter is part of a gene switch. The inducible promoter can be a ligand-inducible promoter of a gene switch. In some cases, the inducible promoter can be a small molecule ligand-inducible, two-polypeptide, ecdysone receptor-based gene switch, such as the RHEOSWITCH® gene switch. In some cases, the gene switch may be any of the following: PCT / US Appln. No. 2001 / 009050 (WO 2001 / 070816); U.S. Pat. Nos. 7,091,038; 7,776,587; 7,807,417; 8,202,718; PCT / US Appln. No. 2001 / 030608 (WO 2002 / 029075); U.S. Pat. Nos. 8,105,825; 8,168,426; PCT / US Appln. No. 2002 / 005235, each of which is incorporated by reference in its entirety. (WO 2002 / 066613); U.S. Patent Application Publication No. 10 / 468,200 (U.S. Publication No. 20120167239); PCT / U.S. Application No. 2002 / 005706 (WO 2002 / 066614); U.S. Patent Nos. 7,531,326; 8,236,556; 8,598,409; PCT / U.S. Application No. 2002 / 005090 (WO 2002 / 066612); U.S. Patent No. 8,715,959 (U.S. Publication No. 20060100416);PCT / US Application No. 2002 / 005234 (WO 2003 / 027266); U.S. Patent Nos. 7,601,508; 7,829,676; 7,919,269; 8,030,067; PCT / US Application No. 2002 / 005708 (WO 2002 / 066615); U.S. Patent Application Publication No. 10 / 468,192 (U.S. Publication No. 20110212528); PCT / US Application No. 2002 / 00 No. 5026 (WO 2003 / 027289); U.S. Patent Nos. 7,563,879; 8,021,878; 8,497,093; PCT / U.S. Appl. No. 2005 / 015089 (WO 2005 / 108617); U.S. Patent Nos. 7,935,510; 8,076,454; PCT / U.S. Appl. No. 52008 / 011270 (WO 2009 / 045370); U.S. Patent Application Publication No. No. 12 / 241,018 (U.S. Publication No. 20090136465); PCT / U.S. Application No. 2008 / 011563 (WO 2009 / 048560); U.S. Patent Application No. 12 / 247,738 (U.S. Publication No. 20090123441); PCT / U.S. Application No. 2009 / 005510 (WO 2010 / 042189); U.S. Patent Application No. 13 / 123,129 (U.S. Publication No. 20110268766) The system may be selected from, but is not limited to, ecdysone-based receptor components of any of the systems described in PCT / US2011 / 029682 (WO 2011 / 119773); U.S. Patent Application Publication No. 13 / 636,473 (U.S. Publication No. 20130195800); PCT / US2012 / 027515 (WO 2012 / 122025); and U.S. Patent No. 9,402,919.
[0148] Provided herein is a method comprising administering to a subject at least one non-viral vector comprising a polynucleotide encoding a polypeptide sequence described herein, comprising at least two functional proteins or portions thereof; at least one promoter; and at least one engineered recombination site; said at least one promoter drives the expression of said at least two functional proteins. In some cases, at least one promoter can be a constitutive promoter. In some cases, at least one promoter can be a tissue-specific promoter. In some cases, at least one promoter can be an inducible promoter. In some cases, the inducible promoter is a small molecule ligand-inducible, two-polypeptide, ecdysone receptor-based gene switch. In other cases, a combination of promoters can be used, where at least one promoter can be inducible and at least one promoter can be activation-specific.
[0149] The inducible promoter uses a ligand for dose-regulating control of the expression of the at least two genes. In some cases, the ligand is selected from the group consisting of ecdy steroids, 9-cis-retinoic acid, synthetic analogs of retinoic acid, N,N'-diacylhydrazines, oxazolines, dibenzoylalkylcyanohydrazines, N-alkyl-N,N'-diaroylhydrazines, N-acyl-N-alkylcarbonylhydrazines, N-aroyl-N-alkyl-N'-aroylhydrazines, arnidoketones, 3,5-di-tert-butyl-4-hydroxy-N-isobutyl-benzamide, 8-O-acetylharpagide, oxysterols, 22(R)hydroxycholesterol, 24(S)hydroxycholesterol, 25-epoxycholesterol, T0901317, 5-alpha-6-alpha-epoxycholesterol-3-sulfate (ECHS), 7- The compound may be selected from the group consisting of ketocholesterol-3-sulfate, furamezole, bile acids, 1,1-biphosphonate esters, juvenile hormone III, RG-115819 (3,5-dimethyl-benzoic acid N-(1-ethyl-2,2-dimethyl-propyl)-N'-(2-methyl-3-methoxy-benzoyl)-hydrazide), RG-115932 ((R)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N'-(2-ethyl-3-methoxy-benzoyl)-hydrazide), and RG-115830 (3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N'-(2-ethyl-3-methoxy-benzoyl)-hydrazide), and any combination thereof.
[0150] In some embodiments, the promoter is an inducible promoter. In some embodiments, the promoter is a non-inducible promoter. In some cases, the promoter can be a tissue-specific promoter. As used herein, "tissue-specific" refers to the regulation of gene expression in a subset of tissues or cell types. In some cases, the tissue-specific promoter can be spatially regulated so that the promoter only drives expression in certain tissues or cell types of an organism. In other cases, the tissue-specific promoter can be temporally regulated so that the promoter differentially drives expression in cell types or tissues over time, including during the development of the organism. In some cases, the tissue-specific promoter is spatially and temporally regulated. In certain embodiments, the tissue-specific promoter is constitutively active in certain cell types, or intermittently active at certain times or at certain stages of cell types. For example, the tissue-specific promoter can be a promoter that is activated when a specific cell, such as a T cell or a NK cell, is activated. T cells can be activated in various ways, for example, when presented with a peptide antigen by MHC class II molecules.
[0151] In one case, at least one promoter is an engineered promoter or a variant thereof.As described herein, the promoter can incorporate a minimal promoter sequence derived from IL-2 and one or more of the following: nuclear factor of activated T cells (NFAT) response element; NFIL2D response element, NFkB / TCF response element, NF_AT / NFIL2B response element, or NFIL2A / OCT response element.Examples of response elements are described in Mattila et al., EMBO J. 9(13):4425-33 (1990), which is incorporated herein in its entirety.
[0152] In some embodiments, at least one promoter comprises an IL-2 core promoter (SEQ ID NO: 26). In one embodiment, at least one promoter comprises an IL-2 minimal promoter (SEQ ID NO: 27). In another embodiment, at least one promoter comprises an IL-2 enhancer / promoter variant (SEQ ID NO: 26-28). In yet another embodiment, at least one promoter comprises an NF-κB binding site (SEQ ID NO: 30-32). In some embodiments, at least one promoter comprises an (NF-κB)1-IL2 promoter variant (SEQ ID NO: 30). In some embodiments, at least one promoter comprises an (NF-κB)3-IL2 promoter variant (SEQ ID NO: 31). In some embodiments, at least one promoter comprises an (NF-κB)6-IL2 promoter variant (SEQ ID NO: 32). In one embodiment, at least one promoter comprises a 1× nuclear factor of activated T cells (NFAT) response element-IL2 promoter variant (SEQ ID NO: 33). In another embodiment, at least one promoter comprises a 3× NFAT response element (SEQ ID NO: 34-35). In yet another embodiment, at least one promoter comprises a 6xNFAT response element-IL2 promoter variant (SEQ ID NO: 36-39). In some embodiments, at least one promoter comprises a human EF1A1 promoter variant (SEQ ID NO: 40-41). In some embodiments, at least one promoter comprises a human EF1A1 promoter / enhancer (SEQ ID NO: 42). In some embodiments, at least one promoter comprises a human UBC promoter (SEQ ID NO: 43). In some embodiments, at least one promoter comprises a 6-site GAL4 inducible proximal factor binding element (PFB). In some embodiments, at least one promoter comprises a synthetic minimal promoter 1 (inducible promoter) (SEQ ID NO: 44).
[0153] The use of a gene switch for ligand-inducible control of IL-12 expression as described herein may improve the safety profile of IL-12, for example, by allowing for regulation of expression and improved therapeutic index. However, the condition for ligand dose-dependent expression of IL-12 using the gene switch is the presence or absence of an activating ligand (e.g., berezimex). In certain embodiments, further conditional control over inducible IL-12 expression is also envisioned. A gene switch component under the control of a T cell activation specific promoter is provided. This results in conditional (e.g., T cell activation) expression of the gene switch component required for berezimex-regulated expression of a transgene under the control of the gene switch. In some embodiments, this results in preferential expression of cytokines such as IL-12 or IL-15 by tumor-specific T cells when berezimex is present and T cells are activated. This may result in increased localized levels of transgene expression controlled by the gene switch.
[0154] For example, T cell activation-specific expression of gene switch components can be controlled by promoters containing nuclear factor of activated T cells (NFAT) response elements. NFAT transcription factors are key modulators of effector T cell states. NFAT is an early transcriptional checkpoint that progressively drives exhaustion. NFAT is rapidly activated in T cells after TCR stimulation and is induced by appropriate co-stimulatory signaling to form a protein complex with AP-1 to regulate effector genes and T cell function. NFAT response elements can be fused to other minimal promoter sequences (e.g., IL2 minimal promoter) to drive expression of transgenes in response to T cell activation.
[0155] Other examples of activation-specific promoters include, but are not limited to, the interleukin 2 (IL2) promoter and the programmed cell death (PD) 1 (CD279) promoter. Gene switch components can also be conditionally expressed upon immune cell activation by fusing binding sites for other nuclear factors, such as NF-κB of the pro-inflammatory signaling pathway, to the minimal promoter sequence (e.g., IL2).
[0156] In certain embodiments, the promoter may be any one or more of IL-2 core promoter, IL-2 minimal promoter, IL-2 enhancer / promoter variant, (NF-κB)1-IL2 promoter variant, (NF-κB)3-IL2 promoter variant, (NF-κB)6-IL2 promoter variant, 1×NFAT response element-IL2 promoter variant, 3×NFAT response element-IL2 promoter variant, 6×NFAT response element-IL2 promoter variant, human EEF1A1 promoter variant, human EEF1A1 promoter / enhancer, human UBC promoter, and synthetic minimal promoter 1. In certain embodiments, the promoter nucleotide may comprise SEQ ID NOs: 26-44.
[0157] Genetic Switch Provided herein are gene switch polypeptides, polynucleotides encoding ligand-inducible gene switch polypeptides, and methods and systems incorporating these polypeptides and / or polynucleotides. In certain aspects, the disclosure is directed to a polynucleotide comprising one or more polynucleotides encoding a gene switch system for inducible control of heterologous gene expression, wherein the heterologous gene expression is regulated by the gene switch system; the heterologous gene comprises a polynucleotide encoding a polypeptide comprising one or more immune response-inducing human papillomavirus (HPV) polypeptides disclosed herein.
[0158] The term "gene switch" refers to a combination of a promoter and associated response element, for example, an EcR-based system that modulates the expression of a gene incorporating the response element and promoter in the presence of one or more ligands. Tightly regulated inducible gene expression systems or gene switches are useful for a variety of applications, including gene therapy, intracellular, large-scale protein production, cell-based high-throughput screening assays, functional genomics, and regulating traits in transgenic plants and animals. Such inducible gene expression systems can include ligand-inducible heterologous gene expression systems.
[0159] Early forms of EcR-based gene switches used Drosophila melanogaster EcR (DmEcR) and mouse (Mus musculus) RXR (MmRXR) polypeptides and showed that these receptors transactivate reporter genes in mammalian cell lines and transgenic mice in the presence of the steroid ponasterone A (Christopherson et al., Proc. Natl. Acad. Sci. USA 89(14):6314-18 (1992); No et al., Proc. Natl. Acad. Sci. USA 93(8):3346-51 (1996)). Subsequently, Suhr et al. (Proc. Natl. Acad. Sci. USA 95(14):7999-8004 (1998)) showed that the nonsteroidal ecdysone agonist tebufenozide induced high levels of transactivation of reporter genes in mammalian cells through the silkworm (Bombyx mori) EcR (BmEcR) in the absence of an exogenous heterodimer partner.
[0160] PCT / US 97 / 05330 (WO 97 / 38117) and PCT / US 99 / 08381 (WO 99 / 58155) disclose a method for modulating the expression of an exogenous gene, in which a DNA construct containing an exogenous gene and an ecdysone response element is activated by a second DNA construct containing an ecdysone receptor that binds to the ecdysone response element and induces gene expression in the presence of its ligand and, optionally, in the presence of a receptor that can act as a silent partner. In this example, the ecdysone receptor was isolated from Drosophila melanogaster. Typically, such a system requires the presence of a silent partner, preferably the retinoid X receptor (RXR), to provide optimal activation. In mammalian cells, the insect ecdysone receptor (EcR) heterodimerizes with the mammalian retinoid X receptor (RXR), which can be used to regulate the expression of target or heterologous genes in a ligand-dependent manner. PCT International Patent Application / US Application No. 98 / 14215 (WO 99 / 02683) discloses that an ecdysone receptor isolated from the silkworm moth, Bombyx mori, is functional in mammalian systems without the need for an exogenous dimer partner.
[0161] US Patent No. 6,265,173 discloses that various members of the steroid / thyroid superfamily of receptors may be combined with the Drosophila melanogaster ultraspiracle receptor (USP) or a fragment thereof, including at least the dimerization domain of USP, for use in gene expression systems. US Patent No. 5,880,333 discloses a heterodimer system of Drosophila melanogaster EcR and ultraspiracle (USP) for use in plants, in which the transactivation and DNA binding domains are located on two different hybrid proteins. In each of these cases, the transactivation domain and the DNA binding domain (as native EcR, as in PCT Int / U.S. Ser. No. 98 / 14215, or as modified EcR, as in PCT Int / U.S. Ser. No. 97 / 05330) were combined into a single molecule, and the other heterodimer partner, USP or RXR, was used in their native state.
[0162] PCT International Patent Application / US Application No. 01 / 0905 discloses an ecdysone receptor-based inducible gene expression system in which the transactivation domain and the DNA binding domain are separated from each other by being placed on two different proteins, resulting in a significant reduction in background activity in the absence of ligand, and a significant increase in activity above background in the presence of ligand. This two-hybrid system is a significantly improved inducible gene expression modulation system compared to the two systems disclosed in PCT / US Application No. 97 / 05330 and PCT / US Application No. 98 / 14215. The two-hybrid system is believed to take advantage of the ability of the pair of interacting proteins to place the transcription activation domain in a more favorable position relative to the DNA binding domain, such that the transactivation domain more effectively activates the promoter when the DNA binding domain binds to the DNA binding site on the gene (see, for example, US Patent No. 5,283,173). The two-hybrid gene expression system comprises two gene expression cassettes, a first gene expression cassette encoding a DNA-binding domain fused to a nuclear receptor polypeptide, and a second gene expression cassette encoding a transactivation domain fused to a different nuclear receptor polypeptide.In the presence of ligand, it is believed that the conformational change of the first polypeptide is induced, which promotes the interaction with the second polypeptide, and this results in the dimerization of the DNA-binding domain and the transactivation domain.Because the DNA-binding domain and the transactivation domain are present on two different molecules, in the absence of ligand, background activity is greatly reduced.
[0163] Another surprising discovery was that certain modifications of the two-hybrid system also resulted in improved sensitivity to non-steroidal ligands, such as diacylhydrazines, when compared to steroidal ligands, such as ponasterone A ("PonA") or muristerone A ("MurA"). That is, the non-steroidal ligands resulted in greater gene transcription activity at low ligand concentrations when compared to steroids. Furthermore, the two-hybrid system also avoids some of the side effects resulting from overexpression of RXR, which may occur when using unmodified RXR as a switching partner. In the preferred two-hybrid system, the native DNA-binding and transactivation domains of EcR or RXR are removed, resulting in these hybrid molecules having a reduced chance of interacting with other steroid hormone receptors present in the cell, thereby resulting in reduced side effects.
[0164] The ecdysone receptor (EcR) is a member of the nuclear receptor superfamily and is classified into subfamily 1, group H (herein referred to as "group H nuclear receptors"). Members of each group share 40-60% amino acid identity within the E (ligand binding) domain (Laudet et al., A Unified Nomenclature System for the Nuclear Receptor Subfamily, 1999; Cell 97: 161-163). In addition to the ecdysone receptor, other members of this nuclear receptor subfamily 1, group H, include the ubiquitous receptor (UR), orphan receptor 1 (OR-1), steroid hormone nuclear receptor 1 (NER-1), RXR-interacting protein 15 (RIP-15), liver x receptor beta (LXRβ), steroid hormone receptor-like protein (RLD-1), liver x receptor (LXR), liver x receptor alpha (LXRα), farnesoid x receptor (FXR), receptor interacting protein 14 (RIP-14), and farnesol receptor (HRR-1).
[0165] Optionally, the inducible promoter can be a small molecule ligand-inducible, two polypeptide, ecdysone receptor-based gene switch, such as the RHEOSWITCH® gene switch from Intrexon Corporation. Optionally, the gene switch can be any of the gene switches described in PCT / US Appl. No. 2001 / 009050 (WO 2001 / 070816); U.S. Patent Nos. 7,091,038; 7,776,587; 7,807,417; 8,202,718; PCT / US Appl. No. 2001 / 030608 (WO 2002 / 029075); U.S. Patent No. 6,202,718, each of which is incorporated by reference in its entirety. No. 8,105,825; No. 8,168,426; PCT / US Application No. 2002 / 005235 (WO 2002 / 066613); U.S. Patent Application Publication No. 10 / 468,200 (U.S. Publication No. 20120167239); PCT / US Application No. 2002 / 005706 (WO 2002 / 066614); U.S. Patent No. 7,531,326; U.S. Patent No. 8,236,556 No. 8,598,409; PCT / US Application No. 2002 / 005090 (WO 2002 / 066612); U.S. Patent No. 8,715,959 (U.S. Publication No. 20060100416); PCT / US Application No. 2002 / 005234 (WO 2003 / 027266); U.S. Patent No. 7,601,508; U.S. Patent No. 7,829,676; U.S. Patent No. 7,919,269; No. 8,030,067; PCT / US Application No. 2002 / 005708 (WO 2002 / 066615); U.S. Patent Application No. 10 / 468,192 (U.S. 20110212528); PCT / US Application No. 2002 / 005026 (WO 2003 / 027289); U.S. Patent Nos. 7,563,879; 8,021,878; 8,497,093;PCT / US Application No. 2005 / 015089 (WO 2005 / 108617); U.S. Patent Nos. 7,935,510; 8,076,454; PCT / US Application No. 2008 / 011270 (WO 2009 / 045370); U.S. Patent Application No. 12 / 241,018 (U.S. 20090136465); PCT / US Application No. 2008 / 011563 (WO 2009 / 048560); U.S. Patent Application No. 12 / 247,738 (U.S. 20090123441); PCT / US Application No. 2009 / 005510 The ecdysone-based receptor component may be selected from, but is not limited to, any of the systems described in PCT / US Publication No. WO 2010 / 042189; U.S. Patent Application Publication No. 13 / 123,129 (U.S. Publication No. 20110268766); PCT / US Publication No. 2011 / 029682 (WO 2011 / 119773); U.S. Patent Application Publication No. 13 / 636,473 (U.S. Publication No. 20130195800); PCT / US Publication No. 2012 / 027515 (WO 2012 / 122025); and U.S. Patent No. 9,402,919.
[0166] Provided is a system for modulating expression of heterologous genes and interleukins in a host cell, the system comprising a polynucleotide that expresses a gene switch polypeptide disclosed herein.
[0167] In some embodiments, the system for modulating the expression of a heterologous gene and a cytokine in a host cell includes a first gene expression cassette comprising a first polynucleotide encoding a first polypeptide; a second gene expression cassette comprising a second polynucleotide encoding a second polypeptide; and a ligand, wherein the first and second polypeptides include one or more of (i) a transactivation domain; (ii) a DNA binding domain; and (iii) a ligand binding domain; (iv) the heterologous gene; and (vi) the cytokine, such that the heterologous gene and the cytokine are expressed in the host cell when the host cell is contacted with the first and second gene expression cassettes in the presence of the ligand. Optionally, the heterologous gene includes an antigen-binding polypeptide as described herein. Optionally, the cytokine includes at least one chemokine, interferon, interleukin, lymphokine, tumor necrosis factor, or a variant or combination thereof. Optionally, the cytokine is an interleukin. Optionally, the interleukin is at least one of IL12, IL2, IL15, IL21, and functional variants and fragments thereof. In some embodiments, the cytokine may be membrane-bound or secreted. In other embodiments, the cytokine may be an intracellular cytokine. The interleukin may include membrane-bound IL-15 (mbIL-15), a fusion of IL-15 and IL-15Rα. In some embodiments, mbIL-15 is a membrane-bound chimeric IL-15 that may be co-expressed using the modified effector cells described herein. In some embodiments, mbIL-15 includes full-length IL-15 (e.g., a native IL-15 polypeptide) or a fragment or variant thereof fused in-frame with full-length IL-15Rα, or the functional fragment or variant. Optionally, IL-15 is indirectly linked to IL-15Rα via a linker.In some cases, the mbIL-15 is as described in Hurton et al., "Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells," Proc. Natl. Acad. Sci. USA 113(48):E7788-E7797 (2016). In another aspect, the interleukin can include IL-12. In some embodiments, the IL-12 is single-chain IL-12 (scIL-12), protease-sensitive IL-12, destabilized IL-12, membrane-bound IL-12, or inserted IL-12. In some embodiments, the IL-12 is mouse IL-12 subunit beta (p40) (SEQ ID NO: 206). In some embodiments, the IL-12 is mouse IL-12 subunit alpha (p35) (SEQ ID NO: 207). In some cases, the IL-12 variant is as described in WO 2015 / 095249, WO 2016 / 048903, and WO 2017 / 062953, all of which are incorporated by reference in their entireties.
[0168] Provided herein is a polynucleotide encoding a gene switch polypeptide, the gene switch polypeptide comprising: a) a first gene switch polypeptide comprising a DNA binding domain fused to a nuclear receptor ligand binding domain; and b) a second gene switch polypeptide comprising a transactivation domain fused to a nuclear receptor ligand binding domain, the first gene switch polypeptide and the second gene switch polypeptide being connected by a linker. In some cases, the linker can be a linker described herein, for example, a GSG linker, a furin link, a 2A linker such as F / T2A, T2A, p2A, GSG-p2A, and variants and derivatives thereof. In other cases, the linker can be an IRES.
[0169] In some cases, the DNA binding domain (DBD) comprises at least one of the DBDs described herein, such as GAL4 (GAL4 DBD), LexADBD, transcription factor DBD, steroid / thyroid hormone nuclear receptor superfamily member DBD, bacterial LacZ DBD, and yeast DBD. The transactivation domain can comprise at least one of the transactivation domains described herein, such as VP16 transactivation domain, p53 transactivation domain, and B42 acidic activator transactivation domain. The nuclear receptor ligand binding domain can comprise at least one of ecdysone receptor (EcR), ubiquitous receptor, orphan receptor 1, NER-1, steroid hormone nuclear receptor 1, retinoid X receptor interacting protein 15, liver X receptor beta, steroid hormone receptor-like protein, liver X receptor, liver X receptor alpha, farnesoid X receptor, receptor interacting protein 14, and farnesol receptor.
[0170] In some cases, gene switch polypeptides connected by a polypeptide linker or ribosome skipping sequence exhibit improved dose-dependent, ligand-inducible control of gene expression compared to a ligand-inducible gene switch, where the gene switch polypeptides are connected by a non-coding sequence, such as an IRES. In some cases, gene switch polypeptides connected by a 2A linker exhibit improved dose-dependent, ligand-inducible control of heterologous gene expression compared to a gene switch, where the gene switch polypeptides are separated by an IRES.
[0171] In some embodiments, the gene switch comprises a VP16 transactivation domain. In one embodiment, the gene switch comprises at least one of ecdysone receptor (EcR), ubiquitous receptor, orphan receptor 1, NER-1, steroid hormone nuclear receptor 1, retinoid X receptor interacting protein 15, liver X receptor beta, steroid hormone receptor-like protein, liver X receptor, liver X receptor alpha, farnesoid X receptor, receptor interacting protein 14, and farnesol receptor. In another embodiment, the DNA binding domain of the gene switch comprises at least one of GAL4 (GAL4 DBD), LexADBD, transcription factor DBD, steroid / thyroid hormone nuclear receptor superfamily member DBD, bacterial LacZ DBD, and yeast DBD. In yet another case, the gene switch further comprises at least one of ultraspiracle protein (USP), retinoid receptor X (RXR), functional fragments and variants thereof, wherein said functional fragments and variants thereof are capable of binding to at least one of EcR.
[0172] The polypeptides and polynucleotides described herein can be expressed in engineered cells.As used herein, engineered cells are cells that are modified from their native or endogenous state.Examples of engineered cells are the cells described herein that are modified (e.g., by transfection of a polynucleotide into the cell) to encode, for example, a gene switch polypeptide, a gene of interest (GOI), a cell tag, a heterologous gene, and any other polypeptides and polynucleotides described herein.
[0173] Ligand In some embodiments, the ligand used for regulation of the inducible gene switch is: N-[(1R)-1-(1,1-dimethylethyl)butyl]-N'-(2-ethyl-3-methoxybenzoyl)-3,5-dimethylbenzohydrazide (also known as berezimex), (2S,3R,5R,9R,10R,13R,14S,17R)-17-[(2S,3R)-3,6-dihydroxy-6-methylheptan-2-yl]-2,3,14-trihydroxy-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene- 6-one;N'-(3,5-dimethylbenzoyl)-N'-[(3R)-2,2-dimethyl-3-hexanyl]-2-ethyl-3-methoxybenzohydrazide;5-Methyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid N'-(3,5-dimethylbenzoyl)-N'-(1-ethyl-2,2-dimethylpropyl)-hydrazide;5-Methyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid N'-(3,5-dimethoxy-4-methylbenzoyl)-N'-(1-ethyl-2,2-dimethylpropyl)-hydrazide 5-Methyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid N'-(1-tert-butyl-butyl)-N'-(3,5-dimethyl-benzoyl)-hydrazide;5-Methyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid N'-(1-tert-butyl-butyl)-N'-(3,5-dimethoxy-4-methyl-benzoyl)-hydrazide;5-Ethyl-2,3-dihydro-benzo[1,4]dioxine-6-carbohydrazide;5-Methyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid N'-(1-tert-butyl-butyl)-N'-(3,5-dimethoxy-4-methyl-benzoyl)-hydrazide 5-Ethyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid N'-(3,5-dimethoxy-4-methyl-benzoyl)-N'-(1-ethyl-2,2-dimethyl-propyl)-hydrazide;5-Ethyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid N'-(1-tert-butyl-butyl)-N'-(3,5-dimethyl-benzoyl)-hydrazide;5-Ethyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid N'-(1-tert-butyl-butyl)-N'-(3,5-dimethoxy-4-methyl-benzoyl)-hydrazide;3,5-Dimethyl-benzoic acid N-(1-ethyl-2,2-dimethyl-propyl)-N'-(3-methoxy-2-methyl-benzoyl)-hydrazide;3,5-Dimethoxy-4-methyl-benzoic acid N-(1-ethyl-2,2-dimethyl-propyl)-N'-(3-methoxy-2-methyl-benzoyl)-hydrazide 3,5-Dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N'-(3-methoxy-2-methyl-benzoyl)-hydrazide;3,5-Dimethoxy-4-methyl-benzoic acid N-(1-tert-butyl-butyl)-N'-(3-methoxy-2-methyl-benzoyl)-hydrazide;3,5-Dimethoxy-4-methyl-benzoic acid N-(1-tert-butyl-butyl)-N'-(3-methoxy-2-methyl-benzoyl)-hydrazide;3,5-Dimethyl-benzoic acid N-(1-ethyl-2,2-dimethyl-propyl)-N'-(2-ethyl-3-methoxy-benzoyl)-hydrazide;3,5-Dimethoxy-4-methyl-benzoic acid N-(1-ethyl 3,5-Dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N'-(2-ethyl-3-methoxy-benzoyl)-hydrazide;3,5-Dimethoxy-4-methyl-benzoic acid N-(1-tert-butyl-butyl)-N'-(2-ethyl-3-methoxy-benzoyl)-hydrazide;2-Methoxy-nicotinic acid N-(1-tert-butyl-pentyl)-N'-(4-ethyl-benzoyl)-hydrazide hydrazide; 3,5-dimethyl-benzoic acid N-(2,2-dimethyl-1-phenyl-propyl)-N'-(4-ethyl-benzoyl)-hydrazide; 3,5-dimethyl-benzoic acid N-(1-tert-butyl-pentyl)-N'-(3-methoxy-2-methyl-benzoyl)-hydrazide; and 3,5-dimethoxy-4-methyl-benzoic acid N-(1-tert-butyl-pentyl)-N'-(3-methoxy-2-methyl-benzoyl)-hydrazide.
[0174] In some cases, the ligand used for dose-regulated control of the ecdysone receptor-based inducible gene switch may be any of the following: ecdysone, 20-hydroxyecdysone, ecdy steroids, such as ponasterone A, muristerone A, 9-cis-retinoic acid, synthetic analogs of retinoic acid, N,N'-diacylhydrazines, such as those disclosed in U.S. Pat. Nos. 6,013,836; 5,117,057; 5,530,028; and 5,378,726, and U.S. Patent Publication Nos. 2005 / 0209283 and 2006 / 0020146, each of which is incorporated herein by reference; oxazolines, such as those described in U.S. Patent Publication No. 2004 / 0171651; European dibenzoylalkylcyanohydrazines such as those disclosed in State Application 461,809; N-alkyl-N,N'-diaroylhydrazines such as those disclosed in U.S. Pat. No. 5,225,443; N-acyl-N-alkylcarbonylhydrazines such as those disclosed in European Application 234,994; N-aroyl-N-alkyl-N'-aroylhydrazines such as those described in U.S. Pat. No. 4,985,461; arnidoketones such as those described in U.S. Application Publication No. 2004 / 0049037;The active ingredient may be selected from any of the other similar materials including, but not limited to, 3,5-di-tert-butyl-4-hydroxy-N-isobutyl-benzamide, 8-O-acetylharpagide, oxysterols, 22(R)hydroxycholesterol, 24(S)hydroxycholesterol, 25-epoxycholesterol, T0901317, 5-alpha-6-alpha-epoxycholesterol-3-sulfate (ECHS), 7-ketocholesterol-3-sulfate, furamesol, bile acids, 1,1-biphosphonate esters, juvenile hormone III, and the like. Examples of diacylhydrazine ligands useful in the present disclosure include RG-115819 (3,5-dimethyl-benzoic acid N-(1-ethyl-2,2-dimethyl-propyl)-N'-(2-methyl-3-methoxy-benzoyl)-hydrazide), RG-115932 ((R)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N'-(2-ethyl-3-methoxy-benzoyl)-hydrazide), and RG-115830 (3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N'-(2-ethyl-3-methoxy-benzoyl)-hydrazide). See, for example, U.S. Patent Application No. 12 / 155,111 and PCT Application / U.S. Application No. 2008 / 006757, both of which are incorporated herein by reference in their entirety.;
[0175] Cytokines In certain embodiments, the HPV vaccine antigens provided herein may be co-delivered and / or co-expressed with other cytokines (e.g., as part of the same HPV antigen delivery vector or via a separate vector). Provided herein are polynucleotides encoding gene switch polypeptides and cytokines, or variants or derivatives thereof, and methods and systems incorporating the same. Cytokines are a class of small proteins, between about 5-20 kDa, involved in cell signaling. In some cases, cytokines include chemokines, interferons, interleukins, colony stimulating factors, or tumor necrosis factors. In some embodiments, chemokines act as chemoattractants that guide cell migration and are classified into four subfamilies: CXC, CC, CX3C, and XC. Exemplary chemokines include those of the CC subfamily: CCL1, CCL2 (MCP-1), CCL3, CCL4, CCL5 (RANTES), CCL6, CCL7, CCL8, CCL9 (or CCL10), CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, and CCL28; the CXC subfamily: CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, and CXCL17; the XC subfamily: XCL1 and XCL2; and chemokines from the CX3C subfamily, CX3CL1.
[0176] In certain embodiments, the HPV vaccine antigens presented herein may be co-delivered and / or co-expressed with interferon (e.g., as part of the same HPV antigen delivery vector or via a separate vector). Interferons (IFNs) include type I interferons (e.g., IFN-α, IFN-β, IFN-ε, IFN-κ, and IFN-ω), type II interferons (e.g., IFN-γ), and type III interferons. In some embodiments, IFN-α is further classified into about 13 subtypes, including IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, and IFNA21.
[0177] In certain embodiments, the HPV vaccine antigens presented herein may be co-delivered and / or co-expressed with other interleukins (e.g., as part of the same HPV antigen delivery vector or via a separate vector). Interleukins are expressed by leukocytes or white blood cells and promote the development and differentiation of T and B lymphocytes and hematopoietic cells. Exemplary interleukins include IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, Including IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32, IL-33, IL-35, and IL-36. In some embodiments, the interleukin is IL-2, IL-12, IL-15, IL-21, or a fusion of IL-15 and IL-15Rα.
[0178] In some aspects, the interleukin may include IL-12. In some embodiments, the IL-12 is single chain IL-12 (scIL-12), protease sensitive IL-12, destabilized IL-12, membrane bound IL-12, or inserted IL-12. In some embodiments, the IL-12 is mouse IL-12 subunit beta (p40) (SEQ ID NO: 206). Optionally, the IL-12 variant is as described in WO2015 / 095249, WO2016 / 048903, WO2017 / 062953, all of which are incorporated by reference in their entirety.
[0179] In some embodiments, the interleukin comprises mbIL-15. In some embodiments, the mbIL-15 is a membrane-bound chimeric IL-15 that can be co-expressed with the modified effector cells described herein. In some embodiments, the mbIL-15 comprises full-length IL-15 (e.g., a native IL-15 polypeptide), or a fragment or variant thereof, fused in-frame with full-length IL-15Rα, or a functional fragment or variant thereof. Optionally, the IL-15 is indirectly linked to the IL-15Rα via a linker. Optionally, the IL-15 is indirectly linked to the IL-15Rα via a linker. Optionally, the mbIL-15 is as described in Hurton et al., "Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells," PNAS 2016.
[0180] In certain embodiments, the HPV vaccine antigens presented herein may be co-delivered and / or co-expressed with tumor necrosis factor (e.g., as part of the same HPV antigen delivery vector or via a separate vector). Tumor necrosis factor (TNF) is a group of cytokines that modulate apoptosis. In some cases, there are about 19 members within the TNF family, including, but not limited to, TNFα, lymphotoxin alpha (LT-alpha), lymphotoxin beta (LT-beta), T cell antigen gp39 (CD40L), CD27L, CD30L, FASL, 4-1BBL, OX40L, and TNF-releasable apoptosis-inducing ligand (TRAIL).
[0181] In certain embodiments, the HPV vaccine antigens presented herein may be co-delivered and / or co-expressed with colony stimulating factors (e.g., as part of the same HPV antigen delivery vector or via a separate vector). Colony stimulating factors (CSFs) are secreted glycoproteins that interact with receptor proteins on the surface of hematopoietic stem cells and subsequently modulate the proliferation and differentiation of the cells into specific types of blood cells. In some cases, the CSF comprises macrophage colony stimulating factor, granulocyte macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), or promegapoietin.
[0182] In some embodiments, the cytokine is a membrane-bound cytokine co-expressed with the chimeric antigen receptor described herein. In some embodiments, one or more of the methods described herein further comprises administration of a cytokine. In some cases, the cytokine comprises a chemokine, an interferon, an interleukin, a colony-stimulating factor, or a tumor necrosis factor. In some cases, one or more of the methods described herein further comprises administration of a cytokine selected from a chemokine, an interferon, an interleukin, a colony-stimulating factor, or a tumor necrosis factor. In some cases, one or more of the methods described herein further comprises administration of a cytokine selected from IL2, IL7, IL12, IL-15, a fusion of IL-15 and IL-15Rα, IL-21, IFNγ, or TNF-α.
[0183] Interleukin 12 In certain embodiments, the HPV vaccine antigens presented herein may be co-delivered and / or co-expressed with interleukin-12 (e.g., as part of the same HPV antigen delivery vector or via a separate vector). Interleukin-12 (IL-12) is an interleukin that is naturally produced by dendritic cells, macrophages, neutrophils, and human B lymphoblastoid cells (NC-37) in response to antigenic stimulation. IL-12 is composed of a bundle of four alpha helices. IL-12 is a heterodimeric cytokine encoded by two separate genes, IL-12A (p35) and IL-12B (p40). The active heterodimer (designated p70) and the homodimer of p40 are formed after synthesis of the protein. IL-12 is the most potent regulator of the immune system. IL-12 promotes immune responses by activating NK and T cells (Figure 11).
[0184] Provided herein are compositions, kits, and systems containing the same, as well as methods of making the same. The present disclosure provides HPV antigen designs (HPV designs 1-5) constructed within a multiply deleted gorilla adenovector (GC46) (SEQ ID NOs: 61-63). Also provided herein are polynucleotides encoding gene switch polypeptides and IL-12, or variants or derivatives thereof, as well as methods and systems incorporating the same (FIG. 12).
[0185] Linker Also disclosed are constructs that include linkers that facilitate the expression and functionality of the polynucleotides and polypeptides described herein. In some embodiments, polynucleotide linkers can be used within the polynucleotides described herein. Polynucleotide linkers can be double-stranded segments of DNA that contain desired restriction sites that can be added to create terminal structures that are compatible with vectors that include the polynucleotides described herein. In some cases, polynucleotide linkers can be useful for modifying vectors that include the polynucleotides described herein. For example, the modification of vectors that include polynucleotide linkers can be the change of multiple cloning sites or the addition of polyhistidine tails. Polynucleotide linkers can also be used to make the ends of blunt-ended insert DNA compatible for cloning into vectors that are cleaved by restriction enzymes and have sticky ends. The use of polynucleotide linkers can be more efficient than blunt-end ligation into vectors and can provide a way to release the insert from the vector in later applications. In some cases, the insert can be a polynucleotide sequence that encodes a polypeptide useful for therapeutic applications. In some cases, the linker can be a cleavable linker.
[0186] The polynucleotide linker can be an oligomer. The polynucleotide linker can be a double-stranded DNA, a single-stranded DNA, or a combination thereof. Optionally, the linker can be RNA. Optionally, the polynucleotide linker can be ligated to the vector comprising the polynucleotide described herein by T4 ligase. To facilitate ligation, an excess amount of the polynucleotide linker can be added to the composition comprising the insert and the vector. Optionally, the insert and the vector are pretreated before the linker is introduced. For example, pretreatment with methylase can prevent the undesired cleavage of the insert DNA.
[0187] In certain embodiments, two or more polypeptides encoded by the polynucleotides described herein can be separated by an intervening sequence that encodes an intervening linker polypeptide. As used herein, the term "intervening linker polypeptide", which refers to an amino acid sequence that separates two or more polypeptides encoded by polynucleotides, is distinguished from the term "peptide linker", which refers to an amino acid sequence that is optionally incorporated into the polypeptide constructs disclosed herein to connect a transmembrane domain to a cell surface polypeptide (including, for example, a truncated variant of a native polypeptide). In certain cases, the intervening linker is a cleavable intervening linker polypeptide. In some embodiments, the linker is a cleavable linker or a ribosome skipping linker. In some embodiments, the cleavable linker or the ribosome skipping linker sequence is selected from the group consisting of 2A, GSG-2A, GSG linker, SGSG linker, furin link, and mutants and derivatives thereof. In some embodiments, the 2A linker is a p2A linker, a T2A linker, an F2A linker, or an E2A linker. In some embodiments, the polypeptide of interest is expressed as a fusion protein linked by a cleavable intervening linker polypeptide. In certain embodiments, the cleavable intervening linker polypeptide can be any one or more of F / T2A, T2A, p2A, 2A, GSG-p2A, GSG linker, and a furin link mutant. The linkers (polynucleotide and polypeptide sequences) disclosed in PCT / US2016 / 061668 (WO2017083750), published May 18, 2017, are incorporated herein by reference. In certain embodiments, the linker polypeptide comprises a linker polypeptide disclosed in the table below.
[0188] [Table 1-1]
[0189] [Table 1-2]
[0190] In some embodiments, the intervening linker polypeptide is a Whitlow linker (SEQ ID NO:64), a GSG linker (SEQ ID NO:66), a SGSG linker (SEQ ID NO:67), a (G4S)3 linker (SEQ ID NO:68), a furin cleavage site / Furlink 1 (SEQ ID NO:69), an Fmdv linker (SEQ ID NO:70), Thea asigna virus 2A region (T2A) (SEQ ID NO:71), furin-GSG-T2A (SEQ ID NO:72), furin-SGSG-T2A (SEQ ID NO:73), porcine teschovirus 1 The intervening linker polypeptide comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, 99.5%, or 100% identity to the amino acid sequence of the 2A region (P2A) (SEQ ID NO: 74), GSG-P2A (SEQ ID NO: 75), Equine rhinitis A virus 2A region (E2A) (SEQ ID NO: 76), or Foot and Mouth Disease virus 2A region (F2A) (SEQ ID NO: 78) (Table 1). In some cases, the intervening linker polypeptide comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, 99.5%, or 100% identity to the amino acid sequence of the linker (SEQ ID NOs: 65, 79-80). In some cases, a viral 2A sequence can be used. The 2A element can be shorter than the IRES, having 5-100 base pairs. In some cases, the 2A sequence can have a length of 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, or 100 nucleotides. 2A linked genes can be expressed in a single open reading frame, and "self-cleavage" can occur co-translationally between the last two amino acids, GP, at the C-terminus of the 2A polypeptide, resulting in equal amounts of co-expressed protein.
[0191] The viral 2A sequence may be about 20 amino acids. In some cases, the viral 2A sequence may contain the consensus motif Asp-Val / Ile-Glu-X-Asn-Pro-Gly-Pro. The consensus motif sequence may act co-translationally. For example, it may prevent the normal peptide bond formation between glycine and proline residues, which may result in ribosome skipping and cleavage of the nascent polypeptide. This effect may result in multiple genes at equimolar levels.
[0192] The 2A peptide may allow translation of multiple proteins within a single open reading frame into polypeptides that may then be cleaved into individual polypeptides via a ribosomal skipping mechanism (Funston et al., J. Gen. Virol. 89(Pt 2):389-96 (2008)). In some embodiments, the 2A sequence may include F / T2A, T2A, p2A, 2A, T2A, E2A, F2A, and BmCPV2A, BmIFV2A, and any combination thereof.
[0193] In some cases, the vector may include an IRES sequence and a 2A linker sequence. In other cases, the expression of multiple genes linked to a 2A peptide may be facilitated by a spacer sequence (GSG) preceding the 2A peptide. In some cases, the construct may combine a spacer, a linker, an adaptor, a promoter, or a combination thereof. For example, the linker may have a spacer (SGSG linker or GSG linker or Whitlow linker) and a furin linker (RAKR) cleavage site with different 2A peptides. The spacer may be I-Ceui. In some cases, the linker may be engineered. For example, the linker may be designed to include chemical features such as hydrophobicity. In some cases, at least two linker sequences may result in the same protein. In other cases, multiple linkers may be used in the vector. For example, the gene of interest may be separated by at least two linkers.
[0194] In certain embodiments, two or more polypeptides encoded by the polynucleotides described herein can be separated by an intervening sequence that encodes a linker polypeptide. In certain cases, the linker is a cleavable linker. In some embodiments, the polypeptide of interest is expressed as a fusion protein linked by a cleavable intervening linker polypeptide. In certain embodiments, the cleavable linker polypeptide can be any one or two of furin link, fmdv, p2a, GSG-p2a, and / or fp2a, as described below. In some cases, the linker is APVKQGSG (SEQ ID NO: 96).
[0195] In certain cases, the linker polypeptide may include the amino acid sequence "RAKR" (SEQ ID NO: 86). In certain cases, the furin linker polypeptide may be encoded by a polynucleotide sequence that includes "CGTGCAAAGCGT" (SEQ ID NO: 69) or "AGAGCTAAGAGG" (SEQ ID NO: 112).
[0196] In some embodiments, linkers can be used in the polynucleotides described herein. Linkers can be flexible linkers, non-flexible linkers, in vivo cleavable linkers, or any combination thereof. In some cases, linkers can link functional domains together (as in the case of flexible and non-flexible linkers), or release functional domains in vivo (as in the case of in vivo cleavable linkers).
[0197] Linkers may improve biological activity, increase expression yields, and achieve desirable pharmacokinetic profiles. Linkers may also include hydrazones, peptides, disulfides, or thioesthers.
[0198] In some cases, the linker sequences described herein may include flexible linkers. Flexible linkers may be applied when the domains to be joined require some degree of movement or interaction. Flexible linkers may be composed of small, non-polar (e.g., Gly), or polar (e.g., Ser or Thr) amino acids. Flexible linkers may have a sequence that is primarily comprised of a string of Gly and Ser residues ("GS" linker). An example of a flexible linker may have the sequence (Gly-Gly-Gly-Gly-Ser)n (SEQ ID NO: 150). By adjusting the copy number "n", the length of this exemplary GS linker may be optimized to achieve proper separation of functional domains while maintaining the required inter-domain interactions. In addition to the GS linker, other flexible linkers may also be used in recombinant fusion proteins. In some cases, the flexible linker may also be rich in small or polar amino acids such as Gly and Ser, but may contain additional amino acids such as Thr and Ala to maintain flexibility. In other cases, polar amino acids such as Lys and Glu may be used to improve solubility.
[0199] The flexible linker incorporated in the linker sequence described herein may be rich in small or polar amino acids, such as Gly and Ser, to provide good flexibility and solubility. Flexible linkers may be suitable when a certain movement or interaction is desired for the fusion protein domain. In addition, flexible linkers may not have a non-flexible structure, but may be used as a passive linker to maintain the distance between functional domains. The length of the flexible linker may be adjusted to allow proper folding and optimal biological activity of the fusion protein.
[0200] The linkers described herein may further include a rigid linker, if desired. A rigid linker may be used to maintain a constant distance between domains of a polypeptide. Examples of rigid linkers may be alpha-helix-forming linkers, Pro-rich sequences, (XP)n, X-Pro scaffolds, A(EAAAK)nA (n=2-5), to name a few. A rigid linker may optionally exhibit a relatively rigid structure by adopting an alpha-helix structure or by containing multiple Pro residues.
[0201] The linkers described herein may be cleavable in some cases. In other cases, the linkers are not cleavable. A non-cleavable linker may covalently join the functional domains together to act as one molecule through in vivo or ex vivo processes. The linkers may also be cleavable in vivo. A cleavable linker may be introduced to release the free functional domain in vivo. A cleavable linker may be cleaved in the presence of a reducing agent, a protease, to name a few. For example, reduction of a disulfide bond may be used to create a cleavable linker. In the case of a disulfide linker, a cleavage event via disulfide exchange with a thiol, such as glutathione, may result in cleavage. In other cases, cleavage of the linker in a recombinant fusion protein in vivo may also be performed by a protease that may be expressed in a specific cell or tissue in vivo under a pathological condition (e.g., cancer or inflammation) or may be restricted to a certain cellular compartment. In some cases, the cleavable linker can allow targeted cleavage. For example, the specificity of many proteases can lead to slow cleavage of the linker in the constrained compartment. The cleavable linker can also include hydrazones, peptides, disulfides, or thioethers. For example, hydrazones can provide stability in serum. In other cases, hydrazones can allow cleavage in acidic compartments. The acidic compartments can have a pH of up to 7. The linker can also include thioethers. The thioethers can be non-reducing. The thioethers can be designed for intracellular proteolysis.
[0202] In certain embodiments, the fmdv linker polypeptide comprises a sequence that may be at least about 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 87. In certain embodiments, the fmdv linker polypeptide is one or more of the linkers encoded within a single vector that link two or more fusion proteins. In certain cases, the fmdv linker polypeptide may be encoded by a nucleic acid sequence of an open reading frame (ORF) of a polynucleotide. In some cases, the ORF encoding fmdv comprises or consists of the sequence of SEQ ID NO: 70). In certain embodiments, the polynucleotide encoding fmdv is at least 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:70.
[0203] In certain cases, the linker polypeptide may be a "p2a" linker. In certain embodiments, the p2a polypeptide may comprise a sequence that may be at least about 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:91. In certain embodiments, the p2a linker polypeptide may be one or more of the linkers encoded within a single vector that link two or more fusion proteins. In some cases, the p2a linker polypeptide may be encoded by a nucleic acid sequence of an open reading frame (ORF) of a polynucleotide. In certain embodiments, the ORF encoding p2a comprises or consists of the sequence of SEQ ID NO:74. In certain cases, the polynucleotide encoding p2a may be SEQ ID NO:74, or may be at least about 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical thereto.
[0204] In some cases, the linker polypeptide may be a "GSG-p2a" linker. In certain embodiments, the GSG-p2a linker polypeptide may comprise a sequence that may be at least about 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:92. In certain embodiments, the GSG-p2a linker polypeptide may be one or more of the linkers encoded within a single vector that link two or more fusion proteins. In some cases, the GSG-p2a linker polypeptide may be encoded by a nucleic acid sequence of an open reading frame (ORF) of a polynucleotide. The ORF encoding GSG p2a may comprise the sequence of SEQ ID NO:75. In some cases, the polynucleotide encoding GSG-p2a may be SEQ ID NO: 75, or may be at least about 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical thereto.
[0205] The linker polypeptide may be the "fp2a" linker provided herein. In certain embodiments, the fp2a linker polypeptide may comprise a sequence that may be at least about 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 95. In certain cases, the fp2a linker polypeptide may be one or more of the linkers encoded in a single vector that link two or more fusion proteins. In some cases, the fp2a linker polypeptide may be encoded by a nucleic acid sequence of an open reading frame (ORF) of a polynucleotide. In certain embodiments, the polynucleotide encoding the fp2a linker may be SEQ ID NO:78, or may be at least about 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical thereto.
[0206] In some cases, the linker can be engineered. For example, the linker can be designed to include chemical features such as hydrophobicity. In some cases, at least two linker sequences can result in the same protein. The sequence can be 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the polypeptide sequence of SEQ ID NO: 82, 96, or 97, or can be approximately identical in these proportions. In other cases, multiple linkers can be used in the vector. For example, the gene of interest and one or more gene switch polypeptide sequences described herein can be separated by at least two linkers. In some cases, the gene can be separated by two, three, four, five, six, seven, eight, nine, or up to ten linkers.
[0207] The linker can be an engineered linker. The method of designing the linker can be a computational method. In some cases, the computational method can include a graphical method. Computational methods can be used to search for suitable peptides from a library of three-dimensional peptide structures derived from a database. For example, the Brookhaven Protein Data Bank (PDB) can be used to measure the spacing distance between selected amino acids of the linker.
[0208] In some embodiments, a polynucleotide is provided that encodes a polypeptide construct comprising a furin polypeptide and a 2A polypeptide, wherein the furin polypeptide and the 2A polypeptide are connected by a polypeptide linker comprising at least three hydrophobic amino acids. Optionally, the at least three hydrophobic amino acids are selected from the list consisting of glycine (Gly) (G), alanine (Ala) (A), valine (Val) (V), leucine (Leu) (L), isoleucine (Ile) (I), proline (Pro) (P), phenylalanine (Phe) (F), methionine (Met) (M), tryptophan (Trp) (W). Optionally, the polypeptide linker may also include one or more GS linker sequences, such as (GS)n, (SG)n, (GSG)n, and (SGSG)n, where n may be any number from 0 to 15.
[0209] A method for obtaining improved expression of a polypeptide construct is provided, comprising the steps of: providing a polynucleotide encoding said polypeptide construct comprising a first functional polypeptide and a second functional polypeptide, said first functional polypeptide and said second functional polypeptide being connected by a linker polypeptide comprising a sequence with at least 60% identity to the sequence APVKQ; and expressing said polynucleotide in a host cell, resulting in improved expression of the polypeptide construct compared to a corresponding polypeptide construct not having a linker polypeptide comprising a sequence with at least 60% identity to the sequence APVKQ.
[0210] IRES elements Also disclosed herein is a construct that comprises an IRES element, which facilitates the expression and functionality of the polynucleotides and polypeptides described herein. The term "internal ribosome entry site (IRES)" as used herein may be intended to mean an internal ribosome entry site. In a vector that comprises an IRES sequence, a first gene may be translated by cap-dependent ribosome scanning, a mechanism involving its own 5'-UTR, while the translation of subsequent genes may be achieved in a cap-independent manner by direct recruitment of ribosomes to the IRES. The IRES sequence may allow eukaryotic ribosomes to bind and initiate translation without binding to the 5' cap end. The IRES sequence may allow the expression of multiple genes from one transcript (Mountford and Smith, Trends Genet. 11(5):179-84 (1995)).
[0211] The term "CAP" or "cap" as used herein refers to a modified nucleotide, generally 7-methylguanosine (7meG-ppp-G), linked 3'-5' to the 5' end of a eukaryotic mRNA as a required element in the normal translation initiation pathway during expression of a protein from that mRNA.
[0212] In certain cases, the IRES region may be derived from a virus, such as the IRES sequence of picornavirus, encephalomyocarditis virus, or hepatitis C virus. In other cases, the IRES region may be derived from an encephalomyocarditis virus. The term "EMCV" or "encephalomyocarditis virus" as used herein refers to any member of the genus Picornaviridae, species Encephalomyocarditis virus, or strain. Examples are EMCV-R (Ruckert) strain virus, Columbia SK virus. In some cases, cellular IRES elements can be used, such as eukaryotic initiation factor 4G, immunoglobulin heavy chain binding protein, c-myc proto-oncogene, vascular endothelial growth factor, fibroblast growth factor 1 IRES, or any combination or modification thereof. In some cases, the cellular IRES may have increased gene expression when compared to the viral IRES.
[0213] Viral IRES sequences, cellular IRES sequences, or a combination thereof can be used in the vector. The IRES can be derived from encephalomyocarditis virus (EMCV) or poliovirus (PV). In some cases, the IRES element is an IRES element that ... padi virus (RhPV), Cricket paralysis virus (CrPV), Ectropis obliqua picorna-like virus (EoPV), Plautia stali enterovirus (PSIV), Triatoma virus (TrV), Honeybee paralysis sistic virus (IAPV, KBV), Blackcurrant reversion virus (BRV), Pelargonium variegation virus (PFBV), Hibiscus chlorotic mottle virus (HCRSV), Crucifer-infecting tobamovirus (CrTMV), Potato leaf roll virus (PLRV), Tobacco etch virus (TEV), Giardia virus (GLV), Leishmania RNA virus 1 (LRV-1), and combinations or modifications thereof.In some cases, the IRES is selected from the group consisting of Apaf-1, XIAP, HIAP2 / c-IAP1, DAP5, Bcl-2, c-myc, CAT-1, INR, differentiation LEF-1, PDGF2, HIF-1a, VEGF, FGF2, BiP, BAG-1, CIRP, p53, SHMT1, PITSLREp58, CDK1, Rpr, hid, hsp70, grim, skl, Antennapedia, dFoxO, dInR, Adh-Adhr, HSP101, ADH, URE-2, GPR1, NCE102, YMR181a, MSN1, BOI1, FLO8, GIC1, and any combination or modification thereof. When an IRES element is incorporated between two open reading frames (ORFs), translation initiation can occur by a canonical 5'-m7GpppN cap-dependent mechanism in the first ORF and a cap-independent mechanism in the second ORF, downstream of the IRES element.
[0214] In some cases, genes can be linked by an internal ribosome entry site (IRES). IRES can allow for simultaneous expression of multiple genes. For example, IRES sequences can allow for the production of multiple proteins from a single mRNA transcript. Ribosomes can bind to the IRES in a 5' cap-independent manner and initiate translation.
[0215] In some cases, the IRES sequence may be 500 base pairs or approximately this length. The IRES sequence may be 300 to 1000 base pairs. For example, the IRES may be 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or 1000 base pairs in length.
[0216] In some cases, the expression of downstream genes in a vector containing an IRES sequence can be reduced. For example, the expression of the gene following the IRES sequence can be reduced relative to the gene preceding the IRES sequence. The reduction in expression can be 1% to 99% reduction relative to the preceding gene.
[0217] Methods for Regulating Expression In one embodiment, a method of regulating expression of a heterologous gene in an engineered cell is provided. A polynucleotide encoding a gene switch polypeptide for ligand-inducible control of heterologous gene expression, an antigen-binding polypeptide, and a heterologous gene are provided. In some cases, the polynucleotide is in one or more gene expression cassettes depicted in any one of Figures 1-16. In other cases, the polynucleotide is incorporated into the engineered cell via a viral or non-viral vector. The viral vector may include a lentiviral vector, a retroviral vector, or an adenoviral vector. The non-viral vector may include a Sleeping Beauty transposon. In other cases, the polynucleotide is incorporated into the engineered cell via a recombinase or a gene editing method. An example of a recombinase is a serine recombinase described herein. An example of a gene editing method may include a CRISPR system or an Argnonaute system. As used herein, "CRISPR gene editing system" or "CRISPR system" refers to any RNA-guided, Cas protein-mediated process for targeting DNA sequence changes to specific regions of a genome. As used herein, "Argonaute gene editing system" refers to any single-stranded DNA-directed, Argonaute endonuclease-mediated process for targeting DNA sequence changes to specific regions of a genome.
[0218] Pharmaceutical Compositions and Dosages The present disclosure provides a composition comprising an adenovirus or adenovirus vector described herein and a carrier therefor (e.g., a pharma- ceutically acceptable carrier). The composition is desirably a physiologically acceptable (e.g., pharma- ceutical) composition comprising a carrier, preferably a physiologically (e.g., pharma- ceutical) acceptable carrier, and an adenovirus or an adenovirus vector. Any suitable carrier can be used within the context of the present disclosure, and such carriers are well known in the art. The choice of carrier will be determined, in part, by the particular use of the composition (e.g., administration to an animal) and the particular method used to administer the composition. Ideally, in the context of a replication-defective adenovirus vector, the pharmaceutical composition preferably does not include a replication-competent adenovirus. The pharmaceutical composition may be optionally sterile.
[0219] Suitable compositions include aqueous and non-aqueous, isotonic sterile solutions, which may contain antioxidants, buffers, and bacteriostatic agents, as well as aqueous and non-aqueous sterile suspensions, which may contain suspending agents, solubilizers, thickeners, stabilizers, and preservatives. The compositions may be presented in unit-dose or multi-dose sealed containers, such as ampoules and vials, but may also be stored in a freeze-dried (lyophilized) state, requiring only the addition of a sterile liquid carrier, e.g., water, immediately prior to use. Ready-to-use solutions and suspensions can be prepared from sterile powders, granules, and tablets. Preferably, the carrier is a buffered saline solution. More preferably, the adenovirus or adenovirus vector is part of a composition that is formulated to protect the adenovirus or adenovirus vector from damage prior to administration. For example, the composition can be formulated to reduce the loss of adenovirus or adenovirus vector on the device used to prepare, store or administer adenovirus or adenovirus vector, such as glass container, syringe or needle.The composition can be formulated to reduce the light sensitivity and / or temperature sensitivity of adenovirus or adenovirus vector.For this purpose, the composition preferably comprises a pharma- ceutically acceptable liquid carrier, such as the liquid carrier described above, and a stabilizer selected from the group consisting of polysorbate 80, L-arginine, poly(vinylpyrrolidone), trehalose, and combinations thereof.The use of such a composition will extend the shelf life of adenovirus or adenovirus vector and facilitate its administration. Compositions containing adenoviruses or adenoviral vectors are further described, for example, in US Pat. No. 6,225,289, US Pat. No. 6,514,943, and WO 2000 / 034444.
[0220] The composition can also be formulated to enhance transduction efficiency. In addition, those skilled in the art will understand that the adenovirus or adenoviral vector can be present in the composition with other therapeutic or biologically active agents. For example, factors that control inflammation, such as ibuprofen or steroids, can also be part of the composition to reduce swelling and inflammation associated with the administration of the adenovirus or adenoviral vector in vivo. When the adenovirus or adenoviral vector is used to deliver a nucleic acid sequence encoding an antigen to a host, immune system stimulators or adjuvants, such as interleukins, lipopolysaccharides, or double-stranded RNA, can be administered to enhance or modify any immune response to the antigen. Antibiotics, i.e., microbicides and fungicides, can also be present to treat existing infections and / or reduce the risk of future infections, such as those associated with gene transfer procedures.
[0221] In some embodiments of the present specification, disclosed is a composition comprising the polynucleotide or polypeptide disclosed herein for administration in a subject.Optionally, disclosed is a modified effector cell composition that encodes the polynucleotide or polypeptide disclosed herein and optionally contains cytokines and / or additional therapeutic agents.Optionally, the present specification also includes a vector that encodes a gene switch polypeptide for regulating the expression of chimeric antigen receptor to modify effector cells.
[0222] In some cases, the pharmaceutical composition of the vector encoding modified effector cell or gene switch polypeptide and chimeric antigen receptor is formulated in a conventional manner using one or more physiologically acceptable carriers, including excipients and auxiliary agents, which facilitate the processing of active compounds into pharmacopoeial preparations.The appropriate formulation depends on the route of administration selected.For example, a summary of the pharmaceutical compositions described herein can be found in Remington: The Science and Practice ofPharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, HA and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, NY, 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins 1999).
[0223] The pharmaceutical compositions are optionally manufactured in a conventional manner, including, by way of example only, conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or compressing processes.
[0224] In certain embodiments, the composition may also include one or more pH adjusters or buffers, including acids such as acetic acid, boric acid, citric acid, lactic acid, phosphoric acid, and hydrochloric acid; bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate, and tris-hydroxymethylaminomethane; and buffers such as citrate / dextrose, sodium bicarbonate, and ammonium chloride. Such acids, bases, and buffers are incorporated in amounts required to maintain the pH of the composition in an acceptable range.
[0225] In other embodiments, the compositions may also include one or more salts in an amount required to bring the osmolality of the composition into an acceptable range. Such salts include salts having sodium, potassium, or ammonium cations and chloride, citrate, ascorbate, borate, phosphate, bicarbonate, sulfate, thiosulfate, or bisulfite anions, with suitable salts including sodium chloride, potassium chloride, sodium thiosulfate, sodium bisulfite, and ammonium sulfate.
[0226] The pharmaceutical compositions described herein are administered by any suitable route, including, but not limited to, oral, parenteral (e.g., intravenous, subcutaneous, intramuscular, intracerebral, intraventricular, intraarticular, intraperitoneal, or intracranial), intranasal, buccal, sublingual, or rectal. In some cases, the pharmaceutical compositions are formulated for parenteral (e.g., intravenous, subcutaneous, intramuscular, intracerebral, intraventricular, intraarticular, intraperitoneal, or intracranial) administration.
[0227] The pharmaceutical compositions described herein are formulated into any suitable dosage form for oral ingestion by the individual to be treated, including but not limited to aqueous oral dispersions, liquids, gels, syrups, elixirs, slurries, suspensions, etc., solid oral dosage forms, aerosols, controlled release formulations, fast melt formulations, effervescent formulations, lyophilized formulations, tablets, powders, pills, dragees, capsules, delayed release formulations, sustained release formulations, pulsed release formulations, multiparticulate formulations, mixtures of immediate release formulations and controlled release formulations. In some embodiments, the pharmaceutical compositions are formulated into capsules. In some embodiments, the pharmaceutical compositions are formulated into solutions (e.g., for intravenous administration). In some cases, the pharmaceutical compositions are formulated as infusion solutions. In some cases, the pharmaceutical compositions are formulated as injection solutions.
[0228] The solid pharmaceutical dosage forms described herein optionally comprise a compound described herein and one or more pharma- ceutically acceptable excipients, such as a compatible carrier, binder, filler, suspending agent, flavoring agent, sweetener, disintegration agent, dispersing agent, surfactant, lubricant, coloring agent, diluent, solubilizer, humectant, plasticizer, stabilizer, penetration enhancer, wetting agent, antifoaming agent, antioxidant, preservative, or one or more combinations thereof.
[0229] In yet another aspect, a thin film coating is applied around the composition using standard coating procedures, such as those described in Remington's Pharmaceutical Sciences, 20th Edition (2000).In some embodiments, the composition is formulated into particles (e.g., for administration by capsules), and some or all of the particles are coated.In some embodiments, the composition is formulated into particles (e.g., for administration by capsules), and some or all of the particles are microencapsulated.In some embodiments, the composition is formulated into particles (e.g., for administration by capsules), and some or all of the particles are not microencapsulated and are uncoated.
[0230] In certain embodiments, the compositions provided herein may also include one or more preservatives that inhibit microbial activity.Suitable preservatives include mercury-containing substances such as merphen and thiomersal; stabilized chlorine dioxide; and quaternary ammonium compounds such as benzalkonium chloride, cetyltrimethylammonium bromide, and cetylpyridinium chloride.
[0231] "Antifoaming agents" reduce foaming during processing that can result in coagulation of the aqueous dispersion, air bubbles in the finished film, or generally impair processing. Exemplary antifoaming agents include silicon emulsion or sorbitan sesquoleate.
[0232] "Antioxidants" include, for example, butylated hydroxytoluene (BHT), sodium ascorbate, ascorbic acid, sodium metabisulfite, and tocopherol. In certain embodiments, antioxidants enhance chemical stability when needed.
[0233] The formulations described herein may benefit from antioxidants, metal chelators, thiol-containing compounds, and other general stabilizing agents. Examples of such stabilizers include, but are not limited to, (a) about 0.5% to about 2% w / v glycerol, (b) about 0.1% to about 1% w / v methionine, (c) about 0.1% to about 2% w / v monothioglycerol, (d) about 1 mM to about 10 mM EDTA, (e) about 0.01% to about 2% w / v ascorbic acid, (f) 0.003% to about 0.02% w / v polysorbate 80, (g) 0.001% to about 0.05% w / v polysorbate 20, (h) arginine, (i) heparin, (j) dextran sulfate, (k) cyclodextrins, (l) pentosan polysulfate and other heparinoids, (m) divalent cations such as magnesium and zinc, or (n) combinations thereof.
[0234] "Binders" impart cohesive properties and include, for example, alginic acid and its salts; cellulose derivatives such as carboxymethylcellulose, methylcellulose (e.g., Methocel®), hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose (e.g., Klucel®), ethylcellulose (e.g., Ethocel®), and microcrystalline cellulose (e.g., Avicel®); microcrystalline dextrose; amylose; magnesium aluminum silicate; polysaccharide acids; bentonite; gelatin; polyvinylpyrrolidone / vinyl acetate copolymer; crospovidone; povidone; starch; alpha Starches; sugars such as tragacanth, dextrin, sucrose (e.g., Dipac®), glucose, dextrose, molasses, mannitol, sorbitol, xylitol (e.g., Xylitab®), and lactose; natural or synthetic gums such as acacia, tragacanth, ghatti gum, mucilage of isapol husk, polyvinylpyrrolidone (e.g., Polyvidone® CL, Kollidon® CL, Polyplasdone® XL-10), arabogalactan from larch, Veegum®, polyethylene glycol, waxes, sodium alginate, etc.
[0235] "Carriers" or "carrier materials" include any excipients commonly used in medicines and are to be selected based on their compatibility with the compounds disclosed herein, such as ibrutinib and anti-cancer compounds, and the release profile characteristics of the desired dosage form. Exemplary carrier materials include, for example, binders, suspending agents, disintegrants, fillers, surfactants, solubilizers, stabilizers, lubricants, humectants, diluents, and the like. "Pharmaceutically compatible carrier materials" may include, but are not limited to, acacia, gelatin, colloidal silicon dioxide, calcium glycerophosphate, calcium lactate, maltodextrin, glycerin, magnesium silicate, polyvinylpyrrolidone (PVP), cholesterol, cholesterol esters, sodium caseinate, soy lecithin, taurocholic acid, phosphatidylcholine, sodium chloride, tricalcium phosphate, dipotassium phosphate, cellulose and cellulose conjugates, sugars, sodium stearoyl lactylate, carrageenan, monoglycerides, diglycerides, pregelatinized starch, and the like. See, e.g., Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, HA and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, NY, 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins 1999).
[0236] "Dispersing agents" and / or "viscosity modulating agents" include materials that control the diffusion and homogeneity of drugs through liquid media or granulation or blending methods. In some embodiments, these agents also enhance the effectiveness of coating or eroding matrices. Exemplary diffusion enhancers / dispersing agents include, for example, hydrophilic polymers, electrolytes, Tween® 60 or Tween® 80, PEG, polyvinylpyrrolidone (PVP; commercially known as Plasdone®), and, for example, hydroxypropylcellulose (e.g., HPC, HPC-SL, and HPC-L), hydroxypropylmethylcellulose (e.g., HPMC K100, HPMC K4M, HPMC K15M, and HPMC K100M), sodium carboxymethylcellulose (carboxymethylcellulose), cellulose acetate (Citrate), cellulose esters (Citrate), cellulose esters (Citrate), cellulose esters (Citrate), cellulose acetate ... sodium), methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate stearate (HPMCAS), amorphous cellulose, carbohydrate-based dispersants, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol (PVA), vinylpyrrolidone / vinyl acetate copolymer (S630), 4-(1,1,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde (also known as tyloxapol), poloxamers (e.g., Pluronics F68®, Pluronics F88®, and Pluronics F108®, which are block copolymers of ethylene oxide and propylene oxide); and poloxamines (e.g., Poloxamine 908® (BASF Corporation, Parsippany, NJ), which are tetrafunctional block copolymers derived from the sequential addition of propylene oxide and ethylene oxide to ethylenediamine).), polyvinylpyrrolidone K12, polyvinylpyrrolidone K17, polyvinylpyrrolidone K25, or polyvinylpyrrolidone K30, polyvinylpyrrolidone / vinyl acetate copolymer (S-630), polyethylene glycol (e.g., the polyethylene glycol can have a molecular weight of about 300 to about 6000, or about 3350 to about 4000, or about 7000 to about 5400), sodium carboxymethylcellulose, methylcellulose, polysorbate 80, sodium alginate, For example, gums such as tragacanth and acacia gums, guar gum, xanthans including xanthan gum, sugars, cellulose derivatives such as sodium carboxymethylcellulose, methylcellulose, sodium carboxymethylcellulose, polysorbate 80, sodium alginate, polyethoxylated sorbitan monolaurate, polyethoxylated sorbitan monolaurate, povidone, carbomer, polyvinyl alcohol (PVA), alginates, chitosan, and combinations thereof. Plasticizers such as cellulose or triethylcellulose can also be used as dispersing agents. Dispersing agents particularly useful in liposomal dispersions and self-emulsifying dispersions are dimyristoyl phosphatidylcholine, natural phosphatidylcholine derived from chicken eggs, natural phosphatidylglycerol derived from chicken eggs, cholesterol, and isopropyl myristate.
[0237] Combinations of one or more erosion promoters with one or more diffusion promoters may also be used in the compositions.
[0238] The term "diluent" refers to a compound that is used to dilute the compound of interest prior to delivery. Diluents can also be used to stabilize the compound, as they can provide a more stable environment. In the art, salts dissolved in buffers (which can also control or maintain pH) are used as diluents, including but not limited to phosphate buffered saline solutions. In certain embodiments, diluents increase the bulk of the composition to facilitate compression or create sufficient bulk for homogeneous blending for capsule filling. Such compounds include, for example, lactose, starch, mannitol, sorbitol, dextrose, microcrystalline cellulose such as Avicel®; dibasic calcium phosphate, dicalcium phosphate dihydrate; tricalcium phosphate, calcium phosphate; anhydrous lactose, spray-dried lactose; pregelatinized starch, compressible sugars such as Di-Pac® (Amstar); mannitol, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate stearate, sucrose-based diluents, powdered sugar; monobasic calcium sulfate monohydrate, calcium sulfate dihydrate; calcium lactate trihydrate, dextrates; hydrolyzed cereal solids, amylose; powdered cellulose, calcium carbonate; glycine, kaolin; mannitol, sodium chloride; inositol, bentonite, and the like.
[0239] "Bulking agents" include compounds such as lactose, calcium carbonate, calcium phosphate, dibasic calcium phosphate, calcium sulfate, microcrystalline cellulose, cellulose powder, dextrose, dextrates, dextran, starch, pregelatinized starch, sucrose, xylitol, lactitol, mannitol, sorbitol, sodium chloride, polyethylene glycol, and the like.
[0240] "Lubricants" and "glidants" are compounds that prevent, reduce, or inhibit adhesion or friction of materials. Exemplary lubricants include, for example, stearic acid, calcium hydroxide, talc, sodium stearyl fumarate, hydrocarbons such as mineral oils or hydrogenated vegetable oils such as hydrogenated soybean oil (Sterotex®), higher fatty acids and their alkali metal and alkaline earth metal salts such as aluminum, calcium, magnesium, zinc, etc., stearic acid, sodium stearate, glycerol, talc, wax, Stearowet®, boric acid, sodium benzoate, sodium acetate, sodium chloride, leucine, polyethylene glycol (e.g., PEG-4000) or methoxypolyethylene glycol such as Carbowax™, sodium oleate, sodium benzoate, glyceryl behenate, polyethylene glycol, magnesium or sodium lauryl sulfate, colloidal silica such as Syloid™, Cab-O-Sil®, starch such as corn starch, silicone oil, surfactants, etc.
[0241] A "plasticizer" is a compound used to soften the microencapsulated material or film coating to make the microencapsulated material less brittle. Suitable plasticizers include, for example, polyethylene glycols such as PEG 300, PEG 400, PEG 600, PEG 1450, PEG 3350, and PEG 800, stearic acid, propylene glycol, oleic acid, triethylcellulose, and triacetin. In some embodiments, the plasticizer may also function as a dispersing agent or humectant.
[0242] "Solubilizing agents" include compounds such as triacetin, triethyl citrate, ethyl oleate, ethyl caprylate, sodium lauryl sulfate, sodium doccusate, vitamin E TPGS, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cyclodextrin, ethanol, n-butanol, isopropyl alcohol, cholesterol, bile salts, polyethylene glycol 200-600, glycofurol, transcutol, propylene glycol, and dimethyl isosorbide.
[0243] "Stabilizers" include compounds such as any antioxidant, buffer, acid, preservative, etc.
[0244] "Suspending agents" include polyvinylpyrrolidone, e.g., polyvinylpyrrolidone K12, polyvinylpyrrolidone K17, polyvinylpyrrolidone K25, or polyvinylpyrrolidone K30, vinylpyrrolidone / vinyl acetate copolymer (S630), polyethylene glycol (e.g., the polyethylene glycol can have a molecular weight of about 300 to about 6000, or about 3350 to about 4000, or about 7000 to about 5400), sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, hydroxymethylcellulose stearate acetate, Polysorbate 80, hydroxyethylcellulose, sodium alginate, e.g., gums such as gum tragacanth and gum acacia, guar gum, xanthans including xanthan gum, sugars, cellulose derivatives such as sodium carboxymethylcellulose, methylcellulose, sodium carboxymethylcellulose, hydroxypropyl methylcellulose, hydroxyethylcellulose, compounds such as polysorbate 80, sodium alginate, polyethoxylated sorbitan monolaurate, polyethoxylated sorbitan monolaurate, povidone, and the like.
[0245] "Surfactants" include compounds such as sodium lauryl sulfate, sodium docusate, Tween 60 or Tween 80, triacetin, vitamin E TPGS, sorbitan monooleate, polyoxyethylene sorbitan monooleate, polysorbate, poloxamer, bile salts, glyceryl monostearate, copolymers of ethylene oxide and propylene oxide, e.g., Pluronic® (BASF). Some other surfactants include polyoxyethylene glycerol fatty acid esters and vegetable oils, e.g., polyoxyethylene (60) hydrogenated castor oil; and polyoxyethylene alkyl ethers and alkyl phenyl ethers, e.g., octoxynol 10, octoxynol 40. In some embodiments, surfactants can be incorporated to enhance physical stability or for other purposes.
[0246] "Viscosity enhancing agents" include, for example, methylcellulose, xanthan gum, carboxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose stearate acetate, hydroxypropylmethylcellulose phthalate, carbomer, polyvinyl alcohol, alginates, acacia, chitosan, and combinations thereof.
[0247] "Moisturizing agents" include compounds such as oleic acid, glyceryl monostearate, sorbitan monooleate, sorbitan monolaurate, triethanolamine oleate, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monolaurate, sodium docusate, sodium oleate, sodium lauryl sulfate, sodium docusate, triacetin, Tween 80, Vitamin E TPGS, ammonium salts, and the like.
[0248] Kits / Products In certain embodiments herein, kits and products are disclosed for use in one or more methods described herein.Such kits include a carrying case, package, or container that is compartmentalized to receive one or more containers, such as vials, test tubes, etc., each of which contains one of the individual elements used in the methods described herein.Suitable containers include, for example, bottles, vials, syringes, and test tubes.In one embodiment, the container is formed from various materials, such as glass or plastic.
[0249] The products presented herein contain packaging materials. Examples of pharmaceutical packaging materials include, but are not limited to, blister packs, bottles, test tubes, bags, containers, bottles, and any packaging materials suitable for the selected formulation and intended mode of administration and treatment.
[0250] The kit typically includes a label listing the contents and / or instructions for use, as well as a package insert with instructions for use. Typically, a set of instructions will also be included.
[0251] In some embodiments, the indicia is affixed to or associated with the container. In one embodiment, the indicia is affixed to the container when letters, numbers, or other symbols forming the indicia are bonded, molded, or etched into the container itself, and the indicia is also associated with the container when present in a receptacle or carrying case that holds the container, for example, as a package insert. In one embodiment, the indicia is used to indicate that the contents are to be used for a specific therapeutic application. The indicia also indicates instructions for the use of the contents, such as in the methods described herein. EXAMPLES
[0252] These examples are presented for illustrative purposes only and are not intended to limit the scope of the claims presented herein.
[0253] [Example 1] Antigen bioinformatics workflow for HPV vaccine design Generation of consensus sequences Sample sequences for E5, E6, and E7 (for serotypes HPV16, HPV17, HPV31, HPV33, and HPV45, which have been determined to have a high predisposition to cancer) were downloaded, converted to FASTQ files, and imported into the R statistical program. Individual amino acid sequences were read into R using the Biostrings package (readAAStringSet function). Multiple sequence alignments were performed using the ClustalW algorithm in the msa R package. Consensus sequences were generated for each subgroup / subtype and output to a PDF / FASTQ file using the msaPrettyPrint function.
[0254] Prediction of binding affinity NetMHC 4.0 was applied to each consensus sequence to predict binding affinity for all major MHC-I alleles (HLA-A0101, HLA-A0201, HLA-A0301, HLA-A2402, HLA-A2601, HLA-B0702, HLA-B0801, HLA-B2705, HLA-B3901, HLA-B4001, HLA-B5801, and HLA-B1501). NetMHC 4.0 uses an artificial neural network to predict the binding affinity of peptide sequences. This analysis was performed for HPV16, HPV18, HPV31, HPV33, and HPV45. Arbitrary thresholds were set at 0.5% (strong binders) and 2% (weak binders) of the ranks. Peptides with predicted binding affinity >99.5% were classified as strong binders, and peptides with predicted binding affinity >98% were classified as weak binders. The position of each amino acid within the peptide sequence was extracted and used to generate density curves (Figures 7A and 7B). These density curves were used to calculate first and second derivatives to determine peaks for strong and weak binders (Figure 7C). Finally, the union of these positions was used to extract amino acid sequences likely to elicit a response.
[0255] Prediction of binding affinity for HPV16, HPV18, HPV31, HPV33, and HPV45 Previous studies have shown that HPV strains 16, 18, 31, 33, and 45 are precursors of cervical cancer. To identify candidate peptides with broad coverage across these strains, binding affinities were predicted within each strain. Sequences with predicted strong / weak binding affinity were extracted. Using protein BLAST, these sequences were aligned against the consensus sequence across all five strains. The alignments were plotted for all five serotypes to assess coverage.
[0256] [Example 2] HPV antigen design Naturally occurring sequence variations in HPV strains could potentially hinder the development of an effective HPV vaccine. To address this concern, the present vaccine design method used bioinformatics and protein engineering techniques to select and design antigens with broad coverage of T cell epitopes, novel mutations, and enhancer agonist peptides. Taking advantage of available information on antigenic regions with extended coverage of CTL-specific epitopes and computational prediction results, the designed HPV vaccine antigens could induce robust HPV-16 / HPV-18 specific responses, potentially benefiting patients at high risk of HPV-driven cancers.
[0257] The new HPV vaccines contain engineered proteins, engineered peptides, and / or modifications of: 1) truncated E5 regions fused to the E6 and E7 domains of HPV16 and HPV18; 2) newly designed point mutations that could potentially abolish p53 binding to known PTPN13-binding mutants (Weiking et al., Cancer Gene Ther. 19(10):667-74 (2012). doi: 10.1038 / cgt.2012.55. Epub 2012 Aug 24); 3) application of novel truncations and p53-binding knockout mutants within the HPV18 E6 non-immunogenic region at the C-terminus; 4) novel truncations of the HPV18 E7 non-immunogenic region at the N-terminus and incorporation of pRb / Mi2B mutants (Weiking et al., 2012); and / or 5) Agonist peptides by Tsang, et al., Vaccine 35(19):2605-2611 (2017) doi: 10.1016 / j.vaccine.2017.03.025. Epub 2017 Apr 4 within newly designed HPV vaccine constructs Includes.
[0258] HPV Design 1 Using the consensus sequence information, the reference sequence of HPV16 / HPV18 was selected for design including all major variants. The vaccine composition including the different protein components of E6, E7, and E5, along with domain boundary and mutation information, is shown in Figure 3. The reference sequence for E6 was obtained from the Human Papillomavirus T-cell antigen database (Bioinformatics Core at Cancer Vaccine Center, Dana-Farber Cancer Institute). The reference sequences for E5 and E7 were obtained from the Papillomavirus Episteme (PaVE) database.
[0259] The designs for HPV16 E5 and HPV18 E5 were conceived through a combination of computational predictions (IEDB and netMHC), and for HPV16 also incorporated findings from Chen et al., J Virol. 78(3):1333-43 (2004); while the design for HPV18 incorporated the N-terminal residues (1-26) and C-terminal residues (41-53, 58-71) (see Figures 4A and 4B).
[0260] To prevent oncogenicity, inactivating mutations for HPV16 and HPV18 were introduced into the peptide sequences of E6 and E7 (Weiking et al., 2012 Oct;19(10):667-74. doi: 10.1038 / cgt.2012.55. Epub 2012 Aug 24). In HPV16 E6, these mutations were E18A, L50G, and alanine substitutions at 148-151 (ETQL to AAAA). In HPV16 E7, four mutations (H2P, C24G, E46A, and L67R) were incorporated (Weiking et al., 2012). In HPV18 E6, two mutations (E18A and L52G) were incorporated. In HPV18 E6, residues starting with amino acid 121 were removed from these designs because only the N-terminal portion was predicted to contain MHC-I binding epitopes (IEDB and netMHC analysis). Additional mutations were incorporated into E6 to further abolish its interaction with p53 protein (Martinez-Zapien et al., Nature 529(7587):541-45 (2016)). In HPV18 E7, two mutations (E55A and L74R) (Weiking et al., 2012) were incorporated, and residues at (1-40) were removed because HPV-18 E7 contains the majority of predicted MHC-I binding epitopes (IEDB and netMHC predictions) within the C-terminal region.
[0261] HPV Design 2 A total of 32 key immunogenic peptides, listed in Table 2, were selected to design recombinant multi-epitope proteins as HPV vaccine antigens. These peptides included CTL-specific peptides from E6 (HPV-16 / HPV-18), E7 (HPV-16 / HPV-18), and E5 (HPV16) genes. Most of these CTL epitopes were reported by multiple immunological assays, immunoproteomics, and were incorporated into predictions by IEDB resources and netMHC. The novelty of this antigen design is to graft the CTL peptides into the human ankyrin repeat protein scaffold for possible generation of new proteins carrying T cell epitopes and / or proteasome cleavage sites.
[0262] Human ankyrin-like repeat ("ALR") protein (PDB code: 1QYM) was selected as a scaffold onto which CTL peptides were randomly assembled and different kinds of protein linker sequences could be embedded between the peptides. ALR proteins are generally highly expressed and highly stable; they could provide a scaffold for HPV peptides and generate novel CTLs. Care was taken to prevent the re-formation of E6 and E7 oncogenic proteins by random shuffling of peptides.
[0263] A homology model (Figure 4A) was used to evaluate the overall structural features and to compare the designs against natural ankyrin repeats. This model suggested that CTL peptides grafted onto the ankyrin scaffold would retain their tertiary structure. The scaffold amino acids connecting these peptides could be used as "linkers" to potentially create new CTL and / or agonist peptide epitopes.
[0264] [Table 2]
[0265] HPV Design 3 Design 3 is similar to design 1, but with the addition of an enhancer agonist peptide (Figure 3). Overall, designs 1 and 3 contain all the necessary sequences from E5, E6, and E7, respectively (Figures 4A and 4B). They were conceived through combinations selected by the inventors using computational epitope prediction analysis and guidance from available information on binding to MHC-I and cytokine production following T cell activation.
[0266] For HPV16, the design includes (1) peptides from Tsang et al., Vaccine 35(19):2605-2611 (2017) doi: 10.1016 / j.vaccine.2017.03.025. Epub 2017 Apr 4 (three peptides containing mutations in E6 (L19V and Q91L / L99V) and E7 (T86V) that exhibit better MHC-I binding and induce more robust cytotoxic T cell lymphocyte (CTL) responses); (3) two enhancer peptides fused to the inactivated N- and C-termini of E6; and (4) one enhancer peptide fused to the inactivated C-terminus of E7.
[0267] For HPV18, the design included (1) three peptides with identical mutations to mimic enhancer agonist peptides similar to those of HPV16 (Tsang et al., 2017), including mutations in E6 (L21V and L101V); and (2) two potential mimic enhancer agonists fused to the N- / C-terminal regions of E6 and another agonist mimic fused to the C-terminal region of E7. HPV18 naturally harbors the previously mentioned mutations in E6 (Q91L) and naturally harbors a mutation in E7 (T95V), so no further modifications were required.
[0268] HPV Design 4 This design is based on design 2 and uses the same ankyrin repeat strategy. However, design 4 contains three more unique agonist peptides (Table 2) derived from the peptides of Tsang et al., 2017, for a total of 35 key immunogenic peptides. To differ from design 2 and for the potential to generate different CTL epitopes, the order of peptides grafted onto the scaffold was again randomized. A homology model for design 4 was generated (Figure 4B). The homology of this design was found to be similar to design 2, but indicated local structural variations.
[0269] HPV Design 5 This design is a multi-epitope vaccine designed by selecting all 35 key immunogenic peptides shown in Table 2. HPV design 5 was assembled with charged dipeptide KK residues. Advantages of this design include the potential for cleavage at the "KK" residues and random modification with the "K" residues added to the CTL epitopes.
[0270] [Example 3] Assessment of predicted binding affinity of HPV vaccine constructs Bioinformatics predictions were performed for the binding affinity of each design. All sequences were loaded into NetMHC and used to evaluate the extent of antigenicity and coverage for various HPV genotypes. Note that Design 4 and Design 5 use the same 35 peptides. The main difference is that Design 4 peptides are grafted to ankyrin protein, while Design 5 peptides are connected by "KK" linkers (Figure 5A). Finally, the prediction of binding affinity in the matched regions for both designs was similar (Figure 5B). HPV designs were compared between each other (Tables 3 and 4) but also to reference sequences, which are shown in Figure 8, Figures 9A-9C, and Figures 10A-10C.
[0271] [Table 3]
[0272] [Table 4]
[0273] The foregoing description of the specific embodiments fully reveals the general nature of the present invention, so that other practitioners, by applying knowledge within the skill of the art, can easily modify and / or adapt such specific embodiments to various applications without undue experimentation, without departing from the general concept of the present invention. Such adaptations and modifications are therefore intended to be within the meaning and range of equivalents of the disclosed embodiments, based on the teaching and guidance presented herein. It is to be understood that the terminology or phraseology herein is for the purpose of description, not for the purpose of limitation, as it would be interpreted by one of ordinary skill in the art in light of the teaching and guidance.
[0274] Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.
[0275] This application claims priority to U.S. Provisional Application No. 62 / 639,354, filed March 6, 2018, which is incorporated by reference in its entirety.
[0276] Embodiment A non-naturally occurring polynucleotide encoding a polypeptide comprising E1.1 or more immune response-inducing human papillomavirus (HPV) polypeptides. E2. The polynucleotide of E1, wherein said non-naturally occurring polynucleotide encodes a polypeptide comprising two or more HPV polypeptides. E3. The polynucleotide of E2, wherein said two or more HPV polypeptides comprise one or more immune response-inducing HPV-16 polypeptide sequences. E4. The polynucleotide of E3, wherein said HPV-16 peptide comprises at least one of an E5 peptide, an E6 peptide, or an E7 peptide. E5. The polynucleotide of E3 or E4, wherein said HPV-16 peptide comprises an E5 peptide, said E5 peptide having the sequence set forth in SEQ ID NO:47. E6. The polynucleotide of any one of E3 to E5, wherein the HPV-16 peptide comprises an E6 peptide, the E6 peptide having the sequence set forth in SEQ ID NO:45. E7. The polynucleotide of any one of E3 to E6, wherein the HPV-16 peptide comprises an E7 peptide, the E7 peptide having the sequence set forth in SEQ ID NO:46. E8. The polynucleotide of any one of E1 to E7, wherein said one or more HPV peptides comprises an HPV-18 peptide. E9. The polynucleotide of E8, wherein said HPV-18 peptide comprises at least one of an E5 peptide, an E6 peptide, or an E7 peptide. E10. The polynucleotide of E8 or E9, wherein said HPV-18 peptide comprises an E5 peptide, said E5 peptide having the sequence set forth in SEQ ID NO:50. E11. The polynucleotide of any one of E8 to E10, wherein said HPV-18 peptide comprises an E6 peptide, said E6 peptide having the sequence set forth in SEQ ID NO:48. E12. The polynucleotide of any one of E8 to E10, wherein said HPV-18 peptide comprises an E7 peptide, said E7 peptide having the sequence set forth in SEQ ID NO:49. E13. The polynucleotide of any one of E1 to E12, wherein the polypeptide has the sequence set forth in SEQ ID NO:51. E14. The polynucleotide of any one of E1 to E13, wherein at least one of the one or more HPV polypeptides is linked to an agonist peptide. E15. The polynucleotide of E14, wherein said agonist peptide has a sequence comprising an agonist peptide sequence shown in Table 2. E16. The polynucleotide of E14 or E15, wherein the polypeptide has the sequence set forth in SEQ ID NO:53. E17. A polynucleotide comprising a polynucleotide as described in any one of E1 to E16, and further comprising one or more polynucleotides encoding a gene switch system for inducible control of heterologous gene expression, wherein said heterologous gene expression is regulated by said gene switch system; said heterologous gene comprising a polynucleotide as described in any one of E1 to E16. E18. The polynucleotide of E17, wherein said gene switch system is an ecdysone receptor-based (EcR-based) gene switch system. E19. The polynucleotide of any one of E1 to E18, wherein said one or more HPV polypeptides is an HPV polypeptide for use in a vaccine. E20. A vector comprising a polynucleotide according to any one of E1 to E19. E21. The vector of E20, which is an adenoviral vector. E22. The vector of E21, wherein said adenovirus vector is a gorilla adenovirus vector. E23. A method of regulating expression of a heterologous gene in a cell, comprising introducing into the cell one or more polynucleotides comprising: (i) an inhibitory gene switch or an inducible gene switch; and (ii) a heterologous immune response-inducible gene whose expression is regulated by the gene switch, the heterologous immune response-inducible gene encoding one or more HPV polypeptides; and exposing the cell to a compound in an amount sufficient to inhibit or induce expression of the heterologous immune response-inducible gene. E24. The method of E23, wherein said target cell is a mammalian cell. E25. The method of E23 or E24, wherein said gene switch comprises a ligand-binding domain derived from at least one of ecdysone receptor (EcR), ubiquitous receptor, orphan receptor 1, NER-1, steroid hormone nuclear receptor 1, retinoid X receptor interacting protein 15, liver X receptor beta, steroid hormone receptor-like protein, liver X receptor, liver X receptor alpha, farnesoid X receptor, receptor interacting protein 14, and farnesol receptor. E26. An E6 peptide comprising an E18A amino acid substitution and at least one of the following amino acid substitutions compared to the wild-type E6 peptide: L50G, E148A, T149A, Q150A, and L151A. E27. The E6 peptide of E26, comprising the E18A amino acid substitution, and the L50G, E148A, T149A, Q150A, and L151A amino acid substitutions. E28. The E6 peptide described in E26, having the sequence set forth in SEQ ID NO:45. E29. The E6 peptide of any one of E26 to E28 fused to an agonist peptide. E30. The E6 peptide of E29, wherein the agonist peptide is fused to at least one of the C-terminus and N-terminus of the E6 peptide. E31. The E6 peptide of any one of E26 to E30, wherein said wild-type E6 peptide is derived from HPV-16. E32. An E6 peptide comprising a deletion compared to a wild-type E6 peptide, said deletion comprising the C-terminus of said wild-type E6 peptide. E33. The E6 peptide of E32, wherein the deletion comprises amino acid 121 to the C-terminus of the wild-type E6 peptide. E34. The E6 peptide of E32 or E33, comprising at least one of the following substitutions compared to the wild-type E6 peptide: E18A and L50G. E35. The E6 peptide of any one of E32 to E34, wherein said wild-type E6 peptide is derived from HPV-18. E36. The E6 peptide of any one of E32 to E35, having the sequence set forth in SEQ ID NO:48. E37. An E7 peptide comprising a deletion compared to a wild-type E7 peptide, said deletion comprising the N-terminus of said wild-type E7 peptide. E38. The E7 peptide of E37, wherein the deletion comprises amino acids 1-39 of the wild-type E7 peptide. E39. The E7 peptide of E37 or E38, comprising at least one of the following substitutions compared to the wild-type E7 peptide: E55A and L74R. E40. The E7 peptide of any one of E37 to E39, wherein said wild type E7 peptide is derived from HPV-18. E41. The E7 peptide of any one of E37 to E40, having the sequence as set forth in SEQ ID NO:49. E42. An E5 peptide comprising a deletion compared to a wild-type E5 peptide, said deletion comprising amino acids 41 to 57 of the wild-type E5 peptide. E43. The E5 peptide described in E42, having the sequence as set forth in SEQ ID NO:47. E44. The E5 peptide of E42 or E43, wherein said wild-type E5 peptide is derived from HPV-16. E45. An E5 peptide comprising a deletion compared to a wild-type E5 peptide, said deletion comprising at least one of amino acids 27-40 or amino acids 54-57 of said wild-type E5 peptide. E46. The E5 peptide described in E45, having the sequence as set forth in SEQ ID NO:50. E47. The E5 peptide of E45 or E46, wherein said wild-type E5 peptide is derived from HPV-18. E48. A polypeptide construct comprising a peptide according to any one of E26 to E47. A polypeptide construct comprising an E49.HPV-16 E6 peptide, said HPV-16 E6 peptide comprising an E18A amino acid substitution and at least one of the following amino acid substitutions compared to a wild-type HPV-16 E6 peptide: L50G, E148A, T149A, Q150A, and L151A. E50. The polypeptide construct of E49, wherein said HPV-16 E6 peptide comprises said E18A amino acid substitution, and said L50G, E148A, T149A, Q150A, and L151A amino acid substitutions. E51. The polypeptide construct of E49 or E50, wherein said HPV-16 E6 peptide has the sequence set forth in SEQ ID NO:45. E52. The polypeptide construct of any one of E49 to E51, further comprising an HPV-16 E7 peptide, said HPV-16 E7 peptide comprising at least one of the following amino acid substitutions compared to the wild-type HPV-16 E7 peptide: H2P, C24G, E46A, and L67R. E53. The polypeptide construct of E52, wherein said HPV-16 E7 peptide comprises the H2P, C24G, E46A, and L67R amino acid substitutions. E54. The polypeptide construct of E53, wherein said HPV-16 E7 peptide has the sequence set forth in SEQ ID NO:46. E55. The polypeptide construct of any one of E49 to E54, further comprising an HPV-16 E5 peptide. E56. The polypeptide construct of E55, wherein said HPV-16 E5 peptide comprises one or more amino acid deletions compared to a wild-type HPV-16 E5 peptide. E57. The polypeptide construct of E56, wherein the deletion comprises amino acids 41 to 57 of the wild-type HPV-16 E5 peptide. E58. The polypeptide construct of any one of E55 to E57, wherein said HPV-16 E5 peptide has the sequence set forth in SEQ ID NO:47. E59. The polypeptide construct of any one of E49 to E58, further comprising an HPV-18 E6 peptide. E60. The polypeptide construct of E59, wherein said HPV-18 E6 peptide comprises the substitutions E18A and L50G compared to a wild-type HPV-18 E6 peptide. E61. The polypeptide construct of E59 or E60, wherein said HPV-18 E6 peptide comprises a deletion of at least one C-terminal amino acid compared to said wild-type HPV-18 E6 peptide. E62. The polypeptide construct of E61, wherein the deletion comprises amino acid 121 to the C-terminus of the wild-type HPV-18 E6 peptide. E63. The polypeptide construct of any one of E59 to E62, wherein said HPV-18 E6 peptide has the sequence set forth in SEQ ID NO:48. E64. The polypeptide construct of any one of E49 to E63, further comprising an HPV-18 E7 peptide. E65. The polypeptide construct of E64, wherein said HPV-18 E7 peptide comprises the following substitutions compared to a wild-type HPV-18 E7 peptide: E55A and L74R. E66. The polypeptide construct of E64 or E65, wherein said HPV-18 E7 peptide comprises a deletion of at least one amino acid from the N-terminus of said HPV-18 E7 peptide. E67. The polypeptide construct of E66, wherein the deletion comprises amino acids 1 to 40 of the wild-type HPV-18 E7 peptide. E68. The polypeptide construct of any one of E64 to E67, wherein said HPV-18 E7 peptide has the sequence set forth in SEQ ID NO:49. E69. The polypeptide construct of any one of E59 to E68, further comprising an HPV-18 E5 peptide. E70. The polypeptide construct of E69, wherein said HPV-18 E5 peptide comprises at least one amino acid deletion compared to a wild-type HPV-18 E5 peptide. E71. The polypeptide construct of E70, wherein the deletion comprises amino acids 27-40 or amino acids 54-57 of the wild-type HPV-18 E5 peptide. E72. The polypeptide construct of any one of E69 to E71, wherein said HPV-18 E5 peptide has the sequence set forth in SEQ ID NO:50. E73. The polypeptide construct of any one of E59 to E72, having the sequence as set forth in SEQ ID NO:51. E74. The polypeptide construct of any one of E59 to E73, further comprising at least one agonist peptide. E75. The polypeptide construct of E74, wherein said at least one agonist peptide has a sequence comprising an agonist peptide sequence shown in Table 2. E76. The polypeptide construct of E74 or E75, having the sequence as set forth in SEQ ID NO:53. E77. A polypeptide construct comprising an ankyrin-like repeat domain and an HPV peptide. E78. The polypeptide construct of E77, wherein said ankyrin-like repeat protein is a human ankyrin-like repeat protein. E79. The polypeptide construct of E77 or E78, wherein said HPV peptide is linked to said ankyrin-like repeat protein by a linker. E80. The polypeptide construct of any one of E77 to E79, wherein said HPV peptide comprises at least one of an HPV-16 peptide or an HPV-18 peptide. E81. The polypeptide construct of any one of E77 to E80, wherein said HPV peptide comprises an HPV-16 peptide, said HPV-16 peptide comprising at least one of an E5 peptide, an E6 peptide, or an E7 peptide. E82. The polypeptide construct of any one of E77 to E81, wherein said HPV peptide comprises an HPV-18 peptide, said HPV-18 peptide comprising at least one of an E6 peptide or an E7 peptide. E83. The polypeptide construct of any one of E77 to E82, wherein said HPV peptide comprises an HPV-16 E5 sequence, an HPV-16 E6 sequence, an HPV-16 E7 sequence, an HPV-18 E6 sequence, or an HPV-18 E7 sequence as shown in Table 2. E84. The polypeptide construct of any one of E77 to E83, having the sequence as set forth in SEQ ID NO:52. E85. The polypeptide construct of any one of E77 to E84, further comprising at least one agonist peptide. E86. A polypeptide construct according to E85, comprising three agonist peptides. E87. The polypeptide construct of E86, having the sequence as set forth in SEQ ID NO:54. E88. A polypeptide construct comprising at least two HPV amino acid sequences as set forth in Table 2, wherein said at least two HPV amino acid sequences are connected by a peptide linker, and said peptide linker is a KK linker. E89. The polypeptide construct of E88, wherein said at least two HPV amino acid sequences comprise at least one of an HPV-16 peptide or an HPV-18 peptide shown in Table 2. E90. The polypeptide construct of E88 or E89, wherein said at least two HPV amino acid sequences comprise an HPV-16 peptide, said HPV-16 peptide comprising at least one of an HPV-16 E5 peptide, an HPV-16 E6 peptide, or an HPV-16 E7 peptide shown in Table 2. E91. The polypeptide construct of any one of E88 to E90, wherein said at least two HPV amino acid sequences comprise an HPV-18 peptide, said HPV-18 peptide comprising at least one of an HPV-18 E6 peptide or an HPV-18 E7 peptide as shown in Table 2. E92. The polypeptide construct of any one of E88 to E91, wherein the at least two HPV amino acid sequences comprise each of the amino acid sequences set forth in Table 2. E93. The polypeptide construct of E92, wherein each of said amino acid sequences is connected to another one of said amino acid sequences by said KK linker. E94. The polypeptide construct of any one of E88 to E93, having a sequence as set forth in SEQ ID NO:55. E95. The polypeptide construct of any one of E48 to E94 for use in a vaccine. E96. A polynucleotide encoding a polypeptide construct according to any one of E58 to E95. A vector comprising the polynucleotide according to E97.E96. E98. The vector of E97, which is an adenoviral vector. E99. The vector of E98, wherein said adenovirus vector is a gorilla adenovirus vector. E100. A vector comprising a polynucleotide encoding at least one HPV peptide, wherein the vector is an adenovirus vector. E101. A vector comprising a polynucleotide encoding at least one HPV peptide, said vector being an adenovirus vector, said adenovirus vector being a gorilla adenovirus vector.
[0277] Provided herein is a representative list of certain sequences that are included in the embodiments presented herein (Table 5).
[0278] [Table 5-1]
[0279]
Table 5-2
[10] 10. A polynucleotide comprising the polynucleotide of any one of claims 1 to 9 and further comprising one or more polynucleotides encoding a gene switch system for inducible control of heterologous gene expression, wherein expression of the heterologous gene is regulated by the gene switch system; the heterologous gene comprising the polynucleotide of any one of claims 1 to 9.
[11] The polynucleotide of claim 10, wherein the gene switch system is an ecdysone receptor-based (EcR-based) gene switch system.
[12] 1. A method for regulating expression of a heterologous gene in a cell, comprising: (a) into said cell, (i) an inhibitory gene switch or an inducible gene switch, and (ii) a heterologous immune response-inducing gene whose expression is regulated by said gene switch, said heterologous immune response-inducing gene encoding at least one of one or more HPV polypeptides. introducing one or more polynucleotides comprising: (b) exposing the cell to a compound in an amount sufficient to inhibit or induce expression of the heterologous immune response-inducing gene; The method includes:
[13] 13. The method of claim 12, wherein the gene switch comprises a ligand-binding domain derived from at least one of ecdysone receptor (EcR), ubiquitous receptor, orphan receptor 1, NER-1, steroid hormone nuclear receptor 1, retinoid X receptor-interacting protein 15, liver X receptor beta, steroid hormone receptor-like protein, liver X receptor, liver X receptor alpha, farnesoid X receptor, receptor-interacting protein 14, and farnesol receptor.
[14] A polypeptide comprising an E6 peptide, the E6 peptide comprising an E18A amino acid substitution and at least one of the following amino acid substitutions compared to a wild-type E6 peptide: L50G, E148A, T149A, Q150A, and L151A.
[15] The polypeptide of claim 14, wherein the E6 peptide has the sequence shown in SEQ ID NO:45.
[16] 16. The polypeptide of claim 13, wherein the E6 peptide is fused to an agonist peptide.
[17] The polypeptide of claim 16, wherein the agonist peptide is fused to at least one of the C-terminus and N-terminus of the E6 peptide.
[18] The E6 peptide of any one of claims 13 to 17, wherein the wild-type E6 peptide is derived from HPV-16.
[19] (i) an E6 peptide comprising a deletion compared to a wild-type E6 peptide, the deletion comprising the C-terminus of the wild-type E6 peptide; (ii) an E7 peptide comprising a deletion compared to a wild-type E7 peptide, the deletion comprising the N-terminus of the wild-type E7 peptide; (iii) an E5 peptide that comprises a deletion compared to a wild-type E5 peptide, the deletion comprising amino acids 41 to 57 of the wild-type E5 peptide; or (iv) an E5 peptide comprising a deletion compared to a wild-type E5 peptide, the deletion comprising at least one of amino acids 27 to 40 or amino acids 54 to 57 of the wild-type E5 peptide; A polypeptide comprising:
[20] (i) the deletion of the E6 peptide comprises amino acids 121 to the C-terminus of the wild-type E6 peptide; or (ii) the deletion of the E7 peptide comprises amino acids 1 to 39 of the wild-type E7 peptide; 20. The polypeptide of claim 19.
[21] (i) the E6 peptide comprises at least one of the following substitutions compared to the wild-type E6 peptide: E18A and L50G; or (ii) the E7 peptide comprises at least one of the following substitutions compared to the wild-type E7 peptide: E55A and L74R; 21. A polypeptide according to claim 19 or 20.
[22] (i) the wild-type E6 peptide is derived from HPV-18; (ii) the wild-type E7 peptide is derived from HPV-18; or (iii) the wild-type E5 peptide is derived from HPV-16 or HPV-18; 22. A polypeptide according to any one of claims 19 to 21.
[23] (i) the E6 peptide has the sequence set forth in SEQ ID NO:48; (ii) the E7 peptide has the sequence set forth in SEQ ID NO:49; or (iii) the E5 peptide has the sequence set forth in SEQ ID NO: 47 or SEQ ID NO: 50; 23. A polypeptide according to any one of claims 19 to 22.
[24] an HPV-16 E6 peptide comprising an E18A amino acid substitution and at least one of the following amino acid substitutions, relative to a wild-type HPV-16 E6 peptide: L50G, E148A, T149A, Q150A, and L151A; and (i) an HPV-16 E7 peptide that contains at least one of the following amino acid substitutions, relative to the wild-type HPV-16 E7 peptide: H2P, C24G, E46A, and L67R; (ii) HPV-16 E5 peptide; (iii) HPV-18 E6 peptide; (iv) HPV-18 E7 peptide; (v) an HPV-18 E5 peptide; or (vi) Any combination of (i) to (v) 2. A polypeptide construct comprising:
[25] (i) the HPV-16 E7 peptide comprises the H2P, C24G, E46A, and L67R amino acid substitutions; (ii) the HPV-16 E5 peptide contains one or more amino acid deletions compared to a wild-type HPV-16 E5 peptide; (iii) the HPV-18 E6 peptide comprises (a) an E18A and L50G substitution compared to a wild-type HPV-18 E6 peptide, (b) a deletion of at least one C-terminal amino acid compared to the wild-type HPV-18 E6 peptide, or both (a) and (b); (iv) the HPV-18 E7 peptide comprises (a) the substitutions E55A and L74R relative to a wild-type HPV-18 E7 peptide, (b) a deletion of at least one amino acid from the N-terminus of the HPV-18 E7 peptide, or both (a) and (b); (v) the HPV-18 E5 peptide comprises at least one amino acid deletion compared to a wild-type HPV-18 E5 peptide; or (vi) Any combination of (i) to (v), 25. A polypeptide construct as described in claim 24.
[26] (i) the deletion of the HPV-16 E5 peptide includes amino acids 41 to 57 of the wild-type HPV-16 E5 peptide; (ii) the deletion of the HPV-18 E6 peptide comprises amino acids 121 to the C-terminus of the wild-type HPV-18 E6 peptide; (iii) the deletion of the HPV-18 E7 peptide comprises amino acids 1 to 40 of the wild-type HPV-18 E7 peptide; (iv) the deletion of the HPV-18 E5 peptide comprises amino acids 27-40 or amino acids 54-57 of the wild-type HPV-18 E5 peptide; or (v) Any combination of (i) to (iv), 26. A polypeptide construct according to claim 25.
[27] (i) the HPV-16 E6 peptide has the sequence set forth in SEQ ID NO:45; (ii) the HPV-16 E7 peptide has the sequence set forth in SEQ ID NO:46; (iii) the HPV-16 E5 peptide has the sequence set forth in SEQ ID NO:47; (iv) the HPV-18 E6 peptide has the sequence set forth in SEQ ID NO:48; (v) the HPV-18 E7 peptide has the sequence set forth in SEQ ID NO:49; (vi) the HPV-18 E5 peptide has the sequence set forth in SEQ ID NO:50; or (v) Any combination of (i) to (vi), 27. A polypeptide construct according to any one of claims 24 to 26.
[28] 28. A polypeptide construct according to any one of claims 24 to 27, having the sequence shown in SEQ ID NO:51.
[29] 29. A polypeptide construct according to any one of claims 24 to 28, further comprising at least one agonist peptide.
[30] 30. The polypeptide construct of claim 29, wherein the at least one agonist peptide has a sequence comprising an agonist peptide sequence shown in Table 2.
[31] 31. A polypeptide construct according to claim 29 or 30, having the sequence shown in SEQ ID NO:53.
[32] A polypeptide construct comprising an ankyrin-like repeat domain and an HPV peptide.
[33] 33. The polypeptide construct of claim 32, wherein the ankyrin-like repeat protein is a human ankyrin-like repeat protein.
[34] 34. The polypeptide construct of claim 32 or 33, wherein the HPV peptide is linked to the ankyrin-like repeat protein by a linker.
[35] 35. The polypeptide construct of any one of claims 32 to 34, wherein the HPV peptide comprises at least one of an HPV-16 peptide or an HPV-18 peptide.
[36] (i) the HPV peptide comprises an HPV-16 peptide, the HPV-16 peptide comprising at least one of an E5 peptide, an E6 peptide, or an E7 peptide; or (ii) the HPV peptide comprises an HPV-18 peptide, the HPV-18 peptide comprising at least one of an E6 peptide or an E7 peptide; 36. A polypeptide construct according to any one of claims 32 to 35.
[37] 37. The polypeptide construct of any one of claims 32 to 36, wherein the HPV peptide comprises an HPV-16 E5 sequence, an HPV-16 E6 sequence, an HPV-16 E7 sequence, an HPV-18 E6 sequence, or an HPV-18 E7 sequence as shown in Table 2.
[38] 38. A polypeptide construct according to any one of claims 32 to 37, having the sequence shown in SEQ ID NO:52.
[39] 39. A polypeptide construct according to any one of claims 32 to 38, further comprising at least one agonist peptide.
[40] 40. The polypeptide construct of claim 39 having the sequence shown in SEQ ID NO:54.
[41] A polypeptide construct comprising at least two HPV amino acid sequences as shown in Table 2, said at least two HPV amino acid sequences being connected by a peptide linker, said peptide linker being a KK linker.
[42] 42. The polypeptide construct of claim 41, wherein the at least two HPV amino acid sequences comprise at least one of the HPV-16 or HPV-18 peptides shown in Table 2.
[43] The at least two HPV amino acid sequences are (i) an HPV-16 peptide comprising at least one of the HPV-16 E5 peptide, the HPV-16 E6 peptide, or the HPV-16 E7 peptide shown in Table 2; (ii) an HPV-18 peptide comprising at least one of the HPV-18 E6 peptide or HPV-18 E7 peptide shown in Table 2; (iii) each of the amino acid sequences set forth in Table 2; or (iv) Any combination of (i) to (iii) 43. The polypeptide construct of claim 41 or 42, comprising:
[44] 44. The polypeptide construct of claim 43, wherein each of the amino acid sequences is connected to another of the amino acid sequences by a KK linker.
[45] 45. A polypeptide construct according to any one of claims 41 to 44, having the sequence shown in SEQ ID NO:55.
[46] 46. A polynucleotide encoding the polypeptide construct of any one of claims 14 to 45.
[47] 47. A vector comprising a polynucleotide according to any one of claims 1 to 11 and 46.
[48] 48. The vector of claim 47 which is an adenovirus vector.
[49] The vector of claim 48, wherein the adenovirus vector is a gorilla adenovirus vector.
[50] 50. A polynucleotide according to any one of claims 1 to 11 and 46, a polypeptide construct according to any one of claims 14 to 45, or a vector according to any one of claims 47 to 49 for use in a vaccine.
Claims
1. A non-naturally occurring polynucleotide encoding a polypeptide comprising the sequence of SEQ ID NO:51 or 53.
2. A polypeptide encoded by the polynucleotide of claim 1.
3. A vector comprising the polynucleotide of claim 1.
4. The vector of claim 3 , wherein the vector is a human adenovirus vector or a gorilla adenovirus vector.
5. The vector of claim 4 , wherein the vector is a gorilla adenovirus vector.
6. The vector of claim 5 , wherein the gorilla adenovirus vector is a GC46 vector.
7. A vaccine comprising the polynucleotide of claim 1 or the polypeptide of claim 2.
8. A composition for regulating expression of a heterologous immune response-inducing gene in a cell, comprising one or more polynucleotides, The one or more polynucleotides: (a) an inhibitory or inducible gene switch, and (b) A heterologous immune response-inducing gene comprising the polynucleotide of claim 1, the expression of which is regulated by a gene switch. Including; wherein the one or more polynucleotides are introduced into the cell and the cell is exposed to a compound in an amount sufficient to suppress or induce expression of a heterologous immune response-inducing gene. composition.
Citation Information
Patent Citations
Papillomavirus polyprotein construct
JP2007054074A
Methods for isolating soluble polypeptides
JP2008536490A
Polynucleotides for the treatment of cancer virus polypeptide-positive tumors
JP2015506179A
How to treat cervical cancer
JP2017525760A
Immunomodulating composition for treatment
WO2017096432A1
